Company Stories V-Z

Stories that earlier appeared in Nelson's News Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) Looking for other older stories? Visit the archives

Vaccinex (Rochester, NY)

Vaccinex (Rochester, HY; $4.4M SBIR) down 58% [Sep 22, 20] Although the study did not meet pre-specified co-primary endpoints, the results of each of the two cognitive assessments demonstrated a strong trend for beneficial change (OTS, p=0.028 and PTAP, p=0.06). These cognitive assessments reflect changes in planning ability and memory associated with disease progression. [company press release, Sep 22, 20]

Vaccinex up 40% [Jul 17, 20]

Vaccinex up 18% [Jul 13, 20]

Vaccinex (Rochester, NY; $4.4M SBIR) down 18% [Feb 28, 20]

Vaccinex up 19% [Jan 28, 20]

Vaccinex (Rochester, NY; $4.5M SBIR) up 36% [Jan 24, 20]

Vaccinex down 15% [Apr 4, 19]

Vaccinex up 23% [Apr 1, 19]

Vaccinex (Rochester, NY; $4.5M SBIR) up 21% [Jan 16, 19] announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2, multi-center, randomized, double-blind, placebo controlled study in subjects with early manifest and late prodromal Huntington's disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503 (pepinemab). [company press release, Jan 16, 19] total funding $12M [crunchbase.com]

Vaccinex down 13% [Sep 19, 18]

Vaccinex (Rochester, NY; $4.4M SBIR) up 14% [Sep 18, 18] IPO August 2018; total fundng $12M [crunchbase.com]

Vaccinex (Rochester, NY; $4.4M SBIR, founded 2001), developing antibody therapies to combat cancer and neurological diseases, filed [for IPO] to raise up to $46 million [nasdaq.com, Jul 16, 18] total funding $12M [crunchbase.com]

Vaccinex (Rochester, NY; $4.3M SBIR) announced that [FDA] granted Fast Track designation for VX15 as a potential treatment for Huntington’s disease (HD). VX15 is the Company’s novel clinical stage monoclonal antibody that blocks the activity of semaphorin 4D (SEMA4D), a molecule that is believed to promote chronic inflammatory responses in the brain. [company press release, Aug 12, 16]

Vaccinogen (Frederick, MD)

pharmaceutical firm Vaccinogen (Baltimore, MD (formerly Frederick, MD); no SBIR) has entered into an exclusive agreement to evaluate and acquire technology from Dublin City University that would speed up drug development. .... will have two years to evaluate DiCAST, a patent-pending technology that speeds the development of new drugs, and decide whether to acquire the platform from Dublin City University. ... specializes in developing drugs targeting cancer. It’s signature OconoVAX is designed to reduce the recurrence of colon cancer. DiCAST’s technology can analyze 35,000 times more patient samples per test than traditional methods and can pick up on qualities of the samples that other methods may miss. [Sarah Gantz, Baltimore Business Journal, Sep 9, 15] Baltimore has a unique Irish link with its Irish Workers Museum which remembers the influx of Irish immigrants in the 19th century.

Vaccinogen (Frederick, MD; no SBIR) announced it had secured $80 million in funding from Stockholm investors and closed the first $10 million tranche of the funding. The funding will support late-stage clinical studies needed to make Vaccinogen’s OncoVAX commercially available. The drug is designed to reduce recurrence of colon cancer. ... As Vaccinogen prepares to begin manufacturing and selling OncoVAX, company leaders are plotting other big moves, including relocating its headquarters to Baltimore, a hiring spree and attempting to join a major stock market. ... A total of 25 employees will work in Baltimore [Sarah Gantz, Baltimore Business Journal, Aug 26, 14]

Vader Systems (East Amherst, NY)

Vader Systems (East Amherst, NY; no SBIR) closed on $500,000 of venture capital, bringing its total amount of seed capital raised since September to $600,000. ... in the home of the company’s father-son team, expects to complete its first full-scale 3-D metal printing machine by April [Dan Miner, Buffalo Business First, Oct 27, 15]

VakSea (Baltimore, MD)

Yield Lab, an agribusiness accelerator based in Creve Coeur [MO], has chosen six software and ingredients companies for its spring class. ... includes two firms from the St. Louis area, three from elsewhere in the United States and one from Argentina. Each gets a $100,000 investment and participates in a business development program at Yield Lab's headquarters. ... Arch Innotek (St. Louis, MO; $300K SBIR) uses a fermentation process to produce natural ingredients. ... VakSea (Baltimore, MD; no SBIR) sells immune-boosting proteins for shrimp aquaculture. [David Nicklaus, St Louis Post Dispatch, Feb 28, 19]

Vala Sciences (San Diego, CA)

The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money. SBIR companies got $10M of it. Bio Time (Berkeley, CA; $300K SBIR) $4.7M; Vistagen Therapeutics (Burlingame, CA; $600K SBIR) $970K; Gamma Medica Ideas (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR) $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K SBIR; Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]

Valencell (Raleigh, NC)

Valencell (Raleigh, NC; $1.1M SBIR) disclosed it has raised $2.6 million. ... develops wearable sensors that can measure health data, such as heart rate. ... What separates Valencell's PerformTek from other sensors – such as what's in your FitBit – is the focus on accuracy, [founder] LeBoeuf said. ... last year it rasied $7M. [Lauren K. Ohnesorge,Triangle Business Journal, Sep 11, 15]

Valencell (Raleigh, NC; $1.1M SBIR) that develops technology for use in wearable fitness devices, has raised $7 million ... has raised more than $13 million in venture capital ... patented PerformTek Precision Biometrics technology enables wearers of headsets, armbands and other devices to accurately monitor key health data such as heart rate, respiratory rate, blood oxygen level and aerobic fitness wherever they go. [David Bracken, Raleigh Nes & Observer, Jun 16, 14]

Valencell (Raleigh, NC; $1.1M SBIR) that makes earbud sensors that allow wearers to monitor their health while listening to music, has raised $5.5 million in venture capital funding. ... to expand its team, increase licensing agreements and expand the capabilities of its products. ... six employees. [David Bracken, Raleigh News & Observer, Jun 21, 11]

Valence Technology (Austin, TX)

Valence Technology (Austin, TX; no SBIR) that has toiled 23 unprofitable years on advanced lithium-ion battery systems, has filed for bankruptcy protection as it negotiates the financing it needs to continue its operations. ... has never produced enough revenue to cover the costs of developing and producing advanced lithium-ion battery systems like the ones used in plug-in electric vehicles. The company relied on funding from its chairman, California billionaire Carl Berg, who has pumped more than $100 million into Valence over the years. .... found itself caught in a common spot for many advanced battery developers, Saxman said. Once a company finishes its research and development, it has to go through another long and costly process to set up and refine its production and ensure the high levels of quality and purity in its materials. [Dan Zehr, Austin American Statesman, Jul 11, 12]

Valence Technology said it won a four-year patent battle against a Canadian company. The company said the courts found that Phostech Lithium Inc. had infringed on Valence's patent involving a way of producing various materials used in its lithium-ion batteries. Valence said future court proceedings will determine the damages and costs that Phostech must pay. [Austin American Statesman, Feb 17]

Carl Berg, the founder, chairman and principal shareholder of Valence Technology, has put another $4.5 million into the rechargeable battery maker. [Austin American Statesman, Dec 6, 10]

Exactly a week after signing a deal worth an estimated $9 million, Valence Technology's founder poured $1 million into the rechargeable battery and energy developer. [Austin Business Journal, Feb 25, 10]

Valence Technology (Austin, TX; no SBIR) said it received a $3.1 million order from Smith Electric Vehicles, a British company that makes electric-powered commercial vehicles. Valence, which makes rechargeable batteries, earlier received a $1.4 million order from Smith parent Tanfield Group PLC, which is increasing production of its Smith Newton truck in the United States. [Austin American Statesman, Jan 13, 10]

California investor Carl Berg bought 1.2 million shares of Valence Technology for $2.5 million in a private placement, according to a regulatory filing. Berg, who is Valence's chairman and co-founder, already was the company's largest shareholder and has provided regular cash infusions. Valence has not made a profit since it was founded in 1989. Valence, which makes lithium-ion batteries, has applied for federal stimulus money to help build an advanced battery plant in Leander. [Austin American Statesman, Jun 16, 09]

ActaCell (Austin, TX; no SBIR) is hardly alone. [CEO] Ott estimates that a dozen companies, many of them startups, are chasing the same goal. Most them are trying to modify the lithium-ion technology now used in many laptop computers and cell phones. One Austin company, Valence Technology Inc., already is making batteries for a variety of vehicles, including the Segway Personal Transporter. ... and $2 billion in federal funds for advanced battery development just passed by Congress — has sparked a rush of investment in startup battery companies and a surge of interest in promoting more manufacturing of advanced batteries in the U.S. [Kirk Ladendorf, Austin American-Statesman, Mar 9, 08]

Lithium Hope and Despair. don't expect the standard lithium ion batteries found in most laptops to go away anytime soon. "It's not going to happen," acknowledged Jim Akridge, who has spent more than 25 years in the battery business. As the CEO of Valence Technology (Austin TX), Akridge runs one of several companies that have developed what they say are safer alternatives to traditional computer batteries. Valence's products use a proprietary chemical mix of lithium and phosphates designed to keep from overheating and catching on fire. ... Ross Dueber is more confident. He says the battery technology developed by his company, Zinc Matrix Power, will eventually replace lithium ion. But although Zinc Matrix Power has existed since 1997, it hasn't been able to make any inroads with computer makers. Until it does, it probably won't even consider making its batteries on a wide scale, Dueber said. [Bob Keefe, Austin American-Statesman, Oct 17]

Validity Sensors (San Jose, CA)

Synaptics has agreed to buy Validity Sensors (San Jose, CA; no SBIR), that sells fingerprint ID technology like that found in the new iPhone 5S, for up to $255 million. .... Synaptics CEO Rick Bergman said his customers, which include the biggest laptop makers in the world, have been pushing him to add fingerprint ID technology for a couple of years. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 9, 13]

Validity Sensors, San Jose start-up the builds advanced fingerprint sensors, has raised $20 million in its latest round of venture capital, in what appears to be a formal financial restart of the company. The round included a “substantial investment” from Qualcomm Ventures, according to the company, which suggests the company’s technology will soon be used for mobile phones. [Venturebeat.com, Oct 17] Venture Beat is Matt Marshall's new site since he left the San Jose Mercury for greener pastures. No SBIRs.'

Valley Tech Systems (Folsom, CA)

Valley Tech Systems (Folsom, CA; $22M SBIR) awarded a subcontract worth up to $94 million for base and future option scope by Lockheed Martin for an advanced solid-propulsion subsystem for its Next Generation Interceptor (NGI) contract with the U.S. Missile Defense Agency (MDA). [company press release, Dec 7, 21]

Valmont Industries (Farmington, MN)

Meanwhile, subsdies in Minnesota. The state of Minnesota approved its first five grants worth $2.27 million to manufacturers as part of the new, $24 million Job Creation Fund. The fund hopes to attract scores of companies to Minnesota and to encourage firms here to stay and expand in the state. ... So far, the state has approved grants to Axis Clinicals (Dilworth, MN; no SBIR) ($779,988) an India-based clinical-trials laboratory that decided to open a new $12 million facility in Dilworth with 100 employees. , Heraeus Medical Components (White Bear Township, MN; no SBIR) ($498,100) Heraeus Medical is expected to add 55 workers. It plans to spend $7.8 million to renovate its existing plant, Bluegrass Proteins (Dawson, MN; no SBIR) ($650,000) Kentucky-based Bluegrass Proteins will bring 56 jobs, plans to invest $18.2 million to buy and retrofit the Associated Milk Producers’ raw milk plant, Harmony Enterprises(Harmony, MN; no SBIR) ($215,000), and Valmont Industries(Farmington, MN; no SBIR) ($129,000). an aluminum pole maker with operations in Minnesota, Indiana and Canada... makes waste compactors and recycling balers. Its plans include 14 new hires and a $1.1 million plant expansion. will add 15 workers. Combined, the five companies plan to add 240 jobs in Minnesota. [Dee DePass, Minneapolis Star Tribune, Apr 1, 14]

Valulytics

The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20] almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics, Shift.org, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release

Vanda Pharmaceuticals (Rockville, MD)

Vanda Pharmaceuticals (Washington, DC; no SBIR) has expanded its portfolio to include research and development into treatments for cystic fibrosis and blood cancer. During a first-quarter earnings call this week, CEO Mihael Polymeropoulos said Vanda is on track to file an investigational new drug application for trichostatin A to the Food and Drug Administration in mid-2017 for clinical study of hematologic malignancies. [Washington Business Journal, May 5, 17]

Vanda Pharmaceuticals (Washington, DC; no SBIR), which this week reported higher revenue on sales of its new sleep disorder treatment, will raise at least $54 million in a secondary offering to fund the drug's marketing as well as additional research .... [stock] has rallied 65 percent this year [Jeff Clabaugh, Washington Business Journal, Oct 29, 14] working to advance the science of developing new medicines through novel approaches to address unmet medical needs and improve the lives of patients ... specifically development and commercialization of products for the treatment of central nervous system disorders ... IPO 2006 [company website]

Vanda Pharmaceuticals (founded 2002; Rockville, MD; no SBIR) rose 626% as the FDA approved the company's schizophrenia drug Fanapt. [Wall Street Journal, May 8, 09] IPO 2006, 24 employees

Vanguard Space Technologies (San Diego, CA)

SolAero Technologies (Albuquerque, NM; no SBIR) that bought Emcore’s solar space division last year, has acquired Vanguard Space Technologies (San Diego, CA; no SBIR). [Joe Cardillo, Albuquerque Business First, May 11, 16] Solero earlier signed a definitive agreement to acquire Alliance Spacesystems, LLC, a leading provider of high-performance composite structures for spacecraft applications. [SolAero press release, Apr 15, 16]

Vantage Robotics (San Leandro, CA)

Vantage Robotics (San Leandro, CA; $1M SBIR), a speciality drone maker, recently announced plans to bring an undisclosed number of jobs to Ohio, after JobsOhio helped incentivize the expansion through its Growth Capital program. Officials from both Vantage Robotics and JobsOhio declined to share the value of that incentive. [Meg Erpenbeck, CincyInno, Jan 27, 2022]

Vapogenix (Houston, TX)

biotech Vapogenix (Houston, TX; no SBIR) announced it raised $8.2 million to pay for Phase 2 clinical trials of its rapidly acting topical analgesic, as an alternative to opioid painkillers. The Series C funding round brings the total amount raised by Vapogenix to $18.2 million. [Angela Shah, xconomy.com, Dec 12, 16]

Variant Pharmaceuticals (Weston, FL)

Variant Pharmaceuticals (Weston, FL; no SBIR, founded 2014), developing first-in-class drugs for patients with rare diseases, is pleased to announce that it has secured $10 Million in financing from Korean company, Incon, in exchange for equity ownership [to] advance clinical and non-clinical development of VAR 200 (2HPβCD), including production of clinical supplies, execution of the Phase 2a trial in patients with FSGS, and support for expanded access and subcutaneous delivery initiatives. [company press release, Dec 3, 18] total prior funding $3M [crunchbase.com]

Vascudyne (Stillwater, MN)

Vascudyne (Stillwater, MN; no SBIR) [UM spinoff] startup that's developing a new replacement for heart valves and veins, has raised $10 million in a Series A round [ Carter Jones, MinneInno, Dec 6, 21]

Vascugen (Indianapolis, IN)

Vascugen (Madison, WI; no SBIR, founded 2017) is applying $10 million in recently raised capital to build out its manufacturing capacity for its product – therapeutics that repair human tissue. ... is developing regenerative medicines technology being licensed from Indiana University [that]repairs human tissue damaged by reduced blood flow due to disease or injury. The Yoder lab at IU was the first to discover rare cells that are responsible for the formation of new blood vessels in the body and to then develop methods for manufacturing those cells, according to the university. [Nick Williams, WisconsinInno, August 25, 2020]

Vascugen (Indianapolis, IN; no SBIR) has licensed technology developed at the IU School of Medicine by its co-founder, Mervin Yoder, that pertains to using adult stem cells to form new blood vessels, says CEO Carter Cliff. ... will soon seek “a substantial VC investment” to carry it through clinical testing, Cliff says. [Sarah Schmid Stevenson, xconomy.com, May 22, 18]

Vascular Biogenics (San Diego, CA)

Vascular Biogenics up 10% [Mar 5, 18]

Vascular Biogenics (San Diego, CA; one SBIR) up 10% [Dec 23, 14]

Vascular Designs (Silicon Valley)

Goldman tweaked and tweaked. He formed a company, Vascular Designs (Silicon Valley; who needs SBIR?) headquartered at his home. He lined up angel investors and $1.8 million in seed money. He added about $3 million of his own. He submitted his design to the Food and Drug Administration. It was rejected. Three times. Then in May, he got it: FDA approval. ... It's too early to know how widely the catheter, known as the IsoFlow, will be deployed. Every cancer case is different and Goldman's catheter is not right for all. Goldman's push now is to persuade doctors to try it. [Mike Cassidy, San Jose Mercury News, Nov 23, 09]

Vascular Genesis

A tissue engineering company developing materials to heal wounds and grow new blood vessels has raised $4.1 million in a round led by a "startup nursery." ParaGen Technologies LLC (Columbus, OH; no SBIR) is a parent company for medical device subsidiaries that use its core microfilament technology for specific applications. The first four are for healing skin, treating sports injuries, growing blood vessels and repairing hernias. company is a joint venture of Nanofiber Solutions LLC ($150K SBIR), which invented the technology, and Ikove Capital Partners. [Carrie Ghose, Columbus Business Journal, Dec 15, 17] three subsidiary companies are RenovoDerm, Atreon Orthopedics, and Vascular Genesis. [ParaGen website]

Vascular Pathways (Los Altos, CA)

Vascular Pathways (Los Altos, CA; no SBIR) which has developed a product for peripheral intravenous access, said Monday it raised $14 million in a second round of funding. [Silicon Valley /San Jose Business Journal, Nov 1, 10]

Vascular Pharmaceuticals (Chapel Hill, NC)

drug developer Vascular Pharmaceuticals (Chapel Hill, NC; $1.4M SBIR) raised $3 million in another round of funding, which will allow it to increase the size of a clinical trial to test its experimental treatment for diabetic nephropathy, the leading cause of chronic kidney disease. [Jason deBruyn, Triangle Business Journal, Jan 11, 16]

Vascular Pharmaceuticals (Chapel Hill, NC; $1.4M SBIR) with UNC roots, has raised an additional $9 million to aid in its search for a new treatment of an incurable diabetes complication. ... to fund its ongoing Phase 2 clinical trial. ... And big pharma is watching – namely Janssen Biotech, which already has the exclusive right to acquire Vascular Pharmaceuticals following the completion of its Phase 2 study. [Lauren K. Ohnesorge, Triangle Business Journal, Mar 3, 15]

Vascular Pharma (Research Triangle Park, NC; $1.4M SBIR) startup has raised $9 million to continue research into its only experimental drug for the treatment of kidney damage caused by diabetes. ... To date Vascular Pharma has raised $25 million and says it has no further plans to raise capital under a business plan that calls for Vascular Pharma to be acquired by [Janssen Biotech, a sub of Johnson&Johnson] upon the completion of Phase II drug trial. [John Murawski, RaleighNews & Observer, Mar 3, 15]

Vascular Pharmaceuticals (Chapel Hill, NC; $1.4M SBIR) has nabbed what CEO Richard Shea calls a “small bridge facility,” referring to $1 million in debt financing. .... struck a deal with Johnson & Johnson subsidiary Janssen Biotech last year, is developing a diabetes candidate. [Lauren Ohnesorge, Triangle Business Journal, Aug 23, 13]

Vascular Solutions (Maple Grove, MN)

The U.S. Army and med-tech company Vascular Solutions (Maple Grove, MN; no SBIR, founded 1997) are teaming up to develop a freeze-dried plasma product for treating battlefield injuries. ... already built a prototype of the product .... won’t need to be thawed, allowing medical personnel to treat injured patients more quickly. .... aims to submit the freeze-dried plasma for regulatory approval in 2018. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Apr 23, 14]

Vasculox (St Louis, MO)

Vasculox, (St. Louis, MO; $400K SBIR) pharmaceutical discovery startup, raised part of a planned $45 million financing round from a group of investors. [Brian Feldt,St. Louis Business Journal, Aug 21, 15] a total of $1.7 million to date from NIH ... focused on the development of proprietary drugs for life-threatening disorders driven by CD47-mediated signaling pathways. Examples of these disorders include leukemia, lymphoma, solid tumors, pulmonary hypertension, and delayed graft function following solid organ transplantation. [company website]

Vasculox (St. Louis, MO; $400K SBIR, 6 employees) pharmaceutical discovery startup, has raised part of a planned $45 million financing round from a group of investors. ... focused on developing drugs for disorders including leukemia, lymphoma and solid tumors. ... The company previously had raised $1.27 million earlier this year [Brian Feldt, St. Louis Business Journal, Aug 13, 15]

Vasculox (St. Louis, MO; $400K SBIR) pharmaceutical discovery startup, has raised $1.27 million from a group of investors, according to [SEC] filing ... developing drugs for disorders including leukemia, lymphoma and solid tumors. ... was already a portfolio company of the MTC and BioGenerator, which has invested about $525,000 into the company to date. The St. Louis Arch Angels have also previously invested in the startup. ... has also received more than $1.7 million since 2009 from the National Heart, Lung and Blood Institute [Brian Feldt, St. Louis Business Journal, Feb 19, 15]

Vasculox (St. Louis, MO; $400K SBIR) startup focused on developing drugs for transplantation and pulmonary hypertension, was awarded $827,018 from [NIH]. ... Last year, Vasculox was awarded $706,733 from [NIH] and received $203,191 (SBIR) in 2009 for a total of $1.7 million to date. .... also received $150,000 from the Missouri Innovation, Development and Entrepreneurship Advancement (IDEA) program, a state program that makes equity investments in startup companies based in Missouri. [Samantha Liss,St Louis Business Journal, May 30, 13]

the Missouri Innovation, Development and Entrepreneurship Advancement (IDEA) program, makes equity investments into Missouri startups. ... established with federal funding that was part of Small Business Jobs Act of 2010. ... had $21 million of funding and is now down to $3.4 million .... [vested interests] in the state pushing for $15 million in annual funding. [Amir Kurtovic, St Louis Business Journal, Apr 19, 13] Of 33 companies on the benficiary list, only one company had SBIR - Vasculox (St Louis, MO; $400K SBIR). SBA hyped the federal law as the most significant piece of small business legislation in over a decade. ... providing critical resources to help small businesses continue to drive economic recovery and create jobs with provision for $21B in SBA lending. In practice, the amounts and the loan structure are insufficient for technical validation of new technology with high economic potential it it works as envisaged. Instead, the money seems earmarked to kiss huge numbers of SBs and pretend to do something of notable value. Naturally, the Iron Triangle - law makers, administrators, and beneficiaries - will all see something of quite notable value, while Tea Party libertarians complain about government intrusion and growing debt creation.

VasoGenix Pharmaceuticals (Lenexa, KS)

The Kansas Bioscience Authority announced four grants totaling $4.85 million to help companies in the state. KC BioMediX of De Soto, VasoGenix Pharmaceuticals of Lenexa , Ventria Bioscience of Junction City ($500K SBIR), MGP Ingredients (public) of Atchison. [Kansas City Business Journal, Jul 15, 08]

Vasoptic Medical (Columbia, MD)

medical device startup Vasoptic Medical (Baltimore, MD; SBIR) raised $250,000 to continue development of its eye imaging technology. ... will serve as a bridge to the larger Series A round Vasoptic later this year ... embarks on the first human clinical trial of its eye imaging technology [that] is designed to allow doctors to examine a patient’s retina without having to dilate the pupil or add dye and could therefore be more readily used at primary care centers, pharmacies and clinics. [Sarah Gantz, Baltimore Business Journal, Feb 24, 16]

Vasoptic Medical (Columbia, MD; no SBIR) won a two-year, $650,000 [NIH SBIR] to develop a portable version of its eye testing technology. ... will help Vasoptic and researchers at Johns Hopkins University develop a specialized camera with the diagnostic technology built in. .... expects the specialized camera to be commercially available in three or four years [Sarah Gantz, Baltimore Business Journal, Jul 1, 14]

The Maryland Technology Development Corp. (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000. • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990 • Weinberg Medical Physics LLC received $60,000 [Baltimore Business Journal, Jul 19, 13]

Vast Therapeutics (Durham, NC)

Vast Therapeutics (Durham, NC; no SBIR) announced that it has completed its [$15M] Series A financing with a single investor, Shionogi & Co., Ltd. of Japan [to] advance their novel nitric oxide powder platform through pre-clinical testing and first-in-human clinical safety and efficacy trials during the next 2 years. [company press release, Dec 5, 18]

Vativ Technologies (San Diego, CA)

San Diego's Entropic Communications has purchased a small semiconductor company whose chips help move high-definition television signals between the TV and other gadgets. Vativ Technologies (San Diego, CA; no SBIR) had raised about $37M in VC since it was founded in 2001. [Mike Freeman, San Diego Union-Tribune, Apr 5]

Vaxart (San Francisco, CA)

Vaxart up 22% [Jun 11, 21]

Vaxart up 17% [Apr 30, 21]

Vaxart up 24% [Feb 8, 21]

Vaxart down 58% [Feb 3, 21] announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its oral COVID-19 tablet vaccine candidate was generally well-tolerated, and immunogenic as measured by multiple markers of immune response to SARS-CoV-2 antigens. [comapny press release, Feb 3, 21] Lifted by a Short Squeeze, Vaxart Stock Sinks on Lackluster Vaccine News [Bill Alpert, Barron's, Feb. 3, 2021]

Vaxart up 50% [Feb 2, 21]

Vaxart up 30% [Feb 1, 21]

Vaxart up 34% [Jan 29, 21]

Vaxart up 41% [Jan 25, 21]

Vaxart up 19% [Nov 11, 20]

Vaxart down 32% [Nov 9, 20]

Vaxart, a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. [company press release, Oct 13, 20]

Vaxart down 15% [Jul 15, 20]

Vaxart up 40% [Jul 14, 20]

Vaxart (South San Francisco, CA; $3.5M SBIR) up 52% [Jul 13, 20] announced that it has raised gross proceeds of approximately $90 million through its At-the-Market (ATM) facility [company press release, Jul 13, 20]

Vaxart (South San Francisco, CA; $3.5M SBIR) up 38% [Jul 7, 20] has soared over 2,000% YTD amid an acceptance to the Russell 3000, joining Operation Warp Speed, and the possibility of an effective COVID-19 'tablet' vaccine. [Seeking Alpha, Jul 7, 20]

Vaxart (San Francisco, CA; $4M SBIR) raised $20 million in a Series C round. The company, which is developing recombinant vaccines that can be taken by tablet rather than injection .... $12.5 million Series B financing in 2010 [Ron Leuty, San Francisco Business Times, Aug 6, 13]

Oral vaccine developer Vaxart (San Francisco, CA; $3.8M SBIR) closed a $12.5 million Series B financing. ... to advance its lead product, a potential avian flu vaccine, through Phase I clinical trials. Ron Leuty, San Francisco Business Times, Mar 5, 10]

Vaxcyte (formerly Sutrovax) (Foster City, CA)

Vaxcyte up 15% [Jun 16, 20]

Vaxcyte, (Foster City, CA; no SBIR, founded 2013) up 63% [Jun 12, 20] a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced the [IPO] pricing of $250.0 million [company press release, Jun 11, 20] prior funding $177M [crunchbase.com]

Vaxess Technologies (Cambridge, MA)

Vaxess Technologies (Cambridge, MA; $4.3M SBIR) which is behind a smart patch designed to slowly release vaccines and other treatments into the skin, raised $2M in debt, according to an SEC filing. [BostInno, Mar 29, 21]

biotech startup Vaxess Technologies (Cambridge, MA; $3.6M SBIR) was awarded a [NSF] grant up to $2M and a subcontract from DARPA to advance two separate projects aimed at developing mRNA-based vaccines and other medical countermeasures. [Rowan Walrath, BostInno, Jan 22, 21]

biotech Vaxess Technologies (Cambridge, MA; $3.3M SBIR, founded 2011) has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC) (TPEx: 6547.TWO), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system. [company press release, Sep 14, 20]

GC Pharma, a manufacturer of influenza vaccines with a global reach, is partnering with Vaxess Technologies (Cambridge, MA; $3M SBIR, founded 2012), a biotech developing the MIMIX smart release patch. They'll work to commercialize Vaxess' flu vaccine patch. [Srividya Kalyanaraman, BostInno, Oct 16, 19] total funding $20M [crunchbase.com]

Michael Schrader, a 2004 Purdue graduate, co-founded Vaxess Technologies (Cambridge, MA; no SBIR), which uses a protein found in silk to stabilize vaccines that can be transported without refrigeration, extending their global reach. ... Vaxess received Verizon’s $1 million Powerful Answers Award, which challenges businesses and entrepreneurs to provide innovative solutions in education, health care, sustainability and transportation. [Joseph Paul, Lafayette (IN) Journal and Courier, Feb 6, 15]

Vaxess Technologies (Cambridge, MA; no SBIR), an early-stage company that is developing a platform that allows vaccines to be stored and shipped without refrigeration, has received a $1 million “accelerator” loan from the Massachusetts Life Sciences Center, a quasi-public agency charged with implementing the state’s $1-billion life sciences initiative. [Chris Reidy, Boston Globe, Dec 19, 13]

h3>VaxGen

After failing to make an effective HIV vaccine and losing its $877M federal contract to make an anthrax vaccine, VaxGen said its last-ditch effort to save itself through a merger has foundered and its days may be numbered. [Steve Johnson, San Jose Mercury News, Mar 29]

A Shot Too Far. The government killed VaxGen's $877M anthrax vaccine contract because the company had not started the clinical trials. Since VaxGen won the contract two years ago, skeptics have questioned the ability of the company, a small biotechnology business, to deliver on such a large order, as well as the administration’s capacity to properly manage the overall $5.6B program, known as BioShield. [Eric Lipton, New York Times, Dec 20] VaxGen had a $2M SBIR from HHS plus another $700K in SBIR awards. The stock price has dropped 90% in two years. It's a huge leap from a $2M SBIR to $877M with the government customer watching every move.

When FDA halted the VaxGen anthrax vaccine approval train because data submitted by the company are insufficient to determine that the product is stable enough to resume clinical testing, the investors jumped off. Down 56%. [Nov 3, 06]

VaxInnate (New Haven, CT)

E coli bacteria are growing to produce an experimental vaccine against influenza. The company running the experiment, VaxInnate (New Haven, CT; $1.8M SBIR) is working on technology that could derive in only six weeks a new vaccine for the H1N1 swine flu, the virus causing the global scare. Then, in the space of a month, it could turn out 2 billion doses--surpassing the annual production capacity of all flu-shot makers combined. "You could vaccinate everybody on the planet without breaking a sweat," says Alan Shaw, VaxInnate's chief executive and a Merck vaccine veteran. ... still five years away from becoming reality .... Only a handful of companies, including GlaxoSmithkline and Sanofi-Aventis make flu vaccines, [because] there's no financial incentive to find new methods. Huge social impact but too little ROI for private investment? Perfect for government "market failure" programs like SBIR should be. The stopgap solution has been to use government grants to make up for this market failure. Novartis has got $700 million to build a plant to make flu shots in dog kidney cells. The government aims to have in place within three years the capacity to make 600 million doses of pandemic flu vaccine in six months. [Matthew Herper, Forbes, May 25, 09]

VaxNewMo (St Louis, MO)

VaxNewMo (St Louis, MO; $500K SBIR) vaccine startup will utilize the [$3M] three-year grant to develop a vaccine designed to provide defense against pneumococcus, which causes illnesses that include bloodstream infections, pneumonia, meningitis and middle ear infections. [Nathan Rubbelke, St Louis Business Journal, Feb 20, 20]

VBI Vaccines (Cambridge, MA)

VBI Vaccines (Cambridge, MA; no SBIR) up 30% {Aug 27, 20], a commercial-stage biopharmaceutical developing next-generation infectious disease and immuno-oncology vaccines, announced data from three preclinical mouse studies conducted to enable selection of optimized clinical candidates for the company's coronavirus program, VBI-2900. As a result of these studies, VBI has selected two vaccine candidates, with the potential to be one-dose vaccines, to take into an adaptive Phase 1/2 human clinical study, expected to begin around year-end 2020, [company press release, Aug 26, 20]

VBI Vaccines up 23% [Jul 17, 20]

VBL Therapeutics (AKA Vascular Biogenics, Israel)

VBL Therapeutics (AKA Vascular Biogenics, Israel) up 73% [Jun 6, 16] , a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced the presentation of updated clinical results from a Phase 1/2 trial of VB-111 in the treatment of patients with recurrent platinum resistant ovarian cancer. They demonstrate a median overall survival of 810 days in the VB-111 therapeutic dose arm, versus 172 days in the low dose arm, a result that was statistically significant. [company press release]

vCalc (Hagerstown, MD)

Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market. .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies: A&G Pharmaceutical (Columbia, MD; no SBIR), Rehabtics LLC (Baltimore, MD; no SBIR) High Impact Environmental (Church Hill, MD; no SBIR), Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR), Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no SBIR), vCalc (Hagerstown, MD; SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094) [Sarah Gantz, Baltimore Business Journal, Feb 26, 14]

Vecna Technologies (College Park, MD)

Executives from 11 New England robotics firms will travel to several cities in China later this month on a trade mission aimed at sparking business deals and more technology collaboration between the U.S. and China. ... large, well-established firms, such as iRobot and Vecna Technologies (Greenbelt, MD; $11M SBIR). also small, young startups, including Soft Robotics (Cambridge, MA; no SBIR) and GreenSight Agronomics (Boston, MA; no SBIR, over a decade of experience fielding these systems for customers including the Department of Defense and NASA). [Jeff Engel, xconomy.com, Oct 14, 16]

Martin Buehler, iRobot’s former director of research - “Robot Guy” - touted the disruption that robotics companies in New England have made, such as Rethink Robotics (no SBIR), iRobot ($8M SBIR), Harvest Automation (no SBIR), Kiva Systems (no SBIR; acquired by Amazon.com), Symbotic (no SBIR) and, of course, his company, Vecna Technologies (Greenbelt, MD; $8.5M SBIR). Buehler showed how iRobot’s devices are used in defenseapplications as well as cleaning floors, pools and gutters. He also showed how Harvest’s robots are used in labor-intensive agriculture applications. The audience was amazed by Kiva’s robots driving efficiency, and how the robots have replaced the “runners” who fill product orders. [Patircia Resende, Boston Business Journal, Mar 7, 13]

wounded soldiers may be carried off the battlefield in the metallic arms of a BEAR, Battlefield Extraction-Assist Robot, a humanoid-shaped rescue machine being designed by Vecna Technologies (College Park, MD; $3M SBIR so far, mostly a $2.7M Phase 2 unrelated to robots). the robot is built for a variety of lifesaving tasks. ... iRobot is also working on a machine to rescue wounded soldiers. But the iRobot Warrior can do considerably more [Hiawatha Bray (usually writes for Boston Globe), The Oregonian, May 17]

Vectorlogics (Birmingham, AL)

DNAtrix (Houston, TX; no SBIR) biotech company that researches the use of viruses to target and destroy cancer cells, announced that it was awarded a $10.8 million grant to further its program for treating an aggressive form of brain cancer. The Cancer Prevention and Research Institute of Texas (CPRIT) gave DNAtrix the grant to help the company usher its product, DNX-2401, a genetically modified adenovirus that attacks brain tumors, through the second stage of its first phase of development. ... In 2012, DNAtrix merged with Vectorlogics (Birmingham, AL; $2.8M SBIR) [Josh Cain, Houston Business Journal, Feb 24, 14]

Vedanta Biosciences (Boston, MA)

microbiome startup Vedanta Biosciences (Cambridge, MA; no SBIR, founded 2010) raised $8M in equity and seeks to raise an additional $8.6M, according to an SEC filing [Rowan Walrath, BostonInno, Sep 21, 19] prior funding $100M [crunchbase.com]

Microbiome drug developer Vedanta Biosciences(Cambridge, MA; no SBIR) has raised $27 million [including from Gates Foundation and Bristol-Myers] to press forward with clinical trials for four therapeutic candidates. Vedanta’s experimental treatments are compositions of live bacteria that the company says trigger a targeted immune response. By shifting the ecosystem of gut bacteria, Vedanta says its therapies can potentially treat autoimmune and allergic diseases, as well as cancer. Vedanta has partnered with Janssen Biotech in a Phase 1 study testing VE202 as a treatment for inflammatory bowel disease. [Frank Vinluan, xconomy.com, Dec 24, 18]

Vedanta Biosciences (Cambridge, MA; no SBIR) an affiliate of PureTech Health developing a new category of therapies for immune and infectious diseases based on rationally designed consortia of human microbiome-derived bacteria, announced that it has exclusively sub-licensed key intellectual property from JSR Corporation (Japan) to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics. These live biotherapeutics have been shown to activate CD8+ T cells, a type of white blood cell that is the predominant effector in cancer immunotherapy. The sub-licensed intellectual property is based on the pioneering research of Dr. Kenya Honda, Professor, of Keio University School of Medicine and his collaborators in the University of Tokyo in Japan. An IND filing for the lead product candidate is planned in 2018. [company press release, Nov 1, 17]

Vedanta Biosciences (Cambridge, MA; no SBIR) raised $50 million with plans to take advance a number of drugs—precise cocktails of bacteria—into clinical testing. Formed by company creator PureTech Health six years ago, Vedanta is trying to understand the relationship between the microbiome and human disease. ... Vedanta’s first candidate is VE-202, for inflammatory bowel disease, and should begin its first trial in the first half of next year, according Olle. Johnson & Johnson, which inked a $339 million licensing deal with Vedanta in 2015, will be in charge of VE-202 development. [Ben Fidler, xconomy.com, Jun 6, 16]

Janssen Biotech (sub of Johnson&Johnson) entered into a licensing agreement for an experimental inflammatory bowel disease treatment under development by Vedanta Biosciences (Boston, MA; no SBIR, founded 2010). ... for the rights to the new microbiome drug candidate called VE202. The human microbiome contains trillions of microorganisms that live in a person's gut, skin and other body parts. [John George, Philadelphia Business Journal, Jan 13, 15] pioneering development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta’s proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes [Vedanta website]

Johnson & Johnson cuts the ribbon on its Boston Innovation Center, the latest step in a broad initiative by the drug giant to help drive biotech innovation in certain life sciences hotspots around the globe—and strike deals t to fatten up its pipeline. Within the past three months, J&J has opened similar innovation centers in London and Menlo Park, CA, and plans to christen a fourth in Shanghai ..... announcing partnerships with a research center (Icahn School of Medicine at Mount Sinai in New York), two local startup biotech companies (Rodin Therapeutics (Cambridge, MA; no SBIR) and Vedanta Biosciences (Boston, MA; no SBIR)), and a non-profit organization (LabCentral), showing the breadth of exactly what it hopes to achieve. [Ben Fidler, xconomy.com, Jun 27, 13]

venture capital firm PureTech Ventures is launching a new company Vedanta Biosciences ... a spin-off from PureTech’s Libra BioSciences (no SBIR), a stealthy entity set up to explore commercialization opportunities in the biogenome field. . Incubated in PureTech’s Boston offices, ... aims to commercialize research newly published today in the academic journal Science that indicates beneficial, gut-dwelling bacteria may also be useful for combating allergies and inflammatory bowel disease (IBD). [Galen Moore, Mass High Tech, Dec 23, 10]

Vedere Bio (Cambridge,MA)

Vedere Bio (Cambridge, MA; no SBIR) stealthy startup focused on restoring functional vision from blindness, was acquired by Novartis for $150M upfront. The startup will be eligible for up to $130M in milestone payments, for a total of $280M. [BostInno,Oct 30, 20]

Veeva Systems (Pleasanton, CA)

The research firm CB Insights recently put together its list of the 15 tech companies that had the best "exits" in 2013 — that is, they delivered the richest return for their investors, whether they were acquired or went public. Topping the list was Veeva Systems (no SBIR), for example, which raised just $4 million of funding and was worth more than $4 billion after its initial public offering. [Scott Kirsner, Boston Globe, Dec 17, 13]. all fifteen are info-tech'ers.

Veeva Systems (Pleasanton, CA; no SBIR) raised nearly twice as much money as expected in a wildly successful IPO this week in which it raised $261 million and its stock jumped more than 80 percent. But it didn't get there by following the crowd. The software company rode two hot sectors — life sciences and the cloud — and it grew to a valuation of more than $4.4 billion by bucking a couple of popular startup strategies. .... Veeva raised a total of only $7 million in outside capital ... The secret to Veeva's success was targeting a single industry and delivering its product in the cloud, he said. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 16, 13] It's a lot easier to raise capital when the only unknown is whether the technology will sell, not whether it will work.

Veezyon

Los Alamos National Laboratory has approved $250,000 in new funding for four companies from its Venture Acceleration Fund [which] provides investments of up to $100,000 to regional entrepreneurs, companies, investors or strategic partners who use LANL technology or expertise to create or grow regional businesses. Award recipients are chosen based on potential for regional impact, team composition, technical feasibility, market opportunity, and the availability of matching funds or in-kind contributions. Retriever Technology (Santa Fe, NM; no SBIR) will receive $25,000 to upgrade a low-light imaging camera for advanced digital imaging into a more user-friendly and functional form for customer demonstration and evaluation. Elemetric Instruments (Los Alamos, NM; no SBIR) will get $100,000 to further develop a prototype of an instrument that immediately detects elements in liquids and gases with continuous online, real-time processing. The device, called an element presence detector, is based on LANL technology with potential markets among food and pharmaceutical makers. STAR Cryoelectronics (Santa Fe, NM; $2M SBIR) will get $75,000 to accelerate development of a high-resolution alpha particle spectrometer to be used in nuclear forensics and nuclear nonproliferation work. Veezyon (somewhere, NM; no SBIR)will receive $50,000 to improve the technical capabilities of its Veezyon.com Web site — a knowledge-based online video site focusing on shared interest user collaboration. Since the venture fund was launched in fall 2006, LANL has awarded about $600,000 to six companies, not including the new grants, [New Mexico Business Weekly, Jan 7, 09]

VeinAid

The Massachusetts Medical Device Development Center reported providing “fast-lane” funding last week to two early-stage companies, MedicaMetrix (Wayland, MA; no SBIR) and VeinAid LLC (Fairfield, CT; no SBIR). MedicaMatrix, founded by Christopher LaFarge, makes the “ProstaGlove,” a disposable glove, with an embedded sensor, used to measure quantitative prostate volume. In addition to funding, the company received clinical trial help and materials development from M2D2. VeinAid, launched by Thomas Kottler, helps relieve varicose vein-associated pain and circulatory issues with its medical device applied externally. The M2D2 funds will aid marketing efforts of the device and assist with venture capital access and mold development. [Mass High Tech, Nov 26, 08]

Velano Vascular (Philadelphia, PA)

Velano Vascular (San Francisco, CA and Philadelphia, PA; no SBIR*) a medical device company said that it raised another $3.5 million [of a $5M Series A] for its needle-free blood draw device, to further develop and commercialize the device. ... A new iteration of the Velano device, which is designed to reduce the number of blood draws for hospitalized patients by temporarily re-purposing peripheral intravenous catheters, won 510(k) clearance from the FDA last month [BRAD PERRIELLO, massdevice.com, Feb 11, 16] *SBA's SBIR database suffers from periodic attention deficit

Velano Vascular (Philadelphia, PA and San Francisco, CA; no SBIR) announced that it raised $5 million in Series A funding. ... is just starting to come out of the woodwork, has created a needle-free method for drawing blood from hospitalized patients, ultimately "bringing compassion into care," said its co-founder and CEO Eric Stone. Stone founded the company with Pitou Devgon, who invented Velano's technology. [Lauren Hertzler, Philadelphia Business Journal, Feb 5, 15]

First Round Capital and PIDC announced a combined $400,000 seed investment in Velano Vascular (Philadelphia, PA; no SBIR), an innovative medical device company, which has pioneered a needle-free method for drawing blood from hospitalized patients ... the StartUp PHL Angel Fund co-invests alongside angel investors to help very early-stage companies build a minimum viable product or validate key assumptions. [startupphl.com, Nov 12, 14]

Velicept Therapeutic (Malvern, PA)

Velicept Therapeutics (Malvern, PA; no SBIR, founded 2015) with potential treatment for overactive bladders raises $15.5M ... lead new drug candidate was originally discovered by GlaxoSmithKline researchers. [John George, Philadelphia Business Journal, Jul 19, 18] total funding $15M [crunchbase.com]

Velicept Therapeutic (Malvern, PA; no SBIR) announced it has closed on the first tranche of a $21 million Series B financing. ... to advance the Phase II development of solabegron, a highly selective beta 3-adrenoceptor agonist for the treatment of overactive bladder (OAB). ... Solabegron was discovered and first developed by GlaxoSmithKline. It was acquired by AltheRx, which merged with Velicept in 2015 to continue the development of solabegron. [company press release, Dec 1, 15]

Velocimed

Innovative Pulmonary Solutions (Bellevue, WA; no SBIR), a stealthy medical device startup, has raised more than $10 million in venture capital and recruited a new CEO with experience selling a couple of other startups, .... sold his previous companies, Lutonix (no SBIR) and Velocimed (no SBIR), to C.R. Bard and St. Jude Medical, respectively. [Luke Timmerman, xconomy.com, Sep 20, 12]

Velomedix (Menlo Park, CA)

Velomedix (Menlo Park, CA; no SBIR) said it has closed $10.2 million in Series B funding.... specializes in treating therapeutic hypothermia, and in December disclosed in a regulatory filing it had raised $9.3 million. ... plans to use the new funds to help support commercializing its technology in the European Union and obtain FDA approval for a clinical study in the United States. [Lisa Sibley, Silicon Valley / San Jose Business Journal, Feb 8, 12]

VelosBio (San Diego, CA)

VelosBio ; no SBIR) cancer therapy developer received $58 million VC, to complete preclinical development and advance the company’s programs into clinical trials. .. developing drugs consisting of a targeting antibody linked to a drug. These antibody-drug conjugates have attracted a great deal of attention because of their potential to precisely kill cancer cells while leaving normal cells alone. [Bradley Fikes, San Diego Union Tribune, Oct 2, 18] previous funding $8M [crunchbase.com]

VenatoRX Pharma

VenatoRxPharma (Malvern, PA; at least $4.3M SBIR), a biopharmaceutical company developing next‐generation antibiotics, announced that it has raised $42 million in a Series B financing l... to advance the company’s portfolio, including lead product candidate VNRX‐5133 for multi‐drug resistant (MDR) gram‐negative infections. [company press release, Jul 25, 17] also announced that it has been awarded up to $9.4 million from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator). The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents β-lactam antibiotic resistance, but with the same safe and effective mechanism of action of β-lactams. [company press release, Jul 27, 17]

Venaxis (Castle Rock, CO)

Venaxis (Castle Rock, CO; no SBIR) medical device company, said it has acquired BiOptix Diagnostics (Boulder, CO; $250K SBIR) for $2M worth of Venaxis stock. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance (“ESPR”) technology platform for the detection of molecular interactions. ... Venaxis, Inc. is an in vitro diagnostic company which had been focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company’s rapid blood based test for appendicitis. [Venaxis press release, Sep 13, 16]

Vendormate

Georgia Tech plans to develop an incubator aimed at nurturing the next generation of medical device companies. ... part of a broader expansion by the Advanced Technology Development Center (ATDC), a 30-year-old business technology incubator that has produced several Atlanta tech companies including Suniva (no SBIR), CardioMEMS (no SBIR) and Vendormate (no SBIR). ... ATDC's plan includes opening multiple satellite offices in Midtown, where it will focus on building startups in niches, such as microelectronics fabrication, advanced manufacturing and clean tech. [Urvaksh Karkaria, Atlanta Business Chronicle, Feb 5, 15]

Veniti (Fremont CA, formerly St Louis, MO

Boston Scientific announced it has signed an agreement to acquire VENITI (Fremont, CA; no SBIR, founded 2010) which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently owns 25 percent of the company [Boston press release, Aug 13, 18] total fundung $65M [crunchbase.com]

Veniti (Fremont, CA and St Louis, MO; no SBIR, founded 2010), a leader in the advancement of treatment for deep venous disease, has closed on $25 million in Series D equity financing from Boston Scientific Corporation. ... to complete the VIRTUS Trial and regulatory filing for the VICI VENOUS STENT® System. The trial is being performed under a [FDA] Investigational Device Exemption (IDE). The company also intends to expand product development and commercial operations. [company press release, Sep 8, 16]

Veniti (St Louis, MO; no SBIR), a medical device startup, raised more than $17 million in a Series C financing round led by previous investors ... [partly] to increase Veniti's international expansion. Veniti is already commercially available in eight countries in Europe and will be available in 15 by the end of the year, Mathes said. [Brian Feldt, St. Louis Business Journal, Mar 10, 15]

Veniti (St. Louis County, MO; no SBIR, 19 employees) has received [FDA] approval for [its Vici Venous Stent System] that looks to treat venous disease. .... has raised more than $23 million to date [Brian Feldt, St. Louis Business Journal, Jul 21, 14]

Veniti (St Louis, MO; no SBIR) a medical device company, developing three products related to venous diseases, raised $10M in June. [Brian Feldt, St Louis Business Journal, Jul 19, 13]

Veniti (St Louis, MO; no SBIR) is building a portfolio of devices that address vein-related ailments, from treating varicose veins, to catching blood clots and treating venous reflux disease. .... closed a $9.72 million Series B funding round June 5. [Amir Kurtovic, St Louis Business Journal, Jun 14, 13]

Vensun Pharmaceuticals (Yardley, PA)

Vensun Pharmaceuticals (Yardley, PA; no SBIR) is seeking to raise a total $15.8 million in the round of equity financing .... to develop, with partners, a portfolio of generic prescription products in various dosage forms covering a broad range of therapeutic categories. [John George, Philadelphia Business Journal, Oct 14, 13]

VentiRx

biotechnology VentiRx (Seattle, WA; no SBIR, 15 employees) revealed it has raised $19.3 million. ... has raised a total of $50 million since opening this round of financing in 2010. ... developing immunotherapies for the treatment of cancer and inflammatory diseases. [Annie Zak, Puget Sound Business Journal, Sep 23, 14]

VentiRx Pharmaceuticals (Seattle, WA; no SBIR) biopharmaceutical working on the treatment of cancer, respiratory and inflammatory diseases, said it's signed a deal with Celgene for a cancer treatment. As part of the deal, New Jersey-based Celgene will provide $35 million for further research and development of the treatment, VTX-2337. [Puget Sound Business Journal, Oct 3, 12]

VentiRx Pharmaceuticals (San Diego, CA; no SBIR) plans to close its business and administrative headquarters in San Diego by the end of the year. ... consolidating is operations in Seattle to conserve cash and concentrate more specifically on an experimental immune-booster for cancer. [Bruce Bigelow, xconomy.com, Sep 15, 11 ]

Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008) startup developing aerosol-based treatments for respiratory diseases, said it has raised a tranched $30 million in Series A venture funding. It’s a sizable round for the [San Diego] life sciences community, but other recent fundings have come close. Last month, VentiRx (no SBIR) raised $25 million, Pfenex (no SBIR) got $24 million, and Zogenix (no SBIR) got $20 million. [Bruce Bigelow, signonsandiego.com, Mar 8, 10]

Ventria Bioscience (Junction City, KS)

The Kansas Bioscience Authority announced four grants totaling $4.85 million to help companies in the state. KC BioMediX of De Soto, VasoGenix Pharmaceuticals of Lenexa , Ventria Bioscience of Junction City ($500K SBIR), MGP Ingredients (public) of Atchison. [Kansas City Business Journal, Jul 15, 08]

Ventrix (San Diego, CA)

VentriGel, a biomaterial scaffold to help regeneration after a heart attack, is in Phase 1 trials by Ventrix (San Diego, CA; $180K SBIR). ... experimental treatment to repair damage from heart attacks is showing early signs that it may be working in people, the discoverer of the technology said. [Bradley Fikes, San Diego Union Tribune, Oct 8, 16]

Ventrus Biosciences (NYC, NY)

Ventrus Biosciences (NYC, NY; no SBIR) an early-stage pharmaceutical company that develops prescription drugs for gastrointestinal disorders, sold 2.9 million shares at the bottom of its indicated $6-to-$7 price range, making for a $17.4 million offering. None of its drugs have received U.S. regulatory approval, and its independent auditor warns that the company mightn't be able to remain in business, given its financial condition [Lynn Cowan, Wall Street Journal, Dec 18, 10]

Ventus Therapeutics (Waltham, MA)

Ventus Therapeutics (Waltham, MA; no SBIR) announced a $60 million Series A financing .. to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets. [company press release, May 6, 20]

Veracode (Burlington, MA)

Security testing company Veracode (Burlington, MA; founded 2006, no SBIR) has reported a financing agreement with investment firm In-Q-Tel that will allow Veracode grow its subscription-based application security solutions. In-Q-Tel is the venture arm of the CIA. Veracode’s security threat detection service, called SecurityReview, can find security holes from SQL injection, cross-site scripting, malicious code and buffer overflows using its static binary testing technology and never accessing a company’s source code. [Mass High-Tech, Jul 30, 08] $19.5 million in funding from lead investors. [company website]

Veracyte (South San Francisco, CA)

Veracyte (South San Francisco, CA; no SBIR, founded 2006) will get backing from Johnson & Johnson to develop a nasal swab test for the early detection of lung cancer. [Frank Vinluan, xconomy.com, Jan 4. 19]

Veracyte (South San Francisco, CA; no SBIR). said it raised $28 million in a second round of funding. ...first product launch later this year, a diagnostic test for thyroid cancer [Silicon Valley/San Jose Business Journal, Jun 9, 10]

Veralox Therapeutics (Frederick, MD)

Veralox Therapeutics (Frederick, MD; $300K SBIR, founded 2017) a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, announced it has raised a $5.4 million seed funding round. [company press release, Sep 5, 19]

Verastem (Boston, MA)

Verastem (Cambridge, MA; no SBIR) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced Wednesday the pricing of its previously announced underwritten public offering of its common stock,expected to [raise] about $51.9 million [Boston Globe, Jul 17, 13]

Verastem (Cambridge, MA; no SBIR) that is seeking to create drugs that target cancer stem cells, is scheduled to launch an IPO next week [DC Dennison, Boston Globe, Jan 20, 12]

Verastem (Cambridge, MA; no SBIR), a biotech focused on treating cancer by targeting cancer stem cells, filed intentions for an [IPO] that could raise up to $50 million. .... most recently raised a$32 million Series B round [Kyle Allspach, Boston Buasiness Journal, Nov 3, 11]

Verastem (Cambridge, MA; no SBIR) startup seeking to develop treatments against cancer stem cells, said that it has raised $32 million through a Series B financing. [Chris Reidy, Boston Globe, Jul 14, 11]

Verastem (Boston, MA; no SBIR) an early stage biotech company that aims to target cancer stem cells, has landed a $16 million Series A financing ... plans to target several cancers, including breast cancer. Verastem’s founders have developed a proprietary approach to identify drug compounds with the potential to selectively kill cancer stem cells.[Julie Donnelly, Mass High Tech, Nov 16,10]

Veran Medical Technologies (St Louis, MO)

medical device startup Veran Medical Technologies (St. Louis, MO; no SBIR), a few months removed from raising more than $41 million from investors, has been awarded two U.S. patents vital to the company’s commercial success. The patents protect the company’s 4D respiratory tracking technology that allows its SPiN Thoracic Navigation System to track a patient's respiration during navigtional procedures. [Brian Feldt, St. Louis Business Journal, Jan 4, 16]

St. Louis-based Prolog Ventures participated in a $7.4 million financing deal for New Mexico-based IntelliCyt (Albuquerque, NM; no SBIR), a provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology. ... According to CrunchBase, the IntelliCyt deal was Prolog’s fifth of 2015 — the company also participated in Veran Medical Technologies’ (no SBIR) $41.7 million round in September; Benson Hill Biosystems (no SBIR) $7.3 million deal in August; and EndoStim (no SBIR) $2.5 million funding in May. [Brian Feldt, St. Louis Business Journal, Oct 23, 15]

medical device maker Veran Medical Technologies (St Louis, MO; no SBIR) has upped its funding efforts to $41.7 million, according to [SEC filing] ... to support the company’s commercial expansion in the U.S. and international markets. ... moved to St. Louis from Nashville in 2013. To date, it’s raised more than $50 million. [Brian Feldt, St. Louis Business Journal, Oct 1, 15]

medical device company Veran Medical Technologies (St. Louis, MO; no SBIR) a leader in image-guided endobronchial and percutaneous technology for diagnosis of lung cancer and therapy delivery, has completed a $30.6 million financing [company press release, Sep 21, 15] moved to St. Louis from Nashville in 2008 after closing a $4.75 million venture capital round led by Prolog Ventures, has now raised nearly $30 million in equity and debt financing. ... has now raised nearly $30 million in equity and debt financing. [Brian Feldt, St. Louis Business Journal, Mar 26, 14]

Veran Medical Technologies (St Louis, MO, no SBIR), moved to St. Louis from Nashville in 2008, a health care technology company raised nearly $3 million in a debt offering, according to [SEC] documents .... has raised more than $20 million ...developing minimally invasive delivery of interventional oncology therapies, now has roughly 40 employees [Brian Feldt, St Louis Business Journal, Jan 15, 14]

VeraSun Energy (Brookings, SD)

IPO Juice. Ethanol is the current rage. VeraSun Energy went public after which the shares jumped 30% in first day trading.

Too Much of a Good Thing. A Florida startup has filed for a permit to build a 110 million-gallon-a-year ethanol plant in Shelby County just as the nation's largest ethanol producer said it's suspending construction of a plant in Northern Indiana [Indianapolis Star, Oct 3] Meanwhile, VeraSun Energy (Brookings, SD), ethanol producer suspended construction of a major plant in Reynolds, IN, blaming market conditions. [Wall Street Journal, Oct 3]

VerAvanti (Redmond,WA)

VerAvanti (Redmond, WA; no SBIR) startup, which is developing a camera that can see inside blood vessels, scooped up $5 million in a July funding round, but that was from friends, family and some investors, not from the venture-capital funding typical of a startup. Gerald McMorrow, VerAvanti’s founder and CEO personally put $12 million, he said. ... Cardiologists now don’t know what causes a third of all ischemic strokes — strokes from clots in the arteries that carry blood to the brain — according to McMorrow and Garrison. Doctors currently use MRIs, computerized tomography, and vascular imaging, such as intravascular ultrasound, to look for problems and causes, but the endoscope would be able to get into tiny veins and stents, areas that are usually missed by other types of imaging. .... McMorrow sold Verathon (Bothell, WA; no SBIR) to Roper Industries in 2009, reportedly for $300 million. [Scott Greenstone, Seattle Times, Sep 27, 17]

Verax Biomedical (Worcester, MA)

Verax Biomedical (Marlborough, MA; $2M SBIR) which specializes in platelet bacterial contamination detection in cells and tissues intended for transfusion and transplantation, raised $2.5M in debt, according to an SEC filing. [Srividya Kalyanaraman, BostonInno, Sep, 19, 19] prior funding $64M [crunchbase.com]

Verax Biomedical (Worcester, MA; $2M SBIR) has raised $1.3 million in an equity funding ... Founded in 1999, Verax Biomedical is developing testing technology for detecting bacterial contamination in cells and tissues meant for use in transfusion and transplantation, the company noted on its website. Verax has created its patented Pan Genera Detection (PGD) technology to use in making these bacterial contamination tests. [Michelle Lang, Mass High Tech, Mar 22, 11]

Verax Biomedical (Worcester, MA; $1M SBIR) got clearance from the U.S. Food and Drug Administration to market its test for detecting bacterial contamination in the U.S. blood supply [Mass High Tech, Sep 20, 07]

Verax Biomedical (Worcester, MA; $1M+ SBIR) asked the FDA to approve marketing its Platelet Pan Genera Detection Test for bacterial contaminants in blood. In 2006, Abbott Diagnostics signed a worldwide exclusive agreement to market and distribute the test, and British Biocell International (BBI) signed a 10-year contract to provide manufacturing. [Mass High Tech, Mar 14]

Verdezyne (previously known as CODA Genomics (Carlsbad, CA)

Verdezyne (Carlsbad, CA, $1.7M SBIR) which is developing gene libraries for use in industrial biology, has raised $6.3 million of a targeted $15 million equity round ... has initially focused on developing renewable technologies for making adipic acid, a key feedstock chemical used to make nylon [Bruce Bigelow, signonsandiego.com, Dec 1, 10]

Verdezyne, previously known as CODA Genomics (Carlsbad, CA; $700K SBIR) which just disclosed a $1.7 million government grant, has raised nearly $3 million of a planned $15.2 million round of venture capital, according to a regulatory filing ... developing genetic engineering techniques and processes for producing industrial chemicals and fuels from microbes [Xconomy.com, Oct 30, 09]

Verdox (Winchester, MA)

Verdox (Winchester, MA; $1M SBIR) Carbon Removal. MIT Chemical Engineers Are Cracking the Carbon Removal Challenge. First developed at MIT, the technology enabled by Verdox enables a flow of air or flue gas (blue) containing carbon dioxide (red) to enter the system from the left. As it passes between thin battery electrode plates, carbon dioxide attaches to the charged plates while the cleaned airstream passes on through and exits at the right. Verdox, founded by MIT chemical engineers and winner of an XPRIZE Carbon Removal milestone award, is working to move the needle on climate change. By most benchmarks, MIT chemical engineering spinoff Verdox has been enjoying an outstanding year. Launched in 2019, the carbon capture and removal startup announced $80 million in funding in February from a group of investors that included Bill Gates’ Breakthrough Energy Ventures. Then, in April — after being recognized by Bloomberg New Energy Finance as one of the year’s top energy pioneers — the company and partner Carbfix won a $1 million XPRIZE Carbon Removal milestone award. This was the first round in the Musk Foundation’s four-year, $100 million competition, which is the largest prize offered in history. [Leda Zimmerman, MIT Department of Chemical Engineering, October 5, 2022]

Verenium (Cambridge, MA)

Cellulosic biofuels technology developer Verenium (no SBIR) is one of two companies slated to receive part of a $40 million grant aimed at fostering the development of small-scale ethanol plants announced today by the DOE. [Mass High Tech, Jul 16]

Verenium (Cambridge, MA; no SBIR) is starting up a research ethanol plant that runs on agricultural waste and wood products instead of corn. The demonstration-scale plant in Jennings, LA., is designed to run on cellulosic feedstocks such as stems and leaves, which are also known as "nonfood biomass," the alternative energy company said. [Boston Globe, May 28]

Vergent Bioscience (Minneapolis, MN)

Vergent Bioscience (Minneapolis, MN; no SBIR, founded 2014), a biotech startup that aims to make it easier for physicians to see cancerous tissue during surgery, raised $8.7 million to fund clinical trials. ... developing a molecularly-targeted probe that binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye. [company press release., Jun 12, 18] total fundong $9M [crunchbase.com]

Vergent Bioscience (Minneapolis, MN; no SBIR, founded 2014) announced it raised $8.7 million in a Series A financing to fund its preclinical and clinical development activities developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. [company press release, Jun 12, 18] came out of stealth mode [Brad Perriello, www.massdevice.com]

Vericel (formerly Aastrom Biosciences,Cambridge, MA)

cell therapy firm Vericel (Cambridge, MA; no SBIR) has forged a $142M deal to license a gel used to help heal burns. The gel uses enzymes to remove burned tissue, with around 93% of subjects experiencing complete removal of the damaged tissue in a Phase 3 clinical trial.

Shares of Vericel (formerly Aastrom Biosciences, Cambridge, MA; $6M SBIR), fell more than 38 percent after some new data emerged from a mid-stage study of its experimental cell therapy for heart failure, known as Ixmyelocel-T. The data, published in the peer reviewed journal The Lancet, showed that Vericel’s treatment missed some secondary goals in its trial. Aastrom changed its name to Vericel after acquiring some cell therapy and regenerative medicine products from Sanofi in 2014. [Ben Fidler, xconomy.com, Apr 8, 16]

Verifica-BG (Lexington, MA)

Khosla Ventures has seeded Verifica-BG (Lexington, MA; no SBIR) startup with $850,000 to develop a spectroscopic medical device related to metabolic diseases.... part of a planned $1.7 round of equity financing, according to [SEC filing]. [Mass High Tech, Apr 21, 10]

Verinata Health

Illumina will buy prenatal test company Verinata Health (no SBIR) for $350 million and up to $100 million in milestone payments through 2015, the companies said [Ron Leuty, San Francisco Business Times, Jan 6,13]

Veritas Genetics (Boston, MA)

Veritas Genetics (Boston, MA; no SBIR), which sells genome sequencing and genetic screening tests, has received a $30 million Series B round of funding to add more products, build out its digital tools for consumers, and ink partnerships with hospitals and researchers around the world. ... For $999 a pop, Veritas sequences whole genomes using machines made by Illumina, and then delivers health insights that can be viewed on a smartphone or computer. [David Holley, xconomy.com, Oct 17, 16]

For the first time, consumers can get their entire genome sequenced and analyzed for less than $1,000, a service that could reveal possible medical threats and help people to live healthier lives. But the $999 program introduced by Veritas Genetics (Boston, MA; no SBIR) is raising questions about whether consumers can grasp and deal with disturbing news that comes from a genetics company. There’s also debate about whether companies like Veritas and San Diego’s Illumina are doing the right thing in requiring customers to get a doctor’s approval for whole-genome sequencing. [Gary Robbins, San Diego Union Tribune, Mar 4, 16]

Vermillion (Austin, TX)

Vermillion (Austin, TX; no SBIR, 30 employees) wants to raise $15 million to fund its cancer test commercialization efforts and expand its portfolio. ... health diagnostics company focused on tests for ovarian cancer. [Greg Barr, Austin Business Journal, Jul 14, 15]

Vermillion (Austin, TX; no SBIR) health diagnostics company specializing in tests for ovarian cancer, has received a $7.5 million grant from the Cancer Prevention and Research Institute of Texas. ... to fund development and validation of a test to asses the presence and health risk of cases of ovarian cancer. [Chad Swiatecki, Austin Business Journal, May 20, 15]

Vermillion (Austin, TX; no SBIR) announced that it has secured $10.5 million in new capital from a group of investment firms and company directors — and they have the option to purchase more shares of the struggling biotech company in mid-2015. ... has pinned most of its business prospects on the OVA1 screening test for ovarian cancer [Chad Swiatecki, Austin Business Journal, Dec 23, 14]

Vermillion (Austin, TX; no SBIR) a multivariate diagnostics company focused on gynecologic cancers and women's health, announced that Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and certain other investors have exercised warrants to purchase 12.1 million shares of Vermillion common stock at an exercise price of $1.46 per share. .... The company's lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. [company press release]

Vermont Composites (Bennington, VT)

Kaman has agreed to buy Vermont Composites (Bennington, VT; no SBIR; founded in 1979, 230 employees and sales of about $32 million this year, ) a maker of composite aerospace components and medical equipment ... products are in several high-profile milirary aircraft, including the the C-130 Hercules transport plane and the Black Hawk helicopter, as well as various unmanned aircraft. [Hartford Courant, Nov 3, 11]

Veros Systems (College Station, TX)

Veros Systems (Austin, TX; $700K SBIR, founded 2001) completed an $8 million Series A round of funding. ... develops software that monitors electric motors and driven assets to detect faults. [Christopher Calnan, Austin Business Journal, Sep 23, 13] In 2006, Veros secured an exclusive worldwide license from Texas A&M University to commercialize technology developed by Dr. Parlos [company website]

Veros Systems (College Station, TX; $700K SBIR), which has developed an industrial monitoring system for large motors, that has commercialized technology from Texas A&M University is moving its headquarters to Austin after raising $5 million from two Austin-based venture capital firms. [Lori Hawkins, Austin American Statesman, Jul 16, 13]

Verrica Pharmaceuticals (West Chester, PA)

Verrica Pharmaceuticals (West Chester, PA; no SBIR, founded 2013) clinical-stage medical dermatology company prices its [IPO] for gross proceeds of $75M. [seekingalpha.com. Jun 7, 18] total funding $2.4M [crunchbase.com]

Versar (Springfield, VA)

Versar up 65% [Oct 15, 14]

Versar (Springfield, VA; $500K SBIR) up 17% [Oct 14, 14] operates as a project management company [Wall Street Journal] [in July 2014] awarded an Iraq Personal Services II contract from the U.S. Army Corps of Engineers (USACE), with a maximum contract value of $10.69 million

Versartis (Mountain View, CA)

Versartis (Menlo Park, CA; no SBIR, 59 employees) down 88% [Sep 22, 17], an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that the VELOCITY Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (GHD) did not meet its primary endpoint of non-inferiority. [press release, Sep 21, 17]

Versartis soars 48 percent after raking in $126 million in IPO; [San Jose Mercury News, Mar 21, 14]

Versartis (Redwood City, CA; no SBIR) filed plans to raise up to $80 million in an IPO on Tuesday, the same day that it announced it had raised $55 million in new venture funding [to help it develop its treatment for growth hormone deficiency]. [Cromwell Schubarth, Silicon Valley Business Journal, Feb 19, 14]

Versartis (Redwood City, CA; no SBIR) raised $20 million in new funding that it said will be used to prepare for an international trial on children of a treatment for growth hormone deficiency. .... has raised more than $60 million in total, with $45 million in this year alone. Versartis said it needs the money to prepare for an international Phase 3 pediatric trial of VRS-317, the company's proprietary long-acting recombinant human growth hormone for the treatment of growth hormone deficiency in pre-puberty children. The tests are being conducted at 30 sites in the U.S. after successful tests on adults. [Cromwell Schubarth, Silicon Valley Business Journal, Oct 8, 13]

Versartis (Redwood City, CA; no SBIR) has raised $20 million in a Series D round of financing that will help fund a Phase 3 trial of a treatment for growth hormone deficiency. ..... brings the total raised by the company to $60 million .... developing treatments for endocrine disorders [John Sailors, San Francisco Business Times, Oct 8, 13]

Biotech drug developer Versartis (Redwood City, CA; no SBIR) raised $25 million in a Series C funding round. ... to fund clinical trials of VRS-317, its experimental, once-a-month form of recombinant human growth hormone to treat growth hormone deficiency in children. [Ron Leuty, San Francisco Business Times, Jan 15, 13]

Versartis (Mountain View, CA; no SBIR) completed a $21 million second round of funding, the company said ... biotechnology startup developing therapeutics for patients with endocrine disorders. ... to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency in adult and pediatric patients. [John Sailors, San Francisco Business Times, Feb 16, 11]

Versatope (Lowell, MA)

Intravacc (Netherlands), one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines and Versatope (Lowell, MA; $1.1M SBIR) developing vaccines and therapeutics, announced that they have signed a research service agreement to further develop a universal vaccine against influenza based on Intravacc's innovative Outer Membrane Vesicles (OMV) technology. Both parties will collaborate to further advance the candidate vaccine through clinical development. signed a research service agreement to further develop a universal vaccine against influenza. Intravacc will provide its services to Versatope in bringing their universal influenza vaccine candidate, VT-105, towards their first clinical trials. [joint press release, Jun 8, 20]

Verseau Therapeutics (Bedford, MA)

Verseau Therapeutics (Bedford, MA; no SBIR) launched with $50 million in financing [to develop] novel, first-in-class immunotherapies that target modulation of macrophages, the master orchestrators of the immune system. ... will support advancement of Verseau’s macrophage checkpoint modulator (MCM) programs to the clinic. [company press release, Oct 21, 19]

VerteCore (Natchez, MS)

The Accelerate Michigan Innovation Competition, hosted by Invest Detroit’s ID Ventures on Nov. 13, announced the 2018 winners selected from a field of 300 applicants. The $500,000 grand prize was VerteCore (Natchez, MS; no SBIR) that makes a wearable device designed to elongate the spinal column and reduce back pain. Second prize and $100,000 went to GreenMark Biomedical (East Lansing, MI; no SBIR) which is developing products using biopolymer nanoparticles produced from natural starch for the medical and dental fields. [Sarah Schmid Stevenson, xconomy.com, Nov 20, 18]

Vertera Spine (Atlanta, GA, at least one SBIR) raised more than $3 million, according to [SEC] documents [Ellie Hensley, Atlanta Business Chronicle, May 31, 17] to address the unmet clinical need for improved spinal fusion solutions by developing and commercializing fusion devices using patented porous PEEK technology. [company website]

Vertex Pharmaceuticals

Vertex Pharmaceuticals and RNA therapeutics developer Ribometrix (Durham, NC; $500K SBIR) announced that the companies have entered into a strategic collaboration to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. The collaboration will combine Ribometrix’s proprietary discovery platform for identifying and optimizing small molecule therapeutics that modulate RNA function by targeting three-dimensional (3D) RNA structures with Vertex’s scientific, clinical and regulatory capabilities for up to three therapeutic programs, including one ongoing discovery program from Ribometrix. [joint companies press release, Sep 30, 19]

Vertex Pharmaceuticals is acquiring Semma Therapeutics (Cambridge, MA; no SBIR) for $950M to advance its diabetes treatment portfolio [Rowan Walrath, BostInno, Oct 2, 19]

Vertex Pharmaceuticals announced a definitive agreement under which Vertex will acquire Semma Therapeutics (Cambridge, MA; no SBIR), pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950 million in cash. [Vertex press release, Sep 3, 19]

biotech giant Vertex Pharmaceuticals’ plans to acquire preclinical gene editing startup Exonics Therapeutics (Cambridge, MA; no SBIR, founded 2017) for $245M. [BostonInno, Jul 2, 19] total funding about $45M [crunchbase.com]

Vertex Pharmaceuticals ($1M SBIR) is committing $420 million in a pair of deals that expand the company’s research scope to experimental genetic treatments for two forms of muscular dystrophy. Vertex announced that it reached an agreement to pay $245 million up front to acquire Exonics Therapeutics (Watertown, MA; no SBIR, prior funding $45M [crunchbase.com]), using gene editing techniques to develop a treatment for Duchenne muscular dystrophy and myotonic dystrophy type 1. Vertex also said it is paying CRISPR Therapeutics (Swiss) $175 M to expand an existing research collaboration to include Duchenne and myotonic dystrophy type 1. [Frank Vinluan, xconomy.com, Jun 7, 19]

Vertex Pharmaceuticals is paying $70 million upfront to work with Kymera Therapeutics on the discovery of drugs that drive the elimination of disease-causing proteins. The early-stage deal features more than $1 billion in milestones tied to the success of six programs. [Nick Paul Taylor, Fierce Biotech, May 15, 19]

Vertex Pharma has regained limited rights to two DNA-dependent protein kinase (DNA-PK) inhibitors from Merck KGaA. Merck licensed the drugs and other assets for $230 million upfront two years ago but has now granted Vertex the right to use them in certain gene-editing applications. [Nick Paul Taylor, Fierce Biotech, Jan 23, 19]

Vertex Pharma said that a cocktail of three of its cystic fibrosis drugs succeeded in two late-stage studies, bolstering the company’s chances to potentially offer a treatment that addresses up to 90 percent of patients who have the debilitating lung disease. Vertex said the data could support the filing of an FDA approval application. [Frank Vinluan, xconomy.com, Nov 27, 18]

Vertex Pharma halted development of VX-210 after a phase 2b acute spinal cord injury trial failed an interim analysis. The lack of efficacy seen in the phase 2b is another, potentially terminal, blow to the prospects of the Rho inhibitor. [Nick Paul Taylor, Fierce Biotech, Oct 25, 18]

The FDA lifted a clinical hold it placed on Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited stem cell therapy for sickle cell disease. The companies are on track to start a human study in sickle cell by the end of the year. [Amirah Al Idrus, Fierce Biotech, Oct 10, 18]

CRISPR Therapeutics and Vertex Pharmaceuticals are the first companies to sponsor a human trial of the gene editing technology. The trial will take place at a single site in Germany and will test a gene therapy in patients with beta-thalassemia. [Amirah Al Idrus, Fierce Biotech, Aug 31, 18]

Vertex Pharmaceuticals invested about $12 million in U.K. biotech Genomics plc as part of a deal to discover drug targets for precision medicines. [Alex Lash, xconomy.com, Aug 31, 18]

Vertex Pharmaceuticals opens expanded San Diego research center with focus on cystic fibrosis. [San Diego Union Tribune, Jun 18, 18]

Data released looks to have eased a potential threat to Vertex Pharmaceuticals’ burgeoning cystic fibrosis franchise,[as] Proteostasis Therapeutics released data from a 49-patient Phase 1 study testing its experimental cystic fibrosis drug, PTI-801, in combination with Vertex’s FDA-approved CF drug ivacaftor/lumacaftor (Orkambi). Proteostasis pointed to statistically significant changes [that] didn’t lead to a statistically significant improvement in lung function—the gold standard for a CF drug’s effectiveness—over Orkambi and a placebo [Ben Fidler, xconomy.com, Jun 7, 18]

The FDA has approved a new Vertex Pharmaceuticals cystic fibrosis drug, clearing the way for the Boston company to bring to the market its third treatment for the inherited disorder. The new Vertex drug pairs the already approved ivacaftor (Kalydeco) with the newly approved drug tezacaftor. Vertex set a list price for its ivacaftor/tezacaftor (Symdeko) combination at $292,000 per year. [Frank Vinluan, xconomy.com, Feb 12, 18]

Vertex Pharmaceuticals bet big on gene editing in 2015, when it poured $105 million into a research collaboration with CRISPR Therapeutics (Swiss). Now, Vertex is licensing the first CRISPR-based treatment to come out of the deal: a candidate targeting beta-thalassemia and sickle cell disease. [Amirah Al Idrus, Fierce Biotch, Dec 12, 17]

Vertex Pharmaceutical could see its annual revenue increase by more than $150 million following an FDA decision that will allow hundreds of new patients to use its cystic fibrosis drug Kalydeco, according to one analyst. [Max Stendahl, Boston Business Journal, Aug 2, 17]

Vertex Pharma up 21% [Jul 19, 17] announced that studies of three experimental drug combinations all reported notable improvement in patients who have a different underlying genetic pattern than patients already eligible for current commercial products. If all plays out well, up to 90 percent of people with CF could have a drug to treat their disease in a few years. [Alex Lash, xconomy.com, Jul 18, 17]

Vertex Pharma up 20% [Mar 29, 17]

Vertex Pharmaceuticalssaid it would seek regulatory approval for one of its experimental cystic-fibrosis drugs after the treatment helped improve patients’ lung function in late-stage studies. The drug, a combination of the compounds tezacaftor and ivacaftor, is intended to treat patients who have one or two copies of a genetic mutation that is the most common cause of cystic fibrosis, a progressive lung disease that affects about 30,000 people in the U.S. [Joseph Walker, Wall Street Journal, Mar 28, 17]

Concert Pharmaceuticals (Lexington, MA; no SBIR) up 62% [Mar 6, 17] has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a threat to Vertex Pharmaceuticals (Boston, MA; $1M SBIR 25 years ago). So rather than wait to find out, Vertex paid $160 million in cash, up front, to bring the drug in house. ... acquired CTP-656, a CF drug currently in Phase 2 testing, from Concert. Vertex could pay Concert another $90 million in downstream payments if the drug progresses and eventually hits the market in the U.S. and other countries. [Ben Fidler, xconomy.com, Mar 6, 17]

Vertex Pharmaceuticals (Boston, MA; $1M SBIR in early 1990s) is unloading a group of ancillary research programs in its portfolio, announcing today it will out-license the potential cancer treatments to Merck .. for $230 million up front [David Holley,xconomy.com, Jan 11, 17]

Vertex Pharmaceuticals lowered full-year revenue predictions for its newest cystic fibrosis drug, effectively confirming fears investors first had a couple of weeks ago following comments by Vertex executives at a conference. [Don Seiffert, Boston Business Journal, Sep 29, 16]

Moderna (Cambridge, MA; no SBIR) is announcing a collaboration with Vertex Pharmaceuticals (Boston, MA: $1M SBIR), a top maker of drugs for cystic fibrosis (CF). The companies say they will use Moderna’s messenger RNA technology to discover and develop a new CF therapy that addresses the underlying cause of the disease. CF stems from a genetic mutation that leaves lungs and other organs unable to produce a protein that is key to maintaining their health and function. [Frank Vinluan, xconomy.com, Jul 6, 16]

Vertex Pharmaceuticals continued its rollout of the combination cystic fibrosis treatment ivacaftor/lumacaftor (Orkambi), winning approval to sell the drug in Australia. Ivacaftor/lumacaftor is already approved in the U.S. and Europe. [Ben Fidler, xconomy.com, Mar 10, 16]

Vertex Pharmaceuticals ($1M SBIR) unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis (Durham, NC; $2.6M SBIR, 14 employees) start-up with no products on the market, has signed the biggest deal in its 16-year history: a licensing agreement worth up to $1.17 billion with Vertex Pharmaceuticals. ... will collaborate to develop an inhaler that stimulates hydration and clears out the sticky mucus clogging the lungs of cystic fibrosis patients. Under the deal, privately-owned Parion will receive an up-front payment of $80 million and nearly $1.1 billion in milestone payments for development of the drug for cystic fibrosis and other pulmonary conditions. [John Murawski, Raleigh News & Observer, Jun 5, 15]

Vertex Pharmaceuticals ($1M SBIR) unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company reach to the most common form of genetic mutation responsible for cystic fibrosis The two Vertex Pharmaceutical ($1M SBIR) buildings on Fan Pier have sold for $1.125 billion, the Boston Business Journal reported. [May 7, 14]

James C. Mullen avoiding any mention of his recent decision to step down from the company’s top post - the mood was generally upbeat. ... companies have been raising more money in follow-on offerings than any time in the past decade, about $6 billion in 2009 ... Another huge market opportunity lies in a drug being developed by Vertex Pharmaceuticals to treat hepatitis C, a largely untreated virus estimated to affect about 3 million Americans and 100 million people globally. “We’re doing a lot to raise awareness of this disease,’’ said new Vertex chief Matthew Emmens. [Robert Weisman, Boston Globe, Jan 14, 10] from the 28th annual J.P. Morgan Healthcare Conference in San Francisco

VeruTEK Technologies (Bloomfield, CT)

VeruTEK Technologies (Bloomfield, CT; no SBIR) sold $2M of stock and warrants. a forward-looking, high-technology, science-driven company, developing innovative, breakthrough, and practical solutions for the tens of thousands of contaminated sites, the result of a legacy of 200 years of industrialization. [company website]

Verve Therapeutic (Cambridge, MA)

Verve Therapeutics (Cambridge, MA; no SBIR, founded 2018) a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, today announced it has raised $63 million in a Series A2 financing [to] use the genetic mutation and the gene editing technology CRISPR to turn off eight genes linked to high cholesterol. [company press release, Jun 11, 20]

Verve Therapeutics (Cambridge, MA; no SBIR, founded 2019), a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, announced it has raised $63 million in a Series A2 financing [to] advance its lead program through IND-enabling studies and fuel follow-on pipeline programs. ... has raised a total of $123M [company press release, Jun 11, 20]

Backed by $58.5 million venture cash, new startup Verve Therapeutics (Cambridge, MA; no SBIR)’s big idea is to use gene editing to give people DNA mutations that have been found to protect the heart health of the people born with them. [Alex Lash, xconomy.com, May 7, 19]

Vesigen Therapeutics (Cambridge, MA)

Vesigen Therapeutics (Cambridge, MA; no SBIR) is developing technology that could best other [cell or gene therapy] approaches at penetrating the cellular membrane, and it launched with $28.5 million to advance its research. [Frank Vinluan, xconomy.com, Jul 22, 20]

Vesper Medical (Wayne. PA)

Vesper Medical (Wayne. PA; no SBIR, founded 2016) a developer of medical devices for minimally invasive peripheral vascular procedures, announced that it completed its Series A financing totaling $10.5 million [to] to complete the development of its Vesper Duo Venous Stent System™ inclusive of the in vivo testing necessary to obtain the approvals required for clinical testing of the Vesper Duo™ stents. [company press release, May 11, 18] total funding $20M [crunchbase.com]

Vestagen Technical Textiles (Orlando, FL)

Vestagen Technical Textiles (Orlando, FL; no SBIR) secured $8.25 million in financing, .... develops and markets advanced performance textile products and technologies, according to a release, including scrubs for health care workers that don’t absorb liquids. [Abraham Aboraya, Orlando Business Journal, Aug 27, 13]

Vestaron (Kalamazoo, MI)

Money for science, again. Vestaron (Kalamazoo, MI; no SBIR, founded 2001) makes an eco-friendly pesticide derived from spider venom. Bagaveev (San Mateo, CA; no SBIR) uses 3-D printers to make rocket engines for nanosatellites. ... raised just $535,000 in seed funding in April from a group of investors to develop reusable launchers that can send a satellite weighing up to 22 pounds into space ... Transatomic Power (Cambridge, MA; no SBIR,founded in 2011 by [MIT] nuclear scientists ) is developing a next-generation [small-scale molten-salt reactors] that could generate reliable, clean energy without creating nuclear waste.reactor. [All] have one money from Silicon Valley [VCs]. .... After years of shying away from science, engineering and clean-technology start-ups, investors are beginning to take an interest in them again, [with] a sense that the field of consumer Internet companies has become impossibly crowded. [HIROKO TABUCHI , New York Times, OCT. 12, 2014]

Vextec (Brentwood, TN)

Vextec (Brentwood, TN; $10M DOD SBIR) can predict with scary accuracy how and when products will fail--before they're made. ... No.1 on FORBES' new list of America's Most Promising Companies ... has raised nearly $20 million, mostly through similar grants awarded by various U.S. federal agencies. [founders] still own 100% of the company, now with 28 employees. ... $3 million in sales in 2008 and has been profitable since its first year in business. [Maureen Farrell, Forbes, Oct 5, 09]

VGo Communications (Nashua, NH)

VGo Communications (Nashua, NH; no SBIR) secured another round of funding. The maker of telepresence robotics products received $882,159 in debt financing .... founded by former iRobot Corp. executives ... Its first product, launched in 2011, is used by doctors and nurses who use VGo to monitor and consult with patients in the hospital. ... founded in 2007, has secured nearly $11 million [Patricia Resende, Mass High Tech, Nov 8, 12]

V-Glass (Milwaukee, WI)

Seven [Wisconsin] companies each will receive a $75,000 grant under a new program aimed at helping them commercialize their products. The first-ever grants are being distributed by a program called SBIR Advance. ... with $1 million from the Wisconsin Economic Development Corp. and administered by the UW-Extension Center for Technology Commercialization. All of the companies have already received [SBIR or STTR]. But they aren't able to use those funds for activities like patent work and customer development and validation. receiving the grants are: C-Motive Technologies (Madison, WI; one SBIR) Isthmus Biosciences (Madison, WI; one SBIR); Nutrient Recovery and Upcycling LLC (Madison, WI; one SBIR); Pan Genome Systems (Madison, WI; one SBIR); V-Glass LLC (Milwaukee, WI; one SBIR); Fiberstar Bio-Ingredient Technologies (Eau Claire,WI; one SBIR); Medical Cyberworlds (Verona, WI; $600K SBIR). [Kathleen Gallagher, Milwaukee Journal Sentinel. Sep 25, 14]

The vacuum-insulated window glass designed by the founder and chief executive officer of V-Glass (Pewaukee, WI; no SBIR, founded 2008) won the advanced manufacturing category in the 2013 Wisconsin Governor's Business Plan Contest last month. .... Vacuum glazing on window glass isn't new. Japanese glass manufacturer Nippon Sheet Glass offers a product called Spacia vacuum glazing, but it's four times as expensive as traditional window glass, it can crack in cold-weather climates and offers only half the insulating value of V-Glass, according to Petit. [Christopher Doyle, Milwaukee Journal Sentinel, Jul 15, 13]

VGBioCogCubed (Minneapolis, MN)

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center. Featured will be: (Rochester, MN; no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care. VGBioCogCubed (Minneapolis, MN; no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN; no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information. [James Walsh, Minneapolis Star Tribune, Sep 25]

VGX Pharmaceuticals

Inovio Pharmaceuticals (originally Genetronics, Plymouth Meeting, PA; no SBIR, market cap $366M ) announced that [it] is collaborating with The Wistar Institute to advance two novel SynCon® vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4.6 million in total grants from the Bill & Melinda Gates Foundation and [NIH]. [company press release, Feb 12, 18] received awarded an appropriation of approximately $1 million by the United States Department of Defense for the development of its gene delivery electroporation technology for application to vaccination against infectious diseases, including potential bioterrorism agents. [company press release, Sep 13, 2005] receive an appropriation of $1.1 million from the United States Department of Defense to develop applications of its electroporation-based gene delivery technology for vaccination against infectious diseases [company press release, Oct 19, 2006] contract is for $1.9 Million over 12 months. Under the contract, VGX will demonstrate in vivo efficacy of novel vaccines derived from DNA plasmid-based pox virus antigens delivered using a skin micro-electroporation system. [company press release, Sep 10, 2007] a contract for $933,000 from the Department of Defense (US Army) to continue research and development of DNA-based vaccines delivered via its proprietary electroporation system [company press release, Sep 23, 2008] merged with VGX Pharmaceuticals July 2008 ... contract, titled “Development of Improved DNA Vaccines and Electroporation Delivery Devices for Prophylactic HIV Vaccines”, provides [VGX Pharma] $23.5 million of funding over seven years [company press release, Oct 1, 2008] sold $30M in shares Oct 2009 .... a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation. [company press release, Apr 10, 2013] ... Closes $63.3 Million Underwritten Financing March 2014 ... raised $15M in common stock March 2013 ... Closes $87.4 Million Underwritten Financing May 2015 .... Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus Dec 2016 .. raised $75M in pubic offering July 2017 ... reported quarterly net loss of $34M in Sep 2017

ViaCell

PerkinElmer has begun a previously announced tender offer to acquire all outstanding shares of common stock of ViaCell (one SBIR).

PerkinElmer will buy ViaCell (Cambridge MA; one Phase 1 SBIR) for $300 M to bolster its genetics-screening business for pregnant women and newborn children. [Todd Wallack, Boston Globe, Oct 2, 07] Is being bought by a larger company good or bad? If you are a life-style company, you think it's bad. But once there is evidence that private capital is ready to step into a technology, the government should stop funding it. Life style OK, but no more SBIR.

ViaCell up 11% after it and Children's Hospital & Research Center Oakland reported results today that children with Sickle Cell Disease and Thalassemia can be cured with umbilical cord blood from a compatible sibling. [Business Wire, Sep 20]

ViaCell up 12% [Nov 3, 06] despite losing more money in the ever exciting stem cell business. One Phase 1 SBIR.

Viacor (Wilmington, MA)

Viacor (Wilmington, MA; no SBIR) medical device maker, has raised $6.58 million according to a [SEC] filing .... develops catheter-based technology to treat heart valve disease. On its website, Viacor notes that its current focus is on percutaneous therapy for mitral valve regurgitation for heart failure patients. [Mass High Tech, Apr 8, 10]

ViaCyte (formerly Novocell) (San Diego, CA)

Vertex is absorbing ViaCyte (San Diego, CA; $2M SBIR) for $320 million, taking a bulldozer to the competition of another stem cell-based treatment for diabetes. [Max Bayer, Fierce Biotech, Jul 11, 2022]

ViaCyte (San Diego, CA; $1.7M SBIR) More than two and a half years after raising an $80 million series D, ViaCyte has expanded the round with a $45 million financing tranche. The San Diego-based clinical stage biotech is developing multiple programs aimed at treating type 1 diabetes. [Kyle LaHucik, Fierce Biotech, Jun 9, 2021]

ViaCyte is recruiting patients for clinical trials testing its experimental stem cell-based diabetes treatment. Now it has $80 million [Series D round] to support that work, and also prepare for IPO. [Sarah de Crescenzo, xconomy.com, Nov 28, 18]

CRISPR Therapeutics is partnering with ViaCyte (San Diego, CA; $1.2M SBIR) to develop off-the-shelf, gene-edited stem cell therapies for diabetes in a deal worth up to $25 million [Amirah Al Idrus, Fierce Biotech, Sep 17, 18]

ViaCyte (formerly Novocell, San Diego, CA; no SBIR) regenerative medicine company, announced that the California Institute for Regenerative Medicine (CIRM) approved [another] grant of $20 million to support the clinical development of ViaCyte’s PEC-Direct™ product candidate. This novel cell replacement therapy is being developed as a functional cure for patients with type 1 diabetes who are at high risk for acute life-threatening complications. [company press release, Sep 28,17]

ViaCyte (originally Novocell, San Diego, CA; no SBIR)said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from severe episodes of low blood sugar (hypoglycemia). ... said it has raised an additional $10 million to initiate the clinical trial and for other corporate purposes [Bruce Bigelow, xconomy.com, May 22, 17]

ViaCyte (San Diego, CA; no SBIR) and W. L. Gore & Associates, a global materials science company, announced a collaborative research agreement whereby the two companies will work together to develop novel implantable cell therapy delivery device technologies that provide protection from immune rejection. [joint companies press release, Mar 29, 17]

ViaCyte (San Diego, CA; no SBIR) is merging with Johnson & Johnson’s Janssen BetaLogics, a deal that consolidates the bets J&J has made on the two rivals leading the field of stem cell-derived therapy for type 1 diabetes. ViaCyte also disclosed early results from a phase 1 study, which is believed to be the first human data from a stem cell-based treatment for diabetes. [Alex Lash, xconomy.com, Feb 5, 16]

Diabetes therapy company ViaCyte appears likely to get nearly $17 million from California's stem cell agency this week. If approved, the grant would bring the total it has received from the agency to more than $55 million. [Bradley Fikes, utsandiego.com, Sep 8, 14]

In an historic announcement for the stem cell field, ViaCyte (San Diego, CA; no SBIR) said it has applied to start human clinical trials of its treatment for Type 1 diabetes. ViaCyte grows replacement insulin-producing cells from human embryonic stem cells. The cells are packaged while maturing in a semi-permeable device and implanted. In animal trials, the cells produce insulin, relieving diabetes. ... the California Institute for Regenerative Medicine has awarded nearly $39 million to ViaCyte to ready its device for human use. .... CIRM itself, funded with $3 billion in state bond funds, has come under pressure to show results from its work. The money is projected to run out in 2017 [Bradley Fikes, utsandiego.com, Jul 17, 14] State legislatures want nearly instant results because they have to divert money from today's voting beneficiaries to tomorrow's maybes.

ViaCyte (San Diego,CA; no SBIR) , a developer of a diabetes treatment from human embryonic stem cells, has raised $10.6 million in a private equity financing. The money will go to ViaCyte’s therapy for type 1 diabetes, the privately held company said [utsandiego.com, Jul 12, 13]

ViaCyte (San Diego, CA; no SBIR) will get an additional $3 million from California's stem cell agency to bring its artificial pancreas to patients, the agency's oversight committee voted .... The award comes on top of a $10.1 million grant in October, and a $20 million award in 2010.The new grant will help ViaCyte raise money to begin clinical trials of its device, which contains insulin-producing cells grown from human embryonic stem cells. [Bradley Fikes, utsandiego, Dec 12, 12]

ViaCyte (formerly Novocell; San Diego, CA), which is developing the implant as a treatment for type 1 diabetes, is now beginning the safety testing required for approval from the U.S. Food and Drug Administration before human testing can start. [Emily Singer, MIT Tech review, Jun 28, 10]

Viamet Pharmaceuticals (Morrisville,NC)

Viamet Pharmaceuticals (Durham, NC; no SBIR, IPO May 2016) announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company’s product candidate, VT -1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis , or fungal nail infection. ... financial detils not disclosed [company press release, Jan 3, 18]

Viamet Pharmaceuticals (Durham, NC; no SBIR) put an [$90M] [IPO] on ice, according to Renaissance Capital, a group that closely tracks IPOs. [Jason deBruyn, Triangle Business Journal, May 13, 16]

Viamet Pharmaceuticals (Durham, NC; no SBIR, 29 employees) drug development company, filed plans for [IPO].... Viamet’s lead drug candidate, VT-1161, is an oral medication for treating vaginal yeast infections and fungal infections in toenails. It is now in Phase 2 clinical trials. The company is also developing a drug to treat meningitis. [David Bracken, Raleigh News & Observer, Apr 11, 16]

Viamet Pharmaceuticals (Durham, NC; no SBIR, founded 2004), the drug discovery firm co-founded by former UNC Chancellor Holden Thorp, has snagged orphan drug status for an in-development antifungal treatment. ... developing metal-binding protein therapeutics to treat fungal diseases [Lauren K. Ohnesorge, Triangle Business Journal, Sep 12, 14]

Viamet Pharmaceuticals (Durham, NC; no SBIR) filed initial paperwork for a public offering. ... proposes to raise a maximum of $75 million [Jason deBruyn, Triangle Business Journal, Jul 1, 14]

Viamet Pharmaceuticals (Durham, NC; no SBIR, founded 2005) [filed for an IPO] to raise $75 million to finance development of antifungals to treat yeast infections, athlete's foot and other fungal infections. .... Another product under development, VT-1129, is an oral drug to treat meningitis, a life-threatening fungal infection of the lining of the brain and spinal cord. [John Murawski, Raleigh News & Observer, Jul 1, 14]

Viamet Pharmaceuticals (Morrisville, NC; no SBIR), co-founded by UNC-Chapel Hill Chancellor Holden Thorp. has raised $18 million. ... to move its treatments into clinical trials. ... employs six people, targets a class of enzymes called metalloenzymes that contain a metal, typically zinc or iron. ... last raised money in June 2007 in a $4 million Series A round..... [one investor] Lilly Ventures, a subsidiary of Eli Lilly and Co., "invests in companies with promising technologies that have the potential to generate multiple, 'best in class' products," managing director Ed Torres wrote in a statement. [Jonathan Cox, Raleigh News & Observer, Jul 8, 09]

ViaSat (Carlsbad, CA)

ViaSat (Carlsbad, CA; $17M SBIR) down 18% [Jul 13, 2023] disclosed that an unexpected event occurred during reflector deployment that may materially impact the performance of the ViaSat-3 Americas satellite. [company press release, Jul 12, 2023]

ViaSat (Carlsbad, CA; $17M SBIR) secured a potential five-year, $325 million contract to provide the U.S. Special Operations Command with related equipment and services in support of its command, control, communications and computer tactical communications systems. [Naomi Cooper, govconwire.com, Nov 23, 2022]

ViaSat (Carlsbad, CA; $17M SBIR) up 27% [Oct 3, 22] announced it has entered into a definitive agreement to sell its Link 16 Tactical Data Links (TDL) business to L3Harris Technologies for $1.96 billion [company press release, Oct 3, 2022]

ViaSat (Carlsbad, CA; $17M SBIR) booked a $99 million order during the second quarter of its 2023 fiscal year to supply Joint Tactical Radio System terminals to the U.S. Navy. The order from Naval Information Warfare Systems Command is part of a potential $998 million indefinite-delivery/indefinite-quantity contract awarded in May 2020, the company said [Naomi Cooper, govconwire.com, Aug 23, 22]

ViaSat (Carlsbad, CA; $17M SBIR) agreed to purchase British satellite services provider Inmarsat for approximately $3.9 billion in cash and stock as both companies aim to offer a global hybrid network for government and enterprise communications. [Naomi Cooper, govcomwire.com, Nov 9, 2021]

ViaSat up 30% [Mar 24, 20] on plus 11% market day

Viasat landed a potential $450M indefinite-delivery/indefinite-quantity from the General Services Administration to provide technology platforms and services for both special operations and general purpose forces. [Matthew Nelson, GovConWire, May 21, 19]

ViaSat landed a potential eight-year, $559.9M contract to provide Ku-band and Ka-band communications service to Defense Information Systems Agency senior leaders and staff when they travel by aircraft [GovConWire, Aug 30, 18]

ViaSat down 14% [Aug 10, 18]

Viasat said it has been awarded a $350 million contract to provide communications technology to U.S. Special Operations forces. [Mike Freeman, San Diego Union Tribune, Jan 17, 18]

Viasat has secured a contract to update NATO control stations for ultra-high-frequency satellite communications systems in an effort to help address the international alliance’s integrated waveform baseline requirement. [GovConWire, Jan 4, 18]

ViaSat received a potential $350 million contract to deliver mission networking sustainment services to the U.S. Special Operations Command‘s procurement division. The Carlsbad, California-based communications firm will primarily carry out work at a ViaSat and USSOCOM facilities through December 2022, the Defense Department said [GovConWire, Dec 21, 17]

Viasat to Enter Production Phase for Air Force Cryptographic Data Module for military handheld devices and unmanned systems that transmit sensitive and classified data ... based on Viasat’s programmable and embeddable PSIAM cryptographic technology. [Ramona Adams, GovConWire, Dec 7, 17]

About eight years ago, ViaSat (Carlsbad, CA; $16M SBIR) CEO Dankberg bet the company he co-founded on satellite broadband, eventually spending $1 billion to transform a technology considered barely better than dial-up into a service that smoothly streams YouTube video. ... Today ViaSat-1, which launched in 2011, is full with 700,000 Internet subscribers. In addition, the satellite powers in-flight Wi-Fi on more than 500 commercial aircraft and USAF One .... plans to launch ViaSat-2 in late March/early April. The satellite will blast off from French Guiana on an Ariane 5 rocket. At around 300 gigabits per second capacity, the new satellite has about twice the bandwidth of ViaSat-1. [Mike Freeman, San Diego Union Tribune, Feb 5, 17]

ViaSat is spreading it wings across the Atlantic — providing in-flight Wi-Fi to Finnair’s short-haul fleet serving Europe. ... working with long-time partner Eutelsat, which will provide the satellite to power Wi-Fi on Finnair’s short haul flights. ViaSat will supply the aircraft antenna and onboard networking technology to run the service. [San Diego Union Tribune, Aug 1,16]

ViaSat has been awarded a federal contract to provide high-speed, in-flight Internet to Air Force One and other government VIP aircraft. ... replaces Boeing, which provided Internet service to these jets for several years. .... $73 million, one-year contract, which includes two six month extension options. ViaSat was the only company to submit a bid. [Mike Freeman, San Diego Union Tribune, Jul 25, 16]

ViaSat up 12% [Feb 16, 16] on speculation that American Airlines might use the Carlsbad company to supply in-flight Wi-Fi on some of its commercial jets. [Mike Freeman, San Diego Union Tribune, Feb 16, 16]

ViaSat said that it has switched from SpaceX to a French-based rocket firm to launch its ViaSat-2 satellite early next year, and the Carlsbad company unveiled plans for a new constellation of ultra-fast broadband satellites that will be expand its footprint globally. [Mike Freeman, San Diego Union Tribune, Feb 9, 16]

ViaSat doubled download speeds on its Exede satellite Internet service in select markets, making it the fastest satellite broadband available in the U.S. ... revs up speeds from 12 megabits to 25 megabits per second for downloads .... puts Exede ahead of its top Internet-satellite competitor, HughesNet. [Mike Freeman, San CDiego Union Tribune, Dec 1, 15]

ViaSat [3,700 employees worldwide] is expanding its footprint in Carlsbad, purchasing 23 acres of vacant land near its current headquarters. [San Diego Union Tribune, Oct 23, 15]

ViaSat is providing the technology backbone for Virgin America Airline to allow passengers to stream Netflix movies for free during flights. ... at no charge through March 2016 on certain aircraft ... To date, it has outfitted 430 JetBlue and United Airlines planes with equipment to power its satellite-based Wi-Fi service. ViaSat says it can deliver 12 megabits per second download speeds to each seat in the aircraft [Mike Freeman, San Diego Union Tribune, Sep 30, 15]

ViaSat said it has acquired Engreen (San Jose, CA and India; no SBIR, founded 2012), a network virtualization technology startup, for an undisclosed price. Engreen has developed network management technology that lowers equipment costs and reduces complexity. [Mike Freeman, utsndiego,com, Jun 11, 15]

Satellite Internet provider ViaSat has joined Qualcomm and Cisco as a potential investor/mentor in startups in the no-strings-attached EvoNexus incubator program. The company will examine companies admitted to EvoNexus for young firms that fit ViaSat’s interest — connected services, telecommunications technology and cyber security. It then could invest up to $250,000 in selected EvoNexus startup [Mike Freeman, utsandiego.com, Feb 12, 15]

The Society of Satellite Professionals International announced last week that ViaSat ($15M SBIR) Co-Founder and Chief Executive Mark Dankberg has been selected for the 2015 Satellite Hall of Fame. ...He cofounded ViaSat with Mark Miller and Steve Hart in 1986 with less than $25,000 in capital. ... went public in 1996. [Mike Freeman, utsandiego.com, Feb 3, 15]

ViaSat said it has settled its patent infringement and breach of contract lawsuits against satellite maker Space Systems Loral for $100 million. .... ViaSat claimed Space System Loral took its novel designs and patents – which were subject to confidentiality agreements — and gave them to archrival Hughes Network Systems. Hughes hired Space Systems Loral to build a copycat satellite called Jupiter-1, which launched about eight months after ViaSat-1. [Mike Freeman, utsandiego.com, Sep 8, 14]

ViaSat said that it has purchased the high-rate modem product line, as well as technology for spacecraft-based earth observation, from Gray Labs (Norcross, GA; no SBIR) for an undisclosed price. [Mike Freeman, utsandiego.com, Jul 28, 14]

ViaSat has inked a roaming deal with French satellite firm Eutelsat that will allow it to offer in-flight Wi-Fi and other satellite broadband services in Europe and the Middle East. [Mike Freeman, utsandiego.com, Jul 1, 14]

A federal jury has awarded $283 million to ViaSat in a patent infringement judgment against the satellite-maker SSL over broadband satellites SSL made for Douglas County-based EchoStar Corp. and others. [Greg Avery, Denver Business Journal, Apr 25, 14]

ViaSat’s high stakes lawsuit against the builder of its Internet satellite kicked off Tuesday in a San Diego federal court, with the Carlsbad company seeking at least $460 million in damages. The technical, complicated case before an eight person jury centers on strict confidentiality agreements between ViaSat and Space Systems Loral for the satellite, plus three patents on the design that ViaSat says Space Systems Loral provided to ViaSat’s arch rival. [Mike Freeman, utsandiego.com, Mar 25, 14]

ViaSat has reworked its deal with JetBlue to pave the way for providing faster in-flight Wi-Fi services to passengers at lower prices or possibly for free. In addition, ViaSat has signed a separate deal with Boeing ..... aims to disrupt the current in-flight Wi-Fi market by offering faster, less expensive connectivity to airline passengers than current providers. [Mike Freeman, utsandiego.com, Jun 20, 13]

ViaSat up 19% [May 17, 13]

ViaSat is teaming up with a division of L-3 to develop an in-flight Internet service for airline-sized planes that are used by heads of state and other VIP customers. [Mike Freeman, utsandiego.com, May 15, 13]

ViaSat up 12% [May 9, 13]

ViaSat said it acquired LonoCloud (La Jolla, CA; no SBIR, 10 employees) for an undisclosed price.The satellite outfit said LonoCloud is an early-stage company with expertise in cloud networking software. ViaSat plans to use the technology with its Exede/WildBlue broadband network [Mike Freeman, utsandiego.com, Apr 12, 13]

ViaSat up 24% [Feb 7, 13] after the company reported better than expected sales and earnings for its fiscal third quarter [utsandiago.com, Feb 7]

ViaSat has been awarded a $12.8 million government contract to provide the U.S. military and other foreign forces with high-tech communications devices, the Defense Department announced [Nathan Max, utsandiego.com, Dec 18, 12]

ViaSat has been chosen by U.S. Marine Corps Systems Command to develop advanced security software for common off-the shelf mobile devices such as smartphones and tablets. [Mike Freeman, utsandiego.com, Nov 30, 12]

ViaSat won a $34 million government contract to further develop and produce a special communications systems used by multiple branches of the U.S. military, [DOD] announced. [Nathan Max, utsandiego.com, Sep 18, 12]

ViaSat down 10% [Aug 3, 12]

ViaSat said it won a $240 million contract to supply satellite modems, antennas and other ground equipment to NBN Co., which is building a nationwide broadband network in Australia.The contract is the single largest non-military deal that ViaSat has ever landed, said Chief Executive Mark Dankberg. ViaSat expects to add more than 100 engineering jobs over time in San Diego County [Mike Freeman, utsandiego.com, Jul 12, 12]

ViaSat has been awarded a $31.5 million contract to provide the government with high-tech communications hardware, the Defense Department announced [Nathan Max, utsandiego.com, Apr 11, 12]

ViaSat - 1 blasted into orbit on Wednesday right on schedule with no apparent problems ... four-year effort to build the $400 million broadband satellite is a big gamble for ViaSat, which aims to provide much faster Internet service to more than 1 million customers outside the reach of cable or DSL services at similar prices to existing satellite broadband. [Mike Freeman, signonsandiego.com, Oct 20, 11]

VSAT down 11% [Aug 8, 11]

Watching workers at Space Systems Loral tape protective thermal blankets on his company’s first satellite, ViaSat Chief Executive Mark Dankberg said he isn’t nervous yet. But in a little over a month, he knows he will be. That’s when the $400 million satellite, called ViaSat 1, is scheduled to blast off from a launch site in Kazakhstan. It’s the linchpin of the 25-year-old Carlsbad company’s transformation from a satellite ground equipment maker for the military to a broadband Internet provider serving rural U.S. consumers. [Mike Freeman, signonsandiego.com, Jun 25, 11]

ViaSat said last week that it has entered into a formal deal with JetBlue Airways to offer high speed Internet access to passengers on more than 170 JetBlue aircraft next year. ... It’s too early to say how much JetBlue will charge for the service, said Rowe. [Mike Freeman, signonsandiago,com, Apr 12,11]

ViaSat said it received $71.1 million follow-on order from the U.S. Army for a tracking systems for vehicles in combat with the aim of reducing friendly fire incidents. [signonsandiego.com, Mar 22, 11]

ViaSat received $13.8 million in orders from the military for ground satellite stations and network control center equipment, as well as vehicle transceivers and other gear. [Mike Freeman, signonsandiego.com, Dec 21, 10]

ViaSat has acquired the SkyLink broadband Internet business of ARINC of Annapolis, MD., boosting ViaSat’s customer base as it prepares to launch a new broadband satellite early next year. [Mike Freeman, signonsandiego, Oct 19, 10]

ViaSat to bring the next generation of in-flight Internet services to airline passengers using ViaSat's new, high-capacity satellite set to launch early next year. [Mike Freeman, signonsandiego.com, Sep 27, 10]

ViaSat said it has received an initial order of $37.7 million for terminals as part of the Army’s next generation battlefield command and control satellite communications system. The order is part of a $477 million contract that the Carlsbad company won to provide equipment for ground vehicles and aircraft, network operations equipment, integration and engineering. [signonsandiego.com, Jul 24, 10]

ViaSathas been awarded a $10 million contract from the National Security Agency (formerly No Such Agency or Never Say Anything) to enhance its line of network encryption technology. [San Diego Union Tribune, Jul 12, 10]

ViaSat awarded a $5.75 million contract for tactical data links and other satellite communications gear from the [Navy]. [signonsandiego.com, Jul 9, 10]

ViaSat plans to buy privately held Stonewood Group of Dorset, England, in a cash and stock deal valued at $20 million, according to a statement today. Stonewood’s products are used to encrypt data on computer hard drives so that a lost or stolen laptop does not result in the compromise of classified information or the loss of intellectual property [Bruce Bigelow, signonsandiego.com, Jun 4, 10]

ViaSat said it has received a $6.6 million additional order for communications terminals from the [Navy] ... on top of a $21.5 million contract for terminals [signonsandiego, Apr 13, 10]

ViaSat is acquiring Wild Blue Communications, a provider of high-speed Internet access via satellite, for $568 million in cash and stock, according to a person familiar with the situation. [AP, Oct 1, 09]

ViaSat down 10% [Aug 6, 09]

ViaSat won two contracts totaling $53 million to provide satellite communications infrastructure in Africa. [San Diego Union Tribune, Jul 13, 09]

ViaSat down 15% [Feb 10, 09] after it reported third-quarter revenue below Wall Street estimates, hurt by a drop in sales of consumer broadband products ... Sales to government agencies, the company's biggest revenue generator, rose 10 percent [Reuters]

ViaSat down 11% [Dec 1, 08] On a stock bloodbath day

ViaSat up 10% [Nov 13, 08]

ViaSat down 17% [Jan 8, 08]

ViaSat up 11%[Nov 2, 07] on good profits.

Forbes's annual list of the best 200 small companies had several SBIR awardees: Ceradyne #12, Flir Systems 37, II-IV 58, ATMI 69, ViaSat 90, Surmodics 105, Micrel 149, OPNET Tech 167.

ViaSat acquired Quincy's Intelligent Compression Technologies [no SBIR] in a deal that could be worth up to $54M. [Mass High Tech, Feb 20, 07]

ViaSat got a $12M order from Taiwan for information distribution system terminals. [Feb 07]

ViaSat is expected to announce a contract to supply equipment slated to go on Gulfstream jets ... onboard terminals and ground stations for an Internet-in-flight service ... Though ViaSat's latest contract is small and is expected to produce only about $12 million in revenue for the company, it highlights continuing interest in providing Internet links -- and increasingly cellular telephone connections -- to airplanes during flight. [Andy Pasztor,Wall Street Journal, Oct 30, 06]Reuters Investor Update maintains a positive view of ViaSat as both a growth and a value stock. By other metrics, though, VSAT appears to be a bargain. Its P/Sales ratio is 1.52, well below the Industry's 5.05. Further, its P/Cash Flow is 14.06, a considerable discount to the 21.00 mean of its peers. [Apr 05]

Smart Money magazine (a Dow Jones product) tagged ViaSat as one of ten stars of rising sales growth, with 42% rise last year and 16% annualized three year. The 16-42 combination means almost all the gain was packed into last year.

ViaSat will sell satellite modems and other equipment for a sweeping project to expand Internet access in Mexico. e-Mexico is a digital divide program that sees opening 3,200 digital community centers is a government project subject to the usual political maneuvering. ViaSat's VP claimed that every site will be a school and every school will have a computer lab. Presidente Fox somehow sees that 4% of Mexicans using Internet will translate to 90%.Which would community rather have - a sewer of an Internet connection? Fox also expects private enterprise to pay for 90% of the project. [story from Mike Freeman, San Diego Union Tribune, Dec 24, 02]

Spooks Buy ViaSat Product (Oct 11,02) ViaSat got a $10M contract from NSA (No Such Agency) to develop a Type-1 High Assurance Internet Protocol Interoperability Specification (HAIPIS) compliant Internet Protocol (IP) In- line Network Encryptor (INE).. Could that title be an encrypted message? Which would enable NSA to talk up to the TOP SECRET at least 1 Gigabit per second over commercial IP Wide Area Networks. What's innovative is NSA's public announcements of such work.

Spreek U Nederlands? ViaSat won a $1M contract for Multifunctional Information Distribution System terminals from the Royal Netherlands Air Force (RNLAF) which is also ready to spend millions more for the remaining terminals needed to integrate MIDS into its F-16 equipped Air Force. Watch out, though, as the Dutch may try to sell something in return as one of world history's great traders which once had the world's fastest sailing ships. Despite such good news, the stock is trading at 12% of its irationally exhuberant 2000 high and at a PE ratio of 66.

ViaSat is being awarded a $29.6M delivery order under previously awarded indefinite-delivery and indefinite-quantity contract to exercise an option for fiscal year 2002 Multifunctional Information Distribution System-Low Volume Terminals. The MIDS-LVT provides secure, high capacity, jam resistant, digital data and voice communications capability for U.S. Navy, U.S. Air Force and U.S. Army platforms. Work will be performed in Carlsbad, Calif. (54%); Melbourne, Fla. (34%); and Cincinnati, Ohio (12%), and is expected to be completed by June 2004. Contract funds in the amount of $4.53 million will expire at the end of the current fiscal year.

ViaSat Making Money(Dec 28)ViaSat got some favorable press from Bloomberg Personal Finance citing no debt and a string of profits since the 1996 IPO. The company says it expects its broadband business portion to expand from the present 20% to 60%. In its latest earnings report ViaSat claimed quarterly sales up 25% to a record $50M and a pro forma profits up 7%. It also said that it made Forbes' list of 200 Best Small Companies for the fifth straight year. ViaSat has had over $20M of military SBIR a healthy portion of which came after the IPO and most of which sounds like late stage engineering of existing technology into deployable hardware.

ViaSat reported quarterly record sales of $49M, up 25%. compared to $39.7 million for the comparable quarter last year, a 24.7% Profits? Well that depends on how many accountants and lawyers get to define them. Pro forma net income, which excludes the effects of acquisition charges (including amortization of intangibles and a charge for in-process research and development), was $3.2M, ... a 7.1% increase

ViaSat said sales were up 150% and profit up 80% if the goodwill charge for the "overpayment" of an acquisition isn't counted.

ViaSat announced record profits for the quarter, up 10% to $3.8M on doubled sales of $17M. That's before the so-called one-time charges of goodwill amortization and acquiring Scientific Atlanta's satellite networks business. Prospects for future business rose as the backlong jumped to $165M from $40M a year ago. The market didn't find the results newly exhilirating and beat the price down 20% in the past month.

ViaSat Record Profits(May 22)ViaSat showed record sales and earnings for its quarter and year. Fourth quarter. Sales up 30% and income up 22% for the quarter and both up 6% for the year. ViaSat also says its had a lot of good happenings last year. 1) bought the Satellite Networks Business of Scientific-Atlanta; 2) earned qualification from the Navy as one of three suppliers on the Certified MIDS Manufacturers Register (CMMR) and first production award for $23.4 million for Multifunctional Information Distribution System (MIDS) terminals with a total contract value of about $30M; 3) awarded an initial $13M part of five-year ordering agreement from the Raytheon Company to supply second-generation, enhanced UHF Satellite Communications (Satcom) Demand Assigned Multiple Access (DAMA) modem modules for Raytheon multiband terminals. It's alphabet soup but it's business. The stock is about quadruple its valus of a year ago and down 60% from its high. It got a start from a $1.2M SBIR from the Navy in 1988 for a PROOF-OF-CONCEPT TEST-BED MODEL OF A COMPACT RF ENVIRONMENT SIMULATOR, and another $1.9M in 1990 and a toal of 21 Phase 2s as it grew from 5 employees in 1986 to 360 today as a public company. The Navy can take some credit even though the Navy was probably just buying capability it wanted. Investmenbt in private sector commercialization is not what the Navy does for its SBIR living. Most of the Phase 2 abstracts sound like modest product improvements with which the conservative military services can feel comfortable.

ViaSat (Carlsbad, CA) rose 13% on news that it had filed to sell 2.5M shares; ViaSat is tenfold its value a year ago.The military has put nearly $20M into ViaSai in a decade for what reads like good sound useful engineering improvements in ViaSta's line of advanced digital satellite telecom and other networking and signal processing equipment. Profits have been nicely rising since 1993 to $7M in 1998. And withy onoy 370 employees it could still tap the military market with SBIR as the convenient vehicle if the military doesn't mind mostly procurement with R&D money. (Mar00)

ViaSat Order(Aug 10) $3.6 million order for ViaSat. The Navy's SPAWAR has placed an order with Carlsbad-based ViaSat Inc. for $3.6M worth of equipment, including the first sale of ViaSat's new UHF DAMA satellite communications modem. ViaSat makes advanced digital communications equipment for military and commercial customers.

Via Separations

Via Separations (Somerville, MA; no SBIR), applying novel filtration to reduce the energy used in separation processes by 90%,announced the close of a $4.8 million Series A financing [company press release, Mar 14, 19]

The Engine, a new VC fund in Cambridge, MA aims to bridge that [long lead time] gap by investing in breakthrough technologies that require extensive time and funding. Its [announced] first round of investments consists of seven startups (Analytical Space (Boston, MA, laser satellite data links w former Gen Pete Worden as advisor), Baseload Renewables (co-founded by Professor Yet-Ming Chiang who co-founded A123 Systems), C2Sense (Cambridge, MA; patented chemiresistive sensing C2Sense is able to selectively target gases unable to be sensed through other methods ), iSee (next generation of humanistic artificial intelligence technology for human and robotic collaborations), Kytopen (better genetically engineer cellsby developing technology that modifies microorganisms 10,000 times faster than current state-of-the-art methods ), Suono Bio (Cambridge, MA, ultrasonic therapeutics), and Via Separations (industrial separation processes, sonme SBIR) in sectors including aerospace, advanced materials, genetic engineering, and renewable energy. .... a for-profit, public-benefit corporation and a fund that’s separate from MIT ... MIT also contributed $25 million to your first investment fund of $200 million. [Elizabeth Woyke, technologyreview.com, Sep 19, 17]

Vical (San Diego, CA)

Vical (San Diego, CA; $13M SBIR, founded 1987) stockholders late last month OK’d a reverse merger with Brickell Biotech (NASDAQ: BBI). ... was developing treatments for life-threatening infectious diseases, including antiviral and antifungal compounds, announced in June that it planned to become part of Brickell (Boulder, CO; no SBIR) developing drugs for skin diseases. [Sarah de Crescenzo, xconomy.com, Sep 10, 19]

Vical (San Diego, CA; $13M SBIR, including one award of $5.7M) will make a component in an HIV vaccine under a $4 million contract, the biotech announced. Funded by the Bill & Melinda Gates Foundation, the contract with the IPPOX Foundation calls for publicly traded Vical to supply plasmid DNA for HIV vaccine clinical trials. [Bradley Fikes, utsandiego.com, Apr 22, 15]

Vical will lay off 47 employees [about 39 percent of its workforce] to cut costs after ending development of its melanoma vaccine, the biotech company said [Bradley Fikes, utsandiego.com, Aug 22, 13]

Vical said it would stop developing its most advanced product, cancer therapy Allovectin, after a late-stage trial failed to show that the treatment was significantly better than chemotherapy. Vical shares sank 53 percent in premarket trade. [Reuters, Aug 12, 13]

Vical up 10% [Aug 1, 13]

Vical ($12M SBIR, incl one of $5.7M) up 12% [Jul 30, 13]

Vical (San Diego, CA; $12.3M SBIR) DNA vaccine developer will get up to $130 million for licensing the development and commercial rights for its experimental TransVax treatment to Astellas Pharma of Japan, the company said ... TransVax prevents the activation of cytomegalovirus, a common herpesvirus that is dormant in most people but can cause illness and even death in those with compromised immune systems. [Keith Darce, signonsansidego.com, Jul 14, 11]

Vical up 22% [May 12, 11]

Vical up 14% [Apr 26, 11]

Vical down 32% [Sep 22, 10] a drug that had showed promise in restoring blood vessel growth in damaged limbs was no better than a placebo in an advanced test. The medicine, known as NV1FGF, failed to meet the study’s goal of preventing limb amputation or patient deaths over 12 months, Sanofi said today in a statement. [Marthe Fourcade, Bloomberg, Sep 22]

Vical down 12% [May 6, 10]

Vical (San Diego, CA; $11M SBIR) said it has secured funding to start clinical trials with a vaccine for H1N1 “swine” flu. The money comes from the U.S. Navy, through the Henry M. Jackson Foundation for the Advancement of Military Medicine. Previously, Vical received a Navy contract to support vaccine manufacturing and other preparations for the trial. [Thomas Kupper, San Diego Union Tribune, Mar 24, 10] Three SBIRs were for $5.7M, $3.1M, and $2.0M.

Vical said a partner received approval to start marketing a vaccine for melanoma in dogs. [Seattle Times, Jan 12, 10]

Vical up 22% [Dec 28, 09] after an independent safety board said it should continue late-stage trials of a melanoma vaccine. ... has been working with the drug Allovectin-7 for more than 15 years ... went public in 1991 but has never turned a profit [San Diego Union Tribune, Dec 29]

Vical up 17% [Dec 18, 09]

Vical down 14% [Oct 28, 09]

Vical up 11% [Jul 24, 09]

Vical down 15% [May 1, 09]

Vical up 18% [Apr 30, 09]

Vical up 10% [Jul 17, 08] after it announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times. [company press release]

Vical up 10% [Mar 27, 08]

Vical up 11% after preliminary late-stage trial results showed a drug candidate successfully treated ischemia by increasing the size of blood vessels.

Vicarious (East Bay, CA)

Vicarious (East Bay, CA; no SBIR for secret companies) , an enigmatic AI company backed by some of the most famous and successful names in Silicon Valley, is developing a new way of processing data, inspired by the way information seems to flow through the brain. The company’s leaders say this gives computers something akin to imagination, which they hope will help make the machines a lot smarter. .... essentially, betting against the current boom in AI. ... has introduced a new kind of neural-network algorithm designed to take into account more of the features that appear in biology. An important one is the ability to picture what the information it’s learned should look like in different scenarios—a kind of artificial imagination [Will Knight, technologyreview.com, May 19, 16]

Vicus Technologies (Kennebunk, ME)

Earmarks Too Tempting. Two former missile-command officials pleaded guilty early this year in federal court to public-corruption and conspiracy charges. Their plea agreements detail a conspiracy in which politically connected defense contractors that lobbied for congressional funding, called earmarks, bribed the officials to steer the funds to sham subcontractors.... The Army Space and Missile Defense Command (the Army's Star Wars component) awards some $500 million a year in research work. In some years as much as one-third of the funds is directed by members of Congress through earmarks or other means to contractors in this military boomtown. Two SBIR firms have been named in news reports of the ongoing probe: Vicus Technologies (Kennebunk, ME; $2M SBIR), and Fiber Materials (Biddeford, ME; $13M SBIR) [John Wilke, Wall Street Journal, Apr 14]

VIDA Diagnostics (Coralville, IA)

VIDA Diagnostics (Coralville, IA; $2.4M SBIR, founded 2004) raised an undisclosed amount. total funding $10M [crunchbase.com]

Vidacare (San Antonio, TX)

The EZ-IO device from Vidacare (San Antonio, TX; $1M SBIR), the company Dr. Larry Miller co-founded in 2001, is the Gold winner in The Wall Street Journal's eighth annual Innovation Awards competition. ... The Silver award went to Audience(no SBIR), a maker of voice processors, for a noise-suppression technology designed to block annoying background noise in mobile-phone calls. ... A team of scientists at the Lawrence Berkeley National Laboratory won the Bronze for their work in developing a microchip that, by analyzing DNA, is able to identify thousands of different varieties of bacteria that might be present in air, water, soil, blood or tissue samples. ...The PhyloChip [not currently available commercially. It is manufactured by Affymetrix], developed by staff scientist Gary Andersen and a team of researchers at the Lawrence Berkeley National Laboratory in Berkeley, Calif., won in [environment] category. ...Nanocomp Technologies (Concord, NH, no SBIR), the winner in [materials and other base technologies] category, has developed a process to create large sheets of fabric and lengths of yarn using carbon nanotubes -- synthetic carbon molecules prized for their exceptional strength and conductivity. [Michael Totty, Wall Street Journal, Sep 29, 08]

Viela Bio (Gaithersburg, MD)

Vielo Bio down 20% [Jun 26, 20]

Viela Bio (Gaithersburg, MD; no SBIR) announced that [FDA] has approved UPLIZNATM (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. [company press release, Jun 11, 20]

Viela Bio up 19% [Apr 14, 20]

VielaBio down 30% [Mar 20, 20]

Vielo Bio up 39% [Mar 20, 20]

Viela Bio down 31% [Mar 16, 20]

Viela Bio up 18% [Mar 4, 20]

Viela Bio up 20% [Feb 18, 20]

Viela Bio down 15% {Jan 17, 20]

Viela Bio up 20% [Dec 17, 19]

Viela Bio up 23% [Oct 3, 19]

Two-year-old biotech Viela Bio (Gaithersburg, MD; no SBIR) has set the terms of its initial public offering, looking to raise about $150M. Viela has said it plans to use the capital to get FDA approval for its first prospective product and to launch it commercially. If all goes well, patients could be using the drug by early next year. [Kieran McQuilkin, DCInno, Sep 25, 19]

drug developer Viela Bio (Gaithersburg, MD; SBIR) filed to go public with a $150M IPO, just more than a year after spinning out from MedImmune. [Kieran McQuilkin, DCInno, Sep 3, 19]

Viela Bio (Gaithersburg, MD; no SBIR, MedImmune spinoff) landed a $220M agreement for Chinese pharmaceutical company Hansoh Pharmaceutical Group to commercialize Viela's lead drug candidate. The partnership allows Hansoh to develop and sell Inebilizumab, the local biotech firm's product for autoimmune diseases. [DCInno, May 29, 19]

Year-old MedImmune spinoff Viela Bio (Gaithersburg, MD; no SBIR), created to focus on autoimmune disease, is raising $75M and could hit the 100-employee target by yearend, CEO Bing Yao told the WBJ. ... would add to a $282M Series A round led by three Chinese investment groups when it launched in February 2018. ... lead candidate is inebilizumab which treats NMOSD, a rare disease that affects the central nervous system. [DCInno, Mar 25, 19]

AstraZeneca spun six of the experimental drugs from its Gaithersburg, MD, R&D hub MedImmune into a new startup, Viela Bio, backed by $250 million in funding from a group of Chinese private equity funds. [Ben Fidler, xconomy.com, Mar 2, 18]

View (Milpitas, CA)

View (Milpitas, CA; no SBIR), the leader in dynamic glass, announced that it has secured $100M in [Series G] investments [that] provides growth capital and enables View to expand its manufacturing capacity and to scale operations in order to meet rapidly growing demand. [company press release, Feb 7, 17]

View (Milpitas, CA; no SBIR, founded 2007), which makes architectural glass that tints automatically, has raised $150 million more from private equity investors. ... built a $100 million manufacturing plant in Mississippi which employs 200 people. The $150 million will be used to expand manufacturing. View has raised more than $500 million to date. [Cromwell Schubarth, Silicon Valley Business Journal, Aug 13, 15]

Smart-glass startup View (formerly Soladigm; no SBIR) raising up to $100 million in fresh capital. ... raised $100 million in early 2014 ... Prior to this latest funding, the company raised $339 million over several rounds ... The tint on glass made by View is controlled by electrical charges, which can be applied automatically when lighting changes or can be controlled on demand. According to the company, the windows can cut 20 percent on heating and cooling costs, 20 percent from lighting costs and can reduce electricity use by as much as 25 percent at peak-use times. [Gina Hall, Silicon Valley Business Journal, Mar 27, 15]

View (Milpitas, CA, fomerly Soladigm,; no SBIR, 300 employees), a startup that makes "dynamic glass" for commercial buildings, secured $100 million in venture capital funding .... manufactures "intelligent" windows with glass that can react to external conditions -- tinting to reject unwanted heat and glare, or lightening to let in winter sunlight. [Dana Hull, San Jose Mercury News, Jan 6, 14]

Vigene Biosciences

Vigene (Rockville, MD; no SBIR, founded 2012) , a biosciences company focused on gene and cell therapies, reported raising $3M in new equity funding. The new SEC filing follows the company's announcement that it has added new programs to help manufacture future COVID-19 vaccines. The company provides viral packaging and cloning services, among other things, for academia, government, research, biotech and pharma applications. This new funding follows a $7.5M round in May last year. DCInno, Mar 29, 20]

Rockville-based biotech Vigene Biosciences announced the close of a $7.5M Series A round to fund the completion of a new facility. The move will more than double its current footprint, giving it dedicated space to develop, manufacture and test drugs. [DCInno, May 28, 19]

Viking Therapeutics (San Diego, CA)

Viking Therapeutics (La Jolla, CA; no SBIR) marked its debut as a newly public company; priced its {IPO for $24M]. ... The biotech is developing metabolic and endocrine disorder therapies. ... Viking is a partner of Ligand Pharmaceuticals (San Diego, CA; one SBIR) which has invested $9 million in the IPO. ... Ligand has licensed small-molecule compounds to Viking, which is developing five drugs based on these compounds. Its lead drug candidate, VK5211, is entering Phase 2 trials for patients who have had non-elective hip fracture surgery. [Bradley Fikes, utsandiego.com, Apr 29, 15]

Viking Therapeutics (San Diego, CA; no SBIR) spun out through a licensing deal with Ligand Pharmaceuticals (one SBIR), was poised to go public [for $50-60M] ... licensed five drugs from Ligand, targeting diabetes and other metabolic and endocrine disorders [Alex Lash, xconomy.com, Sep 18, 14]

Vion Pharmaceuticals

oncology drug maker Vion Pharmaceuticals New Haven, CT; $2M SBIR) has voluntarily filed for bankruptcy under Chapter 11 [Mass High Tech, Dec 18, 09]

Vion Pharmaceuticals ($2M SBIR) says that it had received a letter from Nasdaq stating that the Company's common stock will be delisted from the Nasdaq Capital Market as of the opening of business on May 16, 08. [company press release]

Vion Pharmaceuticals up 37% [Mar 24, 08]

VionX Energy (Woburn, MA)

VionX Energy (founded 2002 as Premium Power, Woburn, MA; no SBIR), flow battery company has taken in $14 million in a debt offering, according to an SEC filing. The company did not respond to a request for information about the funding. [xconomy.com, Apr 26, 19] has developed a grid-scale, long duration energy storage system delivering unmatched performance over a 20+ year life which is certified non-flammable, safe and bankable. The unique long-duration discharge of up to 10 hours at full rated power is enabled by its world leading flow battery stack technology operating at 3X higher power density than any competitor and proprietary vanadium electrolyte processing. [company website] total prior funding $114M [crunchbse.com]

ViraCor Laboratories (Lee’s Summit, MO)

ViraCor Laboratories (Lee’s Summit, MO; $1.5M SBIR) and IBT Laboratories (Lenexa, KS; no SBIR) officially merged Tuesday and have a combined work force of more than 200 employees. [Kansas City Business Journal, Jul 1, 09]

Viracta Therapeutics (San Diego, CA)

Viracta Therapeutics (San Diego, CA; no SBIR) anti-cancer biotech that has been operating below the radar for nearly two years, is today disclosing an initial closing on what could amount to as much as $18.4 million in Series B financing. Viracta plans to use the proceeds to advance its lead drug candidate into mid-stage trials for treating cancers associated with the Epstein Barr Virus. [Bruce Bigelow, xconomy.com, Apr 4, 17]

Viral Genetics (San Marino, CA)

Moving to the Money. The Texas Emerging Technology Fund awarded a $750,000 grant to Viral Genetics (San Marino, CA; no SBIR) which is moving its research facilities to Georgetown. ... will use the [Texas] money for research into biofuels, which are made from sources such as palm or corn oil, as alternatives to petroleum fuels. [Austin American Statesman, Apr 19, 10]

Vir Biotech (San Francisco, CA)

Vir Biotech up 17% [May 20, 20]

Vir Biotech up 32% [May 18, 20] announced the publication of research findings from the company's efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature. The paper, entitled "Cross-neutralization of SARS-CoV and SARS-CoV2 by a human monoclonal antibody" (Pinto, et al., Nature), details the identification and characterization of S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells. [company press release, May 18, 20]

Vir Biotech up 26% [Apr 6, 20] GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer. The partnership will leverage antibody technology from Vir and genomics expertise from GSK. [Frank Vinluan, xconomy.com, Apr 6, 20]

Vir Biotech down 23% [Feb 28, 20]

Vir Biotech up 72% [Feb 27, 20] Vir Biotechnology and WuXi Biologics (China) announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2. [joint companies press release, Feb 25, 20]

Vir Biotech up 61% [Feb 26, 20]

Vir Biotech (San Francisco, CA; no SBIR) down 30% [Oct 10, 19] after raising $142M in IPO [company press release, Oct 10,19]

Navy experimenting fast SBIR with five page proposals, two-week decision, fast start, fast stop Technology Acceleration solicitation. Great idea if competitiveness and fairness can be maintained. Read Navy Plan.

Virdante Pharmaceuticals (Cambridge, MA)

Virdante Pharmaceuticals (Cambridge, MA; no SBIR) reports it has raised new funding to bring its Series A round to $47.75 million, to continue development of antibody-based drugs that have better anti-inflammatory activity, to better treat autoimmune and inflammatory disorders. [Mass High Tech, Oct 29, 09]

Virdia (Redwood City, CA)

Virdia (Redwood City, CA; no SBIR) came out of stealth with a new name (formerly HCL Clean Tech), a fresh $20 million round of funding, and $230 million in financing by the state of Mississippi to build its first major manufacturing facility in that state. ... develops cellulosic sugars.... approximately 50 employees and is growing by about three to five employees per month. [Lisa Sibley, Silicon Valley / San Jose Business Journal, Mar 6, 12]

Virent Energy Systems (Madison, WI)

Virent (Madison, WI) said it has established a consortium that will work to complete the development and commercialization of the company’s technology, which is aimed in part at producing cleaner and more sustainable versions of liquid transportation fuels. Members of the consortium include: Coca-Cola; Toray, a Japanese chemicals company; Johnson Matthey, a U.K.-based business focused on chemicals and sustainable technologies; and Tesoro, which earlier this month said it had acquired Virent for an undisclosed amount. [Jeff Buchanan, xconomy.com, Sep 19, 16]

Virent (Madison, WI; $200K SBIR) and Tesoro announce today they have reached an agreement for Tesoro to become Virent’s new strategic owner. The acquisition will support the scale up and commercialization of Virent’s BioForming® technology for the production of low carbon bio-based fuels and chemicals. As a result of the acquisition, Virent will become a wholly owned subsidiary of Tesoro and remain in Madison, Wisconsin. [joint companies press release, Sep 6, 16]

Virent that is working on technology for plant-based bottles has now worked with a partner to produce what it says are the world's first polyester shirts that are derived entirely from plants. .... worked with Taiwan-based Far East New Century Corp., which also was a partner on producing the Coca-Cola Co. plastic bottles sourced entirely from plants. [Thomas Content, Milwaukee Journal Sentinel, Apr 21, 16]

Virent (Madison, WI; $200K SBIR) entered into a new strategic relationship with Tesoro to accelerate the development and commercialization of Virent’s BioForming technology to produce cost effective, low-carbon, drop-in, bio-based fuels and chemicals. The agreement provides funding to Virent to advance its technology and commercialization while establishing a framework for Tesoro to provide broader support and involvement in Virent’s deployment efforts longer term. [company press release, Feb 1, 16] Bio-jet emissions testing by Rolls-Royce and supported by the Federal Aviation Administration (FAA) ... confirmed that jet fuels containing Virent’s BioForm® Synthesized Aromatic Kerosene (SAK) fuel blend produced a greater than 50% reduction in particulate matter emissions compared to conventional jet fuel.[company press release, Jan 6, 16]

Virent (Madison, WI; $200K SBIR) clean-technology company that’s helping Coca-Cola Co. make plastic bottles from plant sugars has been named the hottest small company in advanced biofuels. ... awarded by the trade publication Biofuels Digest [Thomas Content, Milwaukee Journal Sentinel, Nov 6, 15]

Virent said that it has reached agreement with a group of multinational consumer products companies that plan to buy the plant-based renewable ingredient in plastic that the company plans to produce [Milwaukee Journal Sentinel, Oct 30, 14]

Virent will expand production in Madison of a plant-based chemical that can be used to make renewable plastic bottles, through an additional investment by The Coca-Cola Co. Virent, a Madison-based clean technology company, said that Coca-Cola's new investment will enable it to scale up separation and purification of plant-based paraxylene — a chemical used in PET plastic as well as polyester fibers. .... allows the [whole] bottle to be plant-based. .... Virent is one of three companies working with Coca-Cola on PlantBottle technology. The others are Colorado-based Gevo and Avantium, which is based in the Netherlands. ... the company is vying to build [a commercial-scale plant] to meet a 2020 deadline Coca-Cola has set to have its PlantBottles in mass production [Thomas Content, Milwaukee Journal Sentinel, Sep 8, 14]

Virent announced another step toward production of a key chemical needed by Coca-Cola to make plastic bottles entirely from plants. [Milwaukee Journal Sentinel, Dec 6, 13].... Renmatix (King of Prussia, PA; no SBIR) and Virent announced a strategic collaboration to convert affordable cellulosic sugars to renewable chemicals and bio-based packaging materials. Under the terms of the multi-phase development project, Renmatix’s Plantrose™ platform will be evaluated and potentially optimized to provide an affordable sugar stream for Virent’s Bioforming® process for the large-scale production of bio-based paraxylene. Paraxylene is a basic raw material used in the manufacture of purified terephthalic acid (PTA), an important chemical in the production of plastic bottles and fibers made from polyethylene terephthalate (PET) .... The development of Virent’s BioForming® technology platform is supported through strategic partners including Cargill, The Coca-Cola Company, Honda and Shell, as well as 80 employees [Virent press release, Dec 6]

Virent (Madison, WI; $200K SBIR), which dropped the word "Energy" from its corporate name several years ago, now sees Coca-Cola's quest to make plastic bottles that contain no petroleum as its fastest path toward commercialization and cash flow. . . The company's chemical process takes plant sugars and converts them using a process developed in chemistry labs at the University of Wisconsin-Madison. [Thomas Content, Milwaukee Journal Sentinel, Sep 14, 13]

Virent laid off 35 workers [a third of its workforce] as the biofuels company narrows its focus to commercializing a chemical used to make renewable beverage bottles. [Milwaukee Journal Sentinel, Jul 24, 13]

Virent (Madison, WI; $200K SBIR) has been awarded up to $4M for a research project aimed at bringing down the cost of making biofuels from plants that aren't eaten. one of four that received funding totaling $13M from the U.S. Energy Department ..... to take corn stover and loblolly pine with the bark removed, and strip it down to the hydrocarbons that can then be converted into fuel [Thomas Content, Milwaukee Journal Sentinel, Jul 1, 13]

Virent (Madison, WI' two SBIRs) shipped 100 gallons of its renewable formula jet fuel to the U.S. Air Force Research Laboratory for testing from a new demonstration plant it has opened in Madison. ... under a $1.5 million federal grant from [FAA and DOT]. [Thomas Content, Milwaukee Journal Sentinel, May 1, 13]

A biofuels initiative that aims to reduce the military's reliance on imported petroleum is moving ahead, with companies including Virent(Madison, WI; $200K SBIR in the mid 1990s) invited to submit proposals in a $30 million initiative .... another step in a program launched last year by the U.S. Navy along with the Energy and Agriculture departments that aims to help build up the supply of advanced biofuels - those that don't rely on sugars from plants that are eaten, like corn-based ethanol. ... The Air Force said it will select five companies in the first phase, with plans to award $70 million each to the three companies that advance to the second phase and provide matching private-sector funding. .... Critics include Arizona Sen. John McCain, who has termed it a case of "misplaced priorities" and said the Pentagon shouldn't be in the business of funding and sponsoring new energy technologies. [Thomas Content, Milwaukee Journal Sentinel, Jul 2] McCain was a jet jockey who typically expects unlimited logistics for strapping a ready-to-go jet on his back. Wars, though, are fought with logistics as a combat limiter. Never mind, since there is money to be passed out, the political system will spend its energy steering the money to their constituents.

Using technology licensed from Madison-based biofuels firm Virent, Royal Dutch Shell has built a pilot biofuel plant in Houston. Shell has been a partner of Virent for the past five years .... Virent has 117 employees, up from about 20 five years ago. The company has attracted $75 million in private investment as well as grants from several federal agencies. [Thomas Content,[Milwaukee Journal Sentinel, Feb 28, 12]

Virent Energy signed a multimillion dollar deal to supply Coco-Cola Co. with completely renewable, plant-based bottles ... Virent and two other biofuels technology firms, Gevo (Englewood, CO; $1.5M SBIR) and Avantium(the Netherlands) were all selected to help Coke provide 100% renewable, 100% plant-based bottles. [Thomas Content, Milwaukee Journal Sentinel, Dec 15, 11] As a result, The State of Wisconsin Investment Board said it will commit as much as $80 million to Danville, Calif.-based Northgate Capital. This is the first time the $85 billion public pension fund has had the opportunity to invest with the top venture capital pools, which are willing to take public funds' money because the weak economy has made it more difficult for the funds to lure private investors. [Kathleen Gallagher, Milwaukee Journal Sentinel, Dec 16, 11]

A plant-based jet fuel developed by Virent Energy Systems has passed a round of U.S. Air Force testing. ... a 100% renewable fuel rather than a product that would be blended with petroleum, said Aaron Imrie, Virent commercial fuels manager. ... using a chemical conversion process that was developed in labs at the University of Wisconsin-Madison. Virent's announcement came weeks after a competitor, Gevo(Englewood, CO; $1.5M SBIR) was awarded the biofuel industry's first contract to supply jet fuel to the Air Force. [Thomas Content, Milwaukee Journal Sentinel, Oct 11, 11]

Virent Energy Systems (Madison, WI; two SBIRs in 2003) was awarded up to $4 million for a project to accelerate the development of drop-in biofuels as well as bio-based chemicals. Virent's was one of three small-scale projects awarded funding by the Department of Energy, the agency announced. ... to demonstrate the effectiveness of its process to convert plant sugars into both a hydrocarbon that can be refined and blended into gasoline and jet fuel - as well as chemicals. ... the U.S. Navy and the departments of Energy and Agriculture are teaming up to award up to $510 million to companies to build an undisclosed number of bio-refineries around the country. [Thomas Content, Milwaukee Journal Sentinel, Aug 31, 11]

Virent Energy Systems (Madison, WI; $200K SBIR) has produced "biogasoline" from crops that aren't part of the nation's food supply. ... announced it has made biogasoline from a combination of corn stalks and leaves left on farms after the corn harvest, as well as pine tree branches, needles and stumps left on the forest floor after logging. ... employs about 100 people in Madison. Its technology, developed by Cortright and University of Wisconsin-Madison professor James Dumesic, is one of six that are competing in the consortium. [Thomas Content, Milwaukee Journal Sentinel, Jun 2, 11]

Virent (Madison, WI; $200K SBIR in 2003) announced [with its research partner, Shell, which invested money and technical assistance in the plant] that it has opened the first biogasoline plant, creating gasoline from plant sugars. The company was formed in 2002 to deploy technological innovations developed at the University of Wisconsin-Madison [Thomas Content, Milwaukee Journal Sentinel, Mar 23, 10]

Virent Energy Systems (Madison, WI; two SBIRs) has been awarded $2.4 million from the U.S. Department of Energy to help convert plant sugars into transportation fuels.... included in $33.8 million in funds from the [stimulus] to the National Advanced Biofuels Consortium ... Virent said it started working on pre-treatment and deconstruction of cellulosic biomass in 2007 with a $2 million Advanced Technology Program grant from NIST. [Thomas Content, Milwaukee Journal Sentinel, Feb 4, 10] Note that the stimulus funding is still in its first year when you hear all the political whining that the stimulus failed as measured by the 10% national unemployment. Facts are elastic toys in the hand of politicians eager for theater.

gasoline from cornstalks? ... Co-inventor Randy Cortright was a scientist at the University of Wisconsin when he developed the process in 2001; he left the following year to found Virent and commercialize his findings. Virent (Madison, WI; two SBIRs) can already produce small amounts of fuel from stalks, and Cortright says the process would also work with anything from wheat straw to sugarcane stalks to switchgrass. Grass in; gas out. [Jeremy Caplan, Time, Dec 15, 08]

Virent Energy Systems (Madison WI; two Phase 1 SBIRs) got a $2M NIST grant for its research into making fuels from sugars found in wood and crops. has built demonstration systems that are capable of converting sugars into hydrogen or directly into renewable biofuels. It received $21 million this summer in a round of venture capital financing. [Milwaukee Journal-Sentinel, Oct 2]

Viresco Energy

A biomass energy project was awarded $2.5 million in a congressional earmark that Utah Sen. Bob Bennett included in a pending federal budget bill. Viresco Energy (no SBIR) is a company headed by a Southern California real-estate developer who owns a ranch in Alton in southern Utah, where Jim Guthrie proposes to turn wood waste, manure or coal into 40 barrels of fuel a day. ... Bennett's office says it did some diligence before sponsoring the taxpayer-funded item. [AP, Oct 29, 09]

Virna Therapeutics (Boston, MA)

Virna Therapeutics (Boston, MA: no SBIR) announces that they are partnering with University of Toronto to in-license neutralizing antibodies, to treat COVID-19. The discovery was made in the laboratory of Sachdev Sidhu, PhD., a professor of Molecular Genetics at the University of Toronto ... Virna Therapeutics has a three-pronged strategy to target the COVID-19 virus: (1) neutralizing antibodies that will prevent the virus from entering host cells, (2) CRISPR/Cas13d-based and LNA-based technologies for the treatment and prevention of RNA virus infection and (3) novel protease inhibitors that will prevent replication and release from host cells. [company press release, May 27, 20]

Virobay (Menlo Park, CA)

Drug developer Virobay (Menlo Park, CA; backed by drug maker AbbVie, no SBIR) hopes to raise $50 million [IPO] for a critical year of clinical trials [Ron Leuty, San Francisco Business Times, Sep 10, 14]

ViroPharma

Shire (Ireland) successfully completed its $50 per share tender offer for all the outstanding shares of ViroPharma (Exton, PA; $2.5M SBIR) stock. .... as part of Shire’s $4.2 billion acquisition of ViroPharma. [John George, Philadelphia Business Journal, Jan 24, 14]

Viro Pharma up 26% [Nov 11, 13]

Drug maker Shire says it is buying the rare disease biopharmaceutical company ViroPharma (Exton, PA; $2.5M SBIR mostly in 2003) in a deal worth $4.2 billion. .... ViroPharma makes CINRYZE, which treats hereditary angioedema, a disease characterized by recurrent attacks of swelling of the skin or mucous membranes. It can be painful, disfiguring and potentially life-threatening. [AP, Nov 11, 13]

Viro Pharma up 28% [Sep 13, 13]

A lawsuit filed by ViroPharma(Exton, PA; $2.4M SBIR) in an attempt to keep generic versions of its Vanocin antibiotic off the market has been dismissed, [Bloomberg, Jan 10, 13] said it expects worldwide products sales of between $450 million and $475 million next year, with North American sales of Cinryze accounting for $390 million to $400 million of that total. [John George, Philadelphia Business Journal, Jan 7, 13]

ViroPharma up 14% [Aug 6, 12]

ViroPharma down 10% [May 1, 12]

Viro Pharma down 22% [Apr 10, 12] said that three companies are now selling low-cost generic versions of its drug Vancocin, an antibiotic that brings in half of ViroPharma's revenue.[AP, Apr 10]

ViroPharma up 18% [Dec 14, 11]

ViroPharma’s board of directors authorized the use of up to an additional $200 million to repurchase shares of its common stock and/or its 2 percent senior convertible notes due 2017. The Exton, Pa., biopharmaceutical company also said Thursday it has substantially completed the $150 million securities repurchase announced in March 2011.[Philadelphia Business Journal, Sep 15, 11] Good for the company, but any company that deploys capital that way should be barred from government programs that provide capital where the company cannot get capital in private markets.

The European Commission has granted a marketing authorization to ViroPharma for Buccolam, a treatment for seizures in infants, toddlers, children and adolescents. [Philadelpha Business Journal, Sep 6, 11]

The European Commission approved ViroPharma's application to market Cinryze to adults and adolescents with hereditary angioedema (HAE) for the treatment and routine pre-procedure prevention of angioedema attacks. [Peter Van Allen, Philadelphia Business Journal, Jun 15, 11]

ViroPharma down 10% [Apr 18, 11]

ViroPharma (Exton, PA; $2.5M SBIR a decade ago) board of directors authorized the use of up to $150 million to repurchase shares of its common stock and/or senior convertible notes. ... The company’s lead products are Cinryze, which is used to prevent angioedema attacks in adolescent and adult patients with the hereditary immune system disorder, and Vancocin, a treatment for hospital-acquired infections.[John George, Philadelphia Business Journal, Mar 9, 11]

ViroPharma up 10% [Feb 24, 10]

ViroPharma down 18% [Oct 28, 09] reported weaker-than-expected third-quarter earnings [Wall Street Journal, Oct 29]

Viro Pharma up 12% [Sep 28, 09]

Viropharma up 13% [Jul 29, 09]

ViroPharma up 11%% [Mar 31, 09]

Viropharma up 11% [Mar 27, 09]

ViroPharma up 13% [Mar 13, 09]

Viro Pharma down 11% [Feb 27, 09]

Viro Pharma down 53% [Feb 9, 09] said its experimental antiviral compound, maribavir, failed to meet the main goal of a late-stage study in patients who have had bone marrow transplants [Reuters]

ViroPharma down 11% [Dec 15, 08]

Viro Pharma down 10% [Nov 11, 08] whose Vancocin antibiotic would be in direct competition with Optimer's anti-infective if approved [Wall Street Journal, Nov 12]

Viropharma down 10% [Oct 27, 08]

Viropharma up 10% [Oct 16, 08]

Viropharma up 14% [Oct 13, 08]

Viropharma down 12% [Oct 9, 08]

ViroPharma down 15% [Jul 15, 08] on news that it would acquire Lev Pharma.

ViroPharma up 10% on profit up 84% beating analyst estimates. [Aug 1, 07]

ViroXis (San Antonio, TX)

TFS Corp. an Australian firm that claims to be the world’s largest owner and manager of commercial Indian sandalwood plantations, has struck a deal to buy ViroXis (San Antonio, TX; no SBIR). and Santalis Pharmaceuticals (San Antonio, TX; no SBIR) [for] up to $270 million. ... TFS is expected to invest $25 million over five years in the companies. ... TFS will own the entities, which exclusively develop and sell products containing Indian sandalwood it grows and processes [W. Scott Bailey, San Antonio Business Journal, Jun 18, 15]

ViroXis (San Antonio, TX, no SBIR). is wrapping up a Phase 2 clinical study of its treatment for a virus that causes skin warts.The final patient of the 183-person enrolled study has completed treatment .... has developed a drug for treating the Human Papilloma Virus (HPV) using oils from the East Indian Sandalwood tree. The study is being funded by the proceeds of a $5 million Series B private offering. [Mike Thomas, San Antonio Business Journal , Feb 20, 14]

ViroXis (San Antonio, TX; no SBIR) enrolled its first patient in a Phase II study for treatment of the Human Papilloma Virus (HPV). ...will evaluate three strengths of the drug in a total of 180 patients .... funded by the proceeds of a $5 million Series B private offering. [Mike Thomas, San Antonio Business Journal, Dec 5, 12]

Virtify (Cambridge, MA)

life sciences services firm Virtify (Cambridge,MA; no SBIR, founded 2004) raised $3 million in equity out of a $3.5 million offering, according to federal filings .... to accelerate adoption of its structured content management software suite, which is intended to help companies bring drugs to market sooner. [Don Seiffert, Mass High Tech, Aug 31, 12]

Virtify (Cambridge, MA; no SBIR) has raised $5.5 million of a planned $7.5 million new funding round, the company reported in a federal document. ... makes electronic solutions for regulatory compliance and clinical trial management, intended to help companies bring drugs to market sooner. [Rodney Brown, Mass High Tech, Jun 3, 11]

Virtualitics

Virtual Incision (Lincoln, NE and Pleasanton, CA)

Virtual Incision (Lincoln, NE and Pleasanton, CA; no SBIR, founded 2006) a medical device company pioneering a first-of-its-kind miniaturized surgical robot, announced it has raised $20 million in a Series B+ financing ... the MIRA Surgical Robotic Platform in support of regulatory pathway to approval. The study will evaluate the safety and efficacy of the MIRA platform for colon resection surgeries in patients at a number of U.S. investigational sites. MIRA is an investigational robot that will enable surgeons to perform minimally invasive surgeries in any hospital or surgery center, without the need for a dedicated space or for the infrastructure typically required for other “mainframe” robotic systems ... an investigational device that is not available for sale in the United States [company press release, Jan 8, 20]

medical device company Virtual Incision (a spin-out of the University of Nebraska), (Lincoln, NE and Pleasanton, CA; no SBIR, founded 2006) raised an $18M Series B ... will support the company’s premarket notification submission to [FDA] for its next-generation miniaturized robotically assisted surgical device (RASD). [company press release, Dec 11, 17] total funding to date $43M (crunchbase)

VirtualScopics (Rochester, NY)

Virtual Scopics (Rochester, NY; one SBIR) down 13% [Feb 8, 16]

Virtual Scopics (Rochester, NY; $200K SBIR) up 15% [Dec 17, 15]

VirtualScopics (Linden Oaks, NY; one SBIR) said it has completed the first closing in a sale of a new series of preferred stock to the Merck Global Health Innovation Fund for $3 million. [Smriti Jacob, Rochester Business Jounral, Apr 4, 12]

VirtualScopics (Rochester, NY; one SBIR) said it will partner with GE Healthcare’s Medical Diagnostics Imanet business to analyze more than 40 Positron Emission Tomography imaging biomarkers for drug research [Smriti Jacob, Rochester Business Journal, Jun 4, 10]

Virtusa (Westborough MA)

Virtusa (Westborough MA; no SBIR), an IT company, reports pricing its IPO for $61M. [Mass High Tech, Aug 3]

Viscardia Portland, OR)

medical device developer Viscardia (Portland, OR; no SBIR) says it has completed a Series B financing round while obtaining "assets and technology rights" for a local heart monitor developer [Inovise Medical, Newberg, OR; $1M SBIR] for $12.5 million. ... Inovise is a 20-year-old company that landed $5 million in 2011 [Andy Giegerich, Portland Business Journal, Feb 2, 17]

VisEn Medical (Woburn, MA)

Perkin Elmerhas bought molecular imaging technology company VisEn Medical (Bedford, MA; $3.5M SBIR) ... VisEn Medical develops its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic Imaging Systems, which can be help identify biomarkers and therapeutic efficacy in cells. The technology is used by academic research departments, pharmaceutical research organizations, medical imaging facilities, contract research organizations, biologists and radiologists. ... founded in 2000 by Ralph Weissleder and Kirtland Poss. ... had raised a total of $12.5 million in venture funding, as of the latest report in 2008. [Mass High Tech, Aug 3, 10]

VisEn Medical received venture debt financing worth $3.5 million from GE Healthcare Financial Services [to] assist VisEn in globally commercializing its fluorescence-in vivo imaging technology systems. [Mass High Tech, Jul 23]

Officials at VisEn Medical (Woburn, MA; $3.5M SBIR) say that the medical imaging technology company has landed a $5 million tranche of Series B financing [Mass High Tech, Apr 18, 08]

VisEn Medical, a maker of fluorescence-imaging products, has completed its second round of venture capital financing, - $6.9M. [Mass High Tech, Oct 23]

The VisEn Medical (Woburn, MA; $3.5M SBIR) molecular imaging system relies on large fluorescent-protein probes that interact with disease-related proteins in the body and allow researchers to see where they are and in what concentrations. ... collaborating with Merck, Eli Lilly, and other pharmaceutical companies [Katherine Bourzac, MIT Tech Review, Jul 12] The company was founded in 2000 as a technology spin-out from Mass General Hospital, first SBIR in 2002, and now the board is heavy with VC and business experts - the right structure and flight path for an SBIR success story if the technology works profitably. If not, the SBIR money was at least well risked. And if it does work out, medicine's accuracy will ratchet up again although with another ratchet in the national health care cost.

VisEn Medical (Woburn, MA) made a distribution agreement with Japanese global imaging company Olympus. VisEn makes products that use fluorescence tomography imaging systems (an X-ray technology) to carry out research in the fields of cancer, bone growth and cardiovascular diseases [Mass High-Tech, Aug 7] Since its founding in 2000, it has grown to 25 people with help frm at least 3$M in HHS SBIR, at least $4M VC, and at least one equity investment by the medical arm of Siemens AG. The co-founders are a world class Harvard Medical prof and a biomed business guy.

VisiGen Biotechnologies (Houston, TX)

VisiGen Biotechnologies (Houston, TX; $200K SBIR), a company created by University of Houston researchers, was acquired for $20 million by Invitrogen Corp., which recently merged with Applied Biosystems to form Life Technologies. The company is working on a new process to sequence individual human genomes. [Houston Chronicle, Dec 11, 08]

VisionGate (Phoenix,AZ)

VisionGate (Phoenix, AZ; $500K SBIR) biotech company that offers a lung cancer detection test, has secured worldwide exclusive rights to a drug designed to prevent the deadly disease [Angela Gonzales, Phoenix Business Journal, Jan 7, 16] led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. [company website]

VisionGate (Phoenix, AZ; $500K SBIR, founded 2001) developer of a 3-D cell microscope to detect lung cancer at its earliest stages, is quietly making moves to go public. ...raised $25 million to date — all angel investors and no venture capital — and said the next step is to file an initial public offering to raise an additional $75 million. Nelson said that could happen within the next year. [Angela Gonzales, Phoenix Business Journal, Jul 15, 15]

VisionQuest (Albuquerque, NM)

VisionQuest Biomedical (Albuquerque, NM; $24M SBIR) A disease-detecting device under development at VisionQuest Biomedical is on the fast track for commercialization thanks to a $1 million federal grant. .... is developing a commercial prototype of a biomedical device called i-RxTherm. The device, once FDA-approved, would be used to detect a degenerative nerve damage condition in people with diabetes — called diabetic peripheral neuropathy — in its early stages. [Jacob Maranda, New Mexico Inno, October 14, 2022]

Vision Quest Biomedical (Albuquerque, NM; $1.2M SBIR, founded 2007) awarded a $2M grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to commercialize ASPIRE, a device that uses AI for cerebral malaria diagnosis. [company press release, Jun 12, 21]

Found a sugar daddy. Peter Soliz, founder and CEO of Albuquerque-based VisionQuest, said his company’s rapid retinal screening technology for diabetics might still be languishing in a University of New Mexico lab if it weren’t for [SBIR]. ... has used multiple SBIR grants totaling $16. 3 million to fully develop its rapid retinal screening system and other related technologies for diabetic patients. VisionQuest has received 15 SBIR grants for a total of $16.3 million since launching in 2008, allowing it to fully develop the retinal-imaging technology that Soliz and other engineers originally created at UNM. That federal funding also allowed it to build additional, spin-off technologies to screen diabetic patients for nerve damage in their feet, diagnose retinopathy in infants born prematurely and to identify malarial retinopathy, which can indicate cerebral malaria in patients. [Kevin Robinson-Avila, Albuquerque Journal, Jan 23, 18] Was SBIR invented for full development of commercial products? Don't ask Congress which loves the success stories of local companies and has no time for investigation of such "success" even though government is thereby competing with private capital. in all but the earliest and riskiest stages of technical uncertainty.

;Vision-Sciences (Orangeburg, NY)

Uroplasty (Minnetonka, MN; no SBIR) and Vision Sciences (Orangeburg, NY; two SBIRs) entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50 million for the fiscal year beginning April 1, 2015. ... the combined company will conduct business as Cogentix Medical [joint press release, Dec 22,14]

Medical devices firm Vision-Sciences (Orangeburg, NY) reports plans to shutter its manufacturing facility in Massachusetts [Mass High Tech, Oct 16, 07]

Vision-Sciences (Orangeburg, NY; 92 employees, no SBIR) up 24% as the FDA cleared it to market endoscopes, its core product, featuring miniature cameras.

Vistagen Therapeutics (Burlingame, CA)

VistaGen (South San Francisco, CA; $7M SBIR) announces acquiring Pherin Pharmaceuticals (no SBIR) in a bid to wipe out any future royalty payments in addition to nabbing three new assets. The deal comes more than four years after Vistagen licensed Pherin’s nasal spray to treat social anxiety, which sits atop the former’s pipeline. [Max BayerDec, Fierce Biotech, Dec 21, 2022]

VistaGen Therapeutics (S San Francisco, CA; &$7M SBIR) announced the completion of an interim analysis of PALISADE-2, the Company’s second Phase 3 clinical trial assessing drug candidate PH94B as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD), which concluded that PALISADE-2 should continue as planned. [company press release, Sep 8, 22]

VistaGen (South San Francisco, CA; $7M SBIR) announced that “While we examine the results of our PALISADE-1 Phase 3 study in social anxiety disorder, we have paused enrollment in our PALISADE-2 Phase 3 study and have engaged an independent biostatistician to conduct an interim analysis of data collected to date. [company press release, Aug 11, 22]

VistaGen Therapeutics (South San Francico, CA; $9M SBIR) announced topline results from the ELEVATE study, a Phase 2 study of AV-101, its NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an adjunctive treatment of major depressive disorder (MDD). In this study, the AV-101 treatment arm did not differentiate from placebo on the primary endpoint (change in the Montgomery-Åsberg Depression Rating Scale (MADRS-10) total score compared to baseline) [company press release, Nov 14, 19]

VistaGen Therapeutics (South San Francisco, CA; $8M SBIR founded 1998) has licensed Pherin Pharmaceuticals' (Los Altos, CA; no SBIR) lead candidate, a nasal spray for social anxiety disorder. [Amirah Al Idrus, Fierce Biotech, Sep 13, 18] Vista total funding $55M [crunchbse.con]

VistaGen Therapeutics (S SanFrancisco, CA; $4.8M SBIR ($4.2M in one bite)) up 13% [Jun 21, 16]

VistaGen Therapeutics (South San Francisco, CA; $4.8M SBIR with one of $4.2M) dosed the first patient in its Phase 2a trial of its lead compound, AV-101, to treat depression. [Alex Lash, xconomy.com, Nov 6, 15]

The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money. SBIR companies got $10M of it. Bio Time (Berkeley, CA; $300K SBIR) $4.7M; Vistagen Therapeutics (Burlingame, CA; $600K SBIR) $970K; Gamma Medica Ideas (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR) $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K ; Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]

Vistec Lithography

After holding a job fair that attracted hundreds, Vistec [Lithography] has hired 13 people, including project and software engineers. for its debut in Watervliet Arsenal finding local high-tech workers isn't easy, especially with tech giants such as IBM Corp. -- which has a massive operation in Dutchess County -- as competition [Albany Times-Union, Apr 19]

Vistec Lithography Ltd., the British semiconductor equipment manufacturer that is moving to the Watervliet Arsenal in exchange for $30M in state funding, is leaving behind a precious asset. [Albany Times-Union, Jan 26, 07] The Cambridge Evening News says Vistech is only bringing 20 of its 60 high-tech workers. American speaking techies pour out of RPI across the river; English speakers in comfortable Cambridge seem to want to stay among their own.

The [State] University at Albany got $750K from the state to work with Vistec Lithography to develop the company's electron beam technology. [they] will work together on bringing the technology -- which would enable the production of increasingly powerful computer chips -- to market. Vistec is moving from Cambridge, England, to quarters at Watervliet Arsenal and Albany NanoTech. [Eric Anderson, Albany Times-Union, Jan 23, 07] A simultaneous Michael Hill piece notes that young brains are leaving the Capital District as hand-wringing Politicians from both major parties have promised to revitalize upstate New York, with mixed results. The rich upstate array of good colleges and universities is offset by the cost of living and the brisk winters. New York, although an intellectual giant, has competition from any states offering dollar sweeteners, such as North Carolina.

Guns to Butter. Vistec Lithography Ltd. is moving from Cambridge, England, to the Watervliet (NY) Arsenal to invest $125M atop NY state's $30M and the research capabilities at Albany NanoTech. Vistec makes electron-beam lithography equipment used in the manufacture of computer chips. Hiring is on. [Larry Rulison, Albany Times-Union, Jan 11] The company might find as challenging an intellectual atmosphere around Rensselaer Poly as around Cambridge. [Disclaimer: Watervliet is my home town and RPI my alma mater.]

Visterra (once Parasol Thera) (Cambridge,MA)

Otsuka Pharmaceutical (Japan) is expanding its pipeline and U.S. reach with an agreement to acquire clinical-stage drug developer Visterra (Waltham, MA; one SBIR, founded 2007) for $430 million cash. [Frank Vinluan, xconomy.com, Jul 11, 18] total funding $125M [crunchbase.com]

Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013. ... a spinoff company of the Fred Hutchinson Cancer Research Center .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising. The other Fierce 14 are: Acetylon Pharmaceuticals; AnaptysBio; CytomX (Santa Barbara, CA; $500K SBIR); FibroGen (South San Francisco, CA; $1.3M SBIR); Immunocore; Jounce Therapeutics; Kala Pharmaceuticals; MacroGenics (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; Ultragenyx; UniQure; and Visterra. [Valerie Bauman, Puget Sound Business Journal , Sep 24]

biotech startup Visterra Inc., formerly known as Parasol Therapeutics, (Cambridge, MA; no SBIR) has landed $6 million in its first round of funding ... develops technology to “interrogate how pathogens interact with human cells,” which is used to develop diagnostics, vaccines and therapeutics [Mass High Tech, Jul 12, 10]

Visualase (Houston, TX)

Medtronic (now Irish by US tax dodge) said it will spend up to $105 million to buy Visualase (Houston, TX; no SBIR, founded 2005 as a spin-off from BioTex (Houston, TX; $10M SBIR)) that has developed a system using an MRI-guided laser for minimally invasive surgeries. [Evan Ramstad, Minneapolis Star Tribune, Jul 28, 14]

Vitae Pharmaceuticals (Fort Washington, PA)

Vitae Pharma up 157% [Sep 14, 16] Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals for $639 million, more than double its market value, in a move aimed at strengthening the drugmaker's skin-care pipeline. [Austen Hufford, Dow Jones Newswire, Sep 14, 16]

Vitae Pharma up 18% [May 23, 16]

Vitae Pharma up 17% [May 16, 16]

Vitae Pharma down 10% [May 4, 16]

biotechnology company Vitae Pharmaceuticals (Fort Washington, PA; no SBIR, founded 2001) launched its $35.8 million public stock offering ... went public through a $55 million IPO last September ... to continue the development of its most advanced new drug candidate: VTP-43742. The drug is being developed as a treatment for psoriasis, multiple sclerosis and other autoimmune diseases. [John George, Philadelphia Business Journal, Jan 20, 15]

Vitae Pharmaceuticals (Fort Washington, PA; no SBIR) raised $55 million [IPO] ... developed a proprietary structure-based, drug-discovery platform— called Contour — to find small molecule drugs with the potential to treat a variety of diseases where there is a significant unmet medical need. [Jarad Shelley, Philadelphia Business Journal, Sep 24, 14]

VitalMedix (Minneapolis, MN)

Unable to secure financing in a tough economy, VitalMedix (Hudson, WI; no SBIR), a promising start-up company spun off from the University of Minnesota, will liquidate under federal bankruptcy laws. ... was developing a hemorrhagic shock drug called Tamiasyn designed to keep alive victims suffering near-fatal injuries [Janet Moore, Minneapolis Star Tribune, Feb 25, 10]

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] .... founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers. ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

A Minneapolis biotech company, lured to Hudson by Wisconsin's tax credits, said Monday it has raised $1 million in venture capital. .... VitalMedix is also in line to receive $1.7 million from the Department of Defense and U.S. Army, said Jeffrey M. Williams, VitalMedix president and chief executive. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 31, 09]

Moving for Subsidy. Lured by the state's tax credits for investments in high-growth companies, a biotech start-up said it was moving to Wisconsin. VitalMedix (Minneapolis, MN; no SBIR) is developing a drug that first responders, trauma center surgeons and military medics could use. The drug, Tamiasyn, has the potential to allow humans to endure severe blood loss and inhibit organ damage during resuscitation. .... Minnesota legislators tried to create a similar program but failed. .... The credits had lured another biotech company. Rapid Diagnostek (no SBIR) moved to Hudson last year from St. Paul to take advantage of the credits. The top executive at BioE (no apparent SBIR) a Twin Cities tech company, praised Wisconsin's embrace of tech companies and didn't rule out a move. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 10, 09)

VitalMedix, (Minneapolis, MN; no SBIR) a start-up medical company born of U of M research, might relocate in the Badger State for lack of investors in Minnesota. ... developing a hemorrhagic shock drug designed to keep alive a victim suffering near-fatal injuries, needs $3.5 million to advance its technology to human clinical trials. So far, VitalMedix has attracted only $600,000 from local investors. ... Should VitalMedix move across the border, it could lose $1 million in 2010 federal funding that U.S. Rep. Keith Ellison, D-Minnesota, has been trying to secure in Congress. [Thomas Lee, Minneapolis Star Tribune, May 5, 09]

Vital Therapies (Rancho Bernardo, CA)

Vital Therapies (San Diego, CA; SBIR), maker of a therapy for liver failure, [IPO] for gross proceeds of $54 million. .... has developed a device that acts much like a kidney dialysis machine, performing important metabolic functions for the liver. The device is meant to help patients survive until they get a liver transplant or have their own livers recover enough. It uses cartridges filled with cultured human liver tumor cells that retain their ability to perform most liver functions. .... is now in Phase 3 testing in the United States, Europe and Australia. [Bradley Fikes, utsandiego.com, Apr 17, 14]

Vital Therapies (San Diego, CA; no SBIR) and ’s TetraLogic Pharmaceuticals (Malvern, PA; no SBIR) both postponed their IPOs yesterday, according to the IPO research firm Renaissance Capital. [Bruce Bigelow, xconomy.com, Nov 22, 13]

Vital Therapies (Rancho Bernardo, CA; no SBIR) developer of a liver disease treatment, filed [IPO] of up to $86M ... joins a growing list of biotechs that have filed for IPOs this year under a market "window" more favorable than the industry has seen in years ..... testing a device that helps a patient's liver recover from a short-term disease, or help the patient survive until a liver transplant. [Bradley Fikes, utsandiego.com, Oct 13, 13]

Vital Vio (Troy, NY)

Vital Vio (Troy, NY; SBIR) that has reinvented disinfection with its patented VioSafe™ White Light Disinfection™ technology, announced it has been awarded yet another patent for its continuous disinfection technology that powers its germ-killing LEDs. ...was granted this latest patent for its “Single Diode Disinfection” technology, which allows for single component integration into LED light engines, enabling compatibility across a wide range of industry standard LED light fixtures and other products. [company press release, Apr 21, 18]

Vital Vio (Troy, NY; no SBIR, founded 2013), the health care solutions company that has reinvented disinfection with its patented VioSafe™ White Light Disinfection™ technology, announced it has closed a syndicate investment round to expand applications of its technology and adoption of its germ-killing LEDs. [company press release, Jan 25, 18]

Vital Vio (North Greenbush, NY; no SBIR) startup that designs lights meant to kill bacteria such as MRSA, E. coli and salmonella, has raised $2.25 million [Chelsea Diana, Albany Business Review, May 2, 16]

Vital Vio (Troy, NY; no SBIR, nine employees) startup, plans to increase the number of LED lights it manufactures. This means investing in a larger office and a contract manufacturing partner in 2015. ... lights are designed to kill bacteria that gathers in hospitals, gyms and hotel rooms. The company uses disinfectant white light to kill bacteria such as MRSA, Salmonella and E. Coli. ... co-founded by Rensselaer Polytechnic Institute alumni Colleen Costello and James Peterson in 2012. Costello came up with the idea of using LED lights to kill bacteria after her grandmother became sick while in the hospital. ... initial funding of $450,000 from SOSVentures, an international venture capital fund [Chelsea Diana, Albany Business Review, Dec 30, 14]

The Eastern New York Angels will fund more companies, this time focusing on later stage companies instead of startups.
The goal is to raise $2.5 million by the end of the year. ... recently has invested $1.5 million into six early-stage companies with a seventh pending .... Companies funded in the first round include Paper Battery (Troy, NY; no SBIR), Ener-G-Rotors (Troy, NY; no SBIR), Vital Vio (Troy, NY; no SBIR),ThermoAura (Troy, NY; no SBIR) (a manufacturer of high performing thermo-electric material, will open a new production plant in suburban Albany this summer as it moves into commercialization), and Free Form Fibers (Saratoga Springs, NY; one SBIR). [Keshia Clukey, Albany Business Review, Jun 30, 14]

Tech Valley-based early stage seed investment funds ... have co-invested in Vital Vio (Troy, NY; no SBIR) startup that developed unique LED technology that offers disinfection and therapeutic lighting solutions. The size of the investment wasn’t disclosed. Early tests of its technology indicate it can reduce bacterial growth [Eric Anderson, Albany Times-Union, Aug 8, 13]

VitaPath Genetics (Foster City, CA)

In its first round of venture funding, VitaPath Genetics (Foster City, CA; no SBIR) raised $6 million. ... working on molecular medical tests to help identify genetic problems, particularly birth defects such as Spina Bifida, in time to correct them. [San Francisco Business Times, Sep 10, 09]

Vitriflex (San Jose, CA)

Vitriflex (San Jose, CA; no SBIR) that develops gas barrier film technology for solar panels and mobile displays, raised $3 million in a $5 million equity round. ..... raised $5 million last year [Vincent Lara-Cinisomo,Silicon Valley Business Journal, Aug 7, 13]

Vium (San Mateo, CA)

startup Vium (San Mateo, CA; no SBIR for stealth companies) has a different idea [from microchips that act like human organs], what it calls a “living informatics” approach that combines big data techniques with sensor technologies to try to boost the speed, efficiency, and success rate of animal tests themselves. Vium has been operating stealthily under the name “Mousera” for about three years, but this morning made its first announcement including details about the technology it’s developed. ... has already attracted $33 million in venture financing [Ben Fidler, xconomy.com, Jun 2, 16]

Vivex Biomedical

Vivex Biomedical (Marietta, GA; no SBIR) A biomedical startup that focuses on implant technology and stem cell therapies has raised $7.4 million, according to a [SEC] filing. .... is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells. [Urvaksh Karkaria, Atlanta Business Chronicle, Sep 17, 13]

A biomedical startup Vivex Biomedical (Marietta, GA; no SBIR) that focuses on implant technology and stem cell therapies is raising $5.5 million, according to [SEC] filing. .... is developing implant technology to help stimulate bone regrowth. ... has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells. [Urvaksh Karkaria, Atlanta Business Chronicle, Jul 19, 13]

Amendia (Marietta, GA; no SBIR, a few employees in 2012, founded 2007) will invest up to $50 million to commercialize a biomedical spinoff that focuses on implant technology and stem cell therapies. The new venture, Vivex Biomedical Inc., is developing implant technology to help stimulate bone regrowth. Vivex has also licensed a highly adaptive adult stem cell line, known as MIAMI (Marrow Isolated Adult Multi-lineage Inducible) cells. [Urvaksh Karkaria, Atlanta Business Journal, Apr 12, 13]

Vividion Therapeutics (San Diego, CA)

Vividion Therapeutics (San Diego, CA; no SBIR), discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, announced it has entered into an exclusive worldwide option and license agreement with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range ofoncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at different stages of development. will receive $135 million in a cash upfront payment from Roche and is eligible to receive several billion dollars in payments based on the achievement of preclinical, development and commercial milestones, as well as royalties on sales of commercialized products resulting from the collaboration. [company press release, May 21, 20]

Vividion Therapeutics (San Diego, CA; no SBIR, founded 2013 spun out of The Scripps Research Institute), looking to increase the number of proteins that small molecules can target, has raised $82 million series B which will bring at least one of three programs through clinical proof of concept. [Amirah Al Idrus, Fierce Biotech, Apr 30, 19] prior fnding $155M [crunchbase.com]

Vividion Therapeutics (San Diego, CA; no time for SBIR) is partnering with Celgene to develop new drugs that modulate protein levels as a way of treating disease. Celgene will pay Vividion $101 million up front, which includes an equity investment. The partnership will last four years, but Celgene has the option to pay more to extend it for another two years. ... The startup’s executive chairman is Tom Daniel (pictured), Celgene’s former president of research and early development. Vividion launched last year backed by $50 million in funding. [Frank Vinluan, xconomy.com, Mar 5, 18]

Vivisimo (Pittsburgh, PA) )

Innovation Works and the Pittsburgh Life Sciences Greenhouse have spent the past decade as a tag-team source for fledgling companies — ideas even — to find the financial support needed to grow into viable, productive and profitable companies. .... Looking at the 2001-2005 period, firms funded by the two groups during this period include Aethon (no SBIR), Vivisimo ($700K SBIR), ALung Technologies (no SBIR), Plextronics ($300K SBIR), Inc., RedZone Robotics ($1.6M SBIR) and Thorley Industries (no SBIR) (4moms). Other than Vivisimo, which was bought by IBM in 2012, all of those companies are core firms in the portfolios of local venture capital firms [Ethan Lott, Pittsburgh Business Times, Jul 8, 13]

Vixar (Plymouth, MN)

Osram (Germany) has added to its expertise in semiconductor-based optical security technology by acquiring Vixar (Plymouth, MN; $1.4M SBIR, founded 2005 by two former Honeywell engineers). Already a technology leader in infrared LEDs and infrared laser diodes, Osram will have a unique breadth of technological expertise and an expanded product portfolio after bringing on board Vixar’s specialist capabilities in the field of VCSEL [Osram press release, May 3, 18] total Vixar funding $2.5M [crunchbase.com]

As a top engineer at Honeywell in the 1990s, Mary Hibbs-Brenner helped pioneer the use of lasers in powering short-distance telecommunication systems, technology that later fueled the growth of the Internet. Today, as co-founder and chief executive of Vixar (Plymouth, MN, no SBIR), Hibbs-Brenner hopes to apply that same expertise to office printers and, eventually, to wireless body sensors. ,,,,start-up is developing a high-performance, energy-efficient [VCSEL] that experts say holds great promise for the medical device industry. [Minneapolis Star Tribune, Jun 20]

Vixel Corp (Broomfield, CO)

Trilumina (Albuquerque, NM; no SBIR, founded 2010) announced this week it was expanding its Albuquerque footprint [Collin Krabbe, Albuquerque Business Journal, May 25, 18] delivers a VCSEL technology platform capable of low-cost, small form facto and high power illumination for laser radar (LiDAR) and 3D-Sensing. [company website] Sounds like an outgrowth of VCSEL developed by Jack Jewell's 1980s team at Bell Labs, then funded with some SBIR to Jewell's firms Photonics Research (became Vixel), and Picolight. Jewell is now a consultant claiming 72 issued US patents and 150 publications [https://www.linkedin.com/in/jack-jewell-a1149410]

Vixel Bought, Founders Not in Sight. Data storage chip maker Emulex is buying Vixel for $310M cold cash, or $10 a share. Vixel started life in Albuquerque with an SDIO SBIR in 1991 as Photonics Research with a dream of a future for VCSELs. by Jack Jewell and Greg Olbright. Along the way Greg and Jack parted company as Vixel shifted focus to integrated products and Jack started a new VCSEL company in 1995 with, again, a BMDO SBIR. Jack's Picolight is doing well with 100 employees in Boulder. Last year Vixel lost nearly $10M. As Vixel now disappears in the maw of Emulex, neither Jack nor Greg is in sight. Both Vixel and Picolight can be claimed as two of the few SBIR economic successes.

Vixel jumped 17% Monday (Jun 2) when it said that Fujitsu incorporated a Vixel's "switch-on-a-chip" into storage devices to be shipped very soon. That good news was icing for last week's report of a deal with HP.

Vixel rose 19% when it announced an OEM deal with BlueArc Corporation, provider of the world's highest performance enterprise-class network attached storage (NAS) systems. With this new agreement, BlueArc's Si7500 Storage System, the world's fastest and most scalable NAS system, will incorporate Vixel's Fibre Channel switches to provide high-speed connectivity and path redundancy between servers and storage arrays. The Si7500 Storage System employs BlueArc's unique SiliconServer(TM) Architecture, delivering an unprecedented throughput speed of 2,000 Mb/s. Vixel's crossbar architecture Fibre Channel switches offer the highest READ rates and frame buffers per port of any Fibre Channel switch, ensuring higher I/O performance regardless of scale. Both companies' products offer enterprise storage users new levels of scalability and incorporate no-single point-of-failure designs for exceptionally high availability. [company press release]

Vixel said it shipped its first 9000 Series 2GB per second Fabric Switches to a UK-based user for a manufacturing test environment SAN.

The magazine Technology Investor (Dec 00) lists Vixel as a takeover candidate. At today's trading price, around $5, Vixel could be bought for a lot less than its first day trading price. Vixel started life in Albuquerque with three guys who are no longer around and its focus shifted from the VCSEL technology that Jack Jewell brought it to storage area networks. Jack would hardly recognize his creature.

Lucent Wants VixelStuff(May 3) Vixel says Lucent will integrate Vixel's Fibre Channel switching technology into its OptiStar(TM) product line. Vixel's technology will help Lucent interconnect Storage Area Networks (SANs) over high performance, IP-based Wide Area Networks (WANs). Vixel traders responded by jacking the price up 70% yesterday back up into the range of Vixel's 1999 IPO price. Vixel got its start with a (you guessed it) BMDO SBIR in 1991. The SBIR was seed money and each succeeding Phase 2 had a higher co-investment ratio.

Meanwhile Vixel took a 32% dive when it warned that losses would be a few percent more than street estimates. Don't disappoint First Call!

Vixel IPO Surges(Oct 4) Vixel (Bothell, WA) finished parlaying SBIR into a surging post-IPO trading. First, Vixel got a lot more than it expected from the IPO, $77M, when it priced at $18 instead of the $10-12 expected on the Street. Then the trading rocketed the shares to $42 which implies an instant market cap of $880M. Says one estimate, Vixel provides SANs, or storage area networks, that are designed to interconnect computer systems and data storage devices. Research firm International Data Corp. expects that worldwide revenue from SAN products should grow to $13.3B in 2002 from $2.5B in 1998. Vixel has come a long way from a startup with only an SDIO Phase 1 SBIR in 1992 to Photonics Research Inc, its first name. Vixel got three Phase 2s from SDIO/BMDO, all with a rising co-investment as CEO (now Chairman) Greg Olbright romanced the VCs in Silicon Valley. By 1996, SBIR had done its part as Vixel vertically integrated to the systems that used the VCSELs orginally funded. Happy in mountain redoubt above Boulder should be co-founded Jack Jewell who brought the VCSEL technology from Bell Labs and in 1995 struck out on his own to develop and sell the next generation of VCSELs at Picolight He started again with a BMDO Phasdee 1 SBIR which has grown to Phase 2s with escalating capital inflow. If ever SBIR had a shining example of what kind of entrepreneurs to fund, Olbright and Jewell are the peak.

Vixel on the Verge(Sep 13) Vixel (Bothell, WA) expects to go public later this month. It has come a long way since its SDIO SBIR founding in 1991 in Albuquerque. From just three guys to 166 in eight years with sales of $39M last year. From a beginning with a new-fangled VCSEL from Jack Jewell out of Bell Labs to what Hoover's describes, makes interconnection products for SANs (storage area networks, which link servers and other storage devices to a LAN or WAN). Vixel's switches, hubs, and transceivers are based on fibre channel, a technology that allows faster transmission of data between computer devices than does the older SCSI interconnect architecture. The company also provides software for monitoring and managing SAN interconnections. Vixel sells its products through resellers and directly to such electronics manufacturers as Sun Microsystems (54% of sales), Hewlett-Packard (12%), Compaq, and IBM. It has a distribution pact in Japan and outsources its manufacturing to Solectron.

One founder, Greg Olbright, is the Chairman. The other three of the first four employees are elsewhere and quite successful. Jack Jewell founded Picolight in 1995 for the next generation VCSELs and has at least 28 employees; Rob Bryan formed MicroOptical Devices which was soon bought by Emcore which itself recently went public and is highly recommended as "an explosive growth" company by an industry study; Winston Fu is a VC in Silicon Valley after two years at MBA school. Vixel expects to raise $40M with a post-IPO valuation around $200M. IF SDIO had taken an equity share in the company proportional to its capital contribution at the time, the government would have something like $50M worth of equity in a growing company. On BMDO's total investment of about $3M in Vixel, its ROI would be something the politicians could crow about. But government doesn't take equity (politicians will still crow if they ever discover the facts). And Vixel's success will be claimed by SBIR as a rationale for doing what it does - mostly just the opposite of smart investing in the newborn Vixels.

Public Vixel? The Red Herring (May 98) predicts that Vixel (Bothell, WA) will go public in the next six months.

The Vixel Story. The Red Herring (Mar 98) says Vixel (Bothell, WA) expects to be profitable this year and plans to go public within a year. Vixel started with $1M from Herb Alpert and an SBIR from SDIO which gave two more SBIRs but with rising match requirements. The money blossomed into $33M investment. If the SBIR agencies need an example of what can be done (who, us?), they can look here. Actually, they could try reading The Red Herring for insights into how the private markets work in info tech.

It wasn't until 1989 that Jack Jewell at Bell Labs figured out how to make [VCSELs] practical. Jewell was a long-haired West Coast type in the staid confines of New Jersey and his employers saw his VCSEL project as too harebrained to waste equipment time on. So, when a friend at nearby Bellcore offered the use of his company's equipment one weekend, Jewell was finally able to fabricate the tiny lasers. Amazingly enough, they worked. ... The first rollouts, in the form of network interface cards, have already begun from companies like Vixel and Hewlett-Packard. [Wired, Feb 98] How did the VCSELs get from Jewell's head to Vixel's interface cards? SBIR started it when Jewell bolted AT&T to found Vixel with the help of SDIO SBIR. Today, Vixel rolls on with at least $50M already invested from private capital and Jewell has started yet another VCSEL firm, Picolight, with the help of - you guessed it - BMDO SBIR to get started. But, of course, BMDO won't accept a simplistic linear development model of government Phase 1 and Phase 2 followed by promises of wonderful happening in Phase 3. Vixel didn't get to its present position that way and neither will most SBIR consumers.

Vixel Bags $50M, Moves to Puget Sound(Aug 4) Vixel Corp (Bothell, WA) which ties servers to computers via high-speed fiber-optic links with its eponymous VCSELs, made a $50 million deal with Compaq Computer. Compaq will bundle Vixel's technology with its new server computers, due out later this year. The deal will help Vixel, (most recently of Broomfield, CO) more than triple its sales. ... The company expects to turn profitable later this year, which may enable a 1998 IPO. "In 1996, we finished at roughly $10 million," VP Jeff Vogel said. "We're projecting three times that this year. We're growing at a phenomenal rate." The Compaq deal is one of many OEM deals that Vixel has in the works beyond current customers Sun and HP. The company just signed a deal with NEC, for under $10M but puts Vixel in partnership with Japan's largest server vendor. [facts from MS Baker, Puget Sound Business Journal, July 28] Vixel got its start in Albuquerque in 1991 with BMDO SBIR which led to three Phase 2s with increasing private sector matching. SBIR can do no better than invest in a Vixel. Co-founder, now CEO, Greg Olbright hustled capital from the outset including some from musician Herb Alpert. Vixel was the one company I showcased with a video clip at an international conference in Europe in 1995. Other co-founder Jack Jewell set out again on the start-up route and has three BMDO Phase 2s with increasing matching in his second year of operations at Picolight (Boulder, CO).

Vixel Raises $30M(Feb 10) Vixel Corp (Broomfield, CO) has raised $30M so far for its vertical cavity surface emitting laser technology after getting started with SDIO SBIR in 1991. The Red Herring Mar 97 predicts Vixel profitability in 97 after $10M in revenues in 1996. The most recent money came from an oversubscribed Oct 96 mezzanine round of $20.5M. Few SBIR companies worry about oversubscription. CEO Greg Olbright left Sandia Labs to found Vixel with partner Jack Jewell who left Bell Labs. The three SBIR Phase 2s from BMDO had a steadily escalating match rate of private capital.

Vixiar Medical (Annapolis, MD)

Vixiar Medical (Annapolis, MD; no SBIR) dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it closed its most recent financing of $1.5 million to complete an ongoing clinical trial and to prepare regulatory submissions. [company press release, Mar 21, 19]

Vixiar Medical (Annapolis, MD (Annapolis, MD, a spinout of Johns Hopkins; no SBIR), dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced it has raised seed round financing of over $1.5 million. ... to complete regulatory submissions and fund final engineering and initial production of the Company’s first product, Indicor™, a non-invasive point of care monitoring technology for estimating cardiac filling pressure. [company press release, Jul 17, 17]

Vizgen (Cambridge, MA)

startup Vizgen (Cambridge, MA; no SBIR), debuted with a $14 million Series A round of financing ... technology that is the basis of Vizgen is known as MERFISH, short for multiplexed error-robust fluorescence in situ hybridization. Diagnostics companies and others have been using fluorescence in situ hybridization, or FISH, to detect nucleic acid sequences in cells, tissues and tumors for decades. [Saran de Crescenzo, xconomy.com, Jan 31, 20]

Vizzario (Davis, CA

VSP Global announced a $2 million investment with Vizzario (Los Angeles, CA; no SBIR, founded 2014) startup, to develop eye care technologies to track visual acuity, eye strain, traumatic brain injury, and sports vision performance. ..... At its core, Vizzario operates as a sensory data exchange platform. That platform allows for value creation around data generated from technologies, including smart devices, wearables, eye-tracking tools, electroencephalogram (EEG) systems, virtual reality and augmented reality via head-mounted displays. Vizzario then utilizes advancements in machine learning, computer vision and deep learning techniques to help monitor and predict health outcomes through the analysis of an individual's data. [VSP press release, Apr 11, 16]

Vizzario (Davis, CA; no SBIR) eye-care technology company has raised $2 million — but isn't revealing plans for the money .... led by CEO Khizer Khaderi, who is a faculty member and director of neuro-ophthalmology at the UC Davis Eye Center. [Mark Anderson, Sacramento Business Journal, Jan 19, 16]

Vlingo

Yahoo led a $20M investment into vlingo (no SBIR), a venture-backed start-up that provides voice-recognition technology for mobile devices. OneSearch is available on Blackberry mobile devices now, and will be rolled out to other products in the future. [Carolyn Johnson, Boston Globe, Apr 2]

VLP Therapeutics (Gaithersburg, MD)

VLP Therapeutics (Gaithersburg, MD; $300K SBIR) vaccine developer raised $21 million in a Series A-1 funding round ... to accelerate research and development of a cancer treatment vaccine, the company said, in addition to preventative malaria and dengue vaccines. [Ana Lucía Murillo, DCInno, Dec 27, 21]

VLST (Seattle, WA)

VLST (Seattle, WA; no SBIR) biotech that raised about $50 million in its nine-year history, has wound down all its operations and sold off its remaining assets .... One buyer has scooped up an antibody drug candidate for cancer that’s being prepped for mid-stage clinical trials. Another buyer has obtained VLST’s proprietary drug discovery engine, preclinical drug candidates, and related intellectual property, [CEO] Simonetti said. .... founded 2004 by Immunex veterans Craig Smith and Steve Wiley. .... never put a single drug candidate from its discovery group into clinical trials. [Luke Timmerman, xconomy.com, Aug 7, 13]

VMware

A $360 M return on a two-month investment [in VMware] for a threefold gain. It is the kind of investment that would make a hedge-fund manager's career. ... VMware, not exactly a household name, a $32 billion valuation, nearly as big as the combined market capitalizations of Ford Motor and General Motors. ... But Cisco's investment firepower is aimed at "disruptive technologies," Mr. Hooper says. If that is what VMware really is, ensuring that Cisco gets into the virtual-switching game too may be more valuable than a measly $360 million profit. [Wall Street Journal, Sep 28] How many SBIR "investments" have any hope of becoming a VMware? If SBIR doesn't focus on disruptive technologies, none.

VMware gained 815%, the biggest percentage rise by a NYSE stock. The shares have now risen 128% since the virtualization-software company went public a week ago. [Wall Street Journal, Aug 20]

Software company VMware (no SBIR) jumped 76% over its IPO price in first day trading.

Voci Technologies (Pittsburgh, PA)

Voci Technologies (Pittsburgh, PA; no SBIR) developer of speech recognition technology, has raised $1 million, according to [SEC] filing .... develops hardware and software aimed at helping businesses turn hours of speech gathered at call centers into text that can be mined for business intelligence. [Patty Tascarella, Pittsburgh Business Times, Aug 5, 14]

Volcano (San Diego, CA)

medical device maker Volcano (San Diego, CA; $100K SBIR, in 2006 as Volcano Therapeutics in Rancho Cordova, founded 2001) notified the state it will lay off 60 employees in Rancho Cordova. ... At its peak, the company had nearly 700 employees at the local plant ... makes intravascular imaging devices and disposable catheters.... now a wholly owned subsidiary of Dutch conglomerate Royal Philips NV [Mark Anderson, Sacramento Business Journal, Dec 11, 15]

Volcano up 55% [Dec 17, 14] after acquisition announcement by Royal Philips NV

Royal Philips NV has agreed to acquire U.S.-based medical device maker Volcano (Rancho Cordova, CA; one SBIR in 2006) for $1.2 billion including debt, its largest healthcare acquisition in seven years and a bid to cash in on an aging population's need for more complex treatments. ... at $18 per Volcano share, a premium of 57 percent to its Tuesday closing price ... Philips, until recently a diversified conglomerate that made everything from televisions to lightbulbs to X-ray machines, is spinning off its historic lighting division to focus on its higher-margin healthcare business. [Thomas Escritt, Reuters, Dec 17, 14]

Volcano (San Diego, CA $100K SBIR, founded 2001) will be laying off 170 manufacturing employees in Rancho Cordova [to] bring the local employment for Volcano to fewer than 100 employees. At its peak, the company had nearly 700 employees at the local plant ... developer and manufacturer of precision guided therapy tools for diagnosis and therapy of vascular disease. Volcano manufactures catheters and intravascular guidance technologies. [Mark Anderson, Sacramento Business Journal, Oct 29, 14]

medical device maker Volcano (San Diego, CA; one SBIR) is paying at least $115 million to acquire -based AtheroMed (Menlo Park, CA; no SBIR) and its Phoenix system for opening up narrowed coronary arteries, which was cleared for sale in the U.S. earlier this year. With AtheroMed’s technology in its portfolio, Volcano said it will gain a stronger presence in the global atherectomy market, estimated at $350 million to $400 million and growing 7 percent a year. [Alex Lash, xconomy.com, May 29, 14]

Volexion (Chicago, IL)

Volexion (Wilmette, IL; $200K SBIR) landed $1.1M to improve the performance of lithium-ion batteries just landed funding from a pair of climate-focused VC firms. [Jim Dallke, ChicagoInno, Apr 8, 21]

Volexion (Chicago, IL; $200K STTR, founded 2018) materials startup developing a graphene coating for lithium-ion batteries to improve the performance ... just landed $1.1 million part of a $2.2 million round from a pair of climate-focused VC firms. ... founded by Northwestern professor Mark Hersam, [Jim Dallke, ChicagoInno, Apr 9, 21]

Voltron Therapeutics (Kenosha, WI)

scientists working for a spinoff of Massachusetts General Hospital called Voltron Therapeutics (no SBIR) started looking for partners to help develop a vaccine as quickly as possible. They formed a joint venture with Hoth Therapeutics, named HaloVax, and tasked it with using a vaccine technology developed at MGH to find a COVID-19 candidate. Now HaloVax is preparing to take its COVID-19 vaccine into animal trials this month, Voltron announced late last week. [Fierce Biotech, Apr 6, 20]

Hoth Therapeutics (New York NY; no SBIR) up 39% [Mar 23, 20] announced it has reached an agreement with Voltron Therapeutics (Kenosha, WI; no SBIR) to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital. ... also announced pricing of $5M stock offering [Hoth press release, Mar 23, 20]

VoltServer (Charlestown, RI)

The Slater Technology Fund, a state-backed economic development fund that works like a venture capital firm in Rhode Island, announced Monday that it is behind a recent $250,000 investment in VoltServer (Charlestown, RI; no SBIR) ....a recent spinout from Eaves Devices (no SBIR) ... developing so-called packet energy transfer technology to transmit electricity in discrete packets that contain both energy and real-time data about the energy. [Don Seiffert, Mass High Tech, Jul 23, 12]

VORAGO Technologies (previously Silicon Space Technology, Austin, TX))

VORAGO Technologies (previously Silicon Space Technology, Austin, TX; $8.6M SBIR) the leading provider of radiation-and extreme heat-hardened embedded systems technology, today announcedit has closeda $10 million round of funding. ... to fuel organic growthand fund new product and technology development, expanding VORAGO’s microcontroller portfolio and its technology-licensing platform. [company press release, Sep 1, 15]

Vorbeck Materials (Jessup, MD)

A startup company hopes later this year to bring to market one of the first products based on the nanomaterial graphene. Vorbeck Materials (Jessup, MD; no SBIR) is making conductive inks based on graphene that can be used to print RFID antennas and electrical contacts for flexible displays. The company, which is banking on the low cost of the graphene inks, has an agreement with the German chemical giant BASF and last month received $5.1 million in financing from private-investment firm Stoneham Partners. [Katherine Bourzac, MIT Tech Review, Aug 17]

Vor BioPharma (Boston, MA)

Vor Biopharma (Cambridge, MA; no SBIR, founded 2016), an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced it has raised $110 million in a Series B financing [to] advance the company’s lead candidate VOR33 into clinical trials, deepen its portfolio, and accelerate the validation of additional targets for its scientific platform, which is designed to remove redundant proteins so that transplanted stem cells become invisible to targeted therapies while leaving diseased cells vulnerable. [company press release, Jul 7, 20] prior funding $42M [crunchbase.com]

PureTech’s Vor Biopharma (Boston, MA; no SBIR) raised $42 million in its series A round, which will support the development of its lead asset, an engineered stem cell therapy for acute myeloid leukemia (AML). [Amirah Al Idrus, Fierce Biotech, Feb 14, 19]

Hours after announcing its newest spinout, a cell therapy-focused startup [Vor BioPharma (Boston, MA), which is focusing on “CAR-T” therapy, a type of cell therapy for cancer that has shown some impressive early results against certain blood cancers], [PureTech Health] says it is launching Alivio Therapeutics (Boston, MA) to develop a therapy for chronic and acute inflammation. Alivio has a hydrogel material that it said is designed to adhere to inflamed tissue and deliver drugs based on the level of inflammation. ... As Fidler reported in March, PureTech unveiled Commense (Boston, MA), which aims to build on research into the human microbiome—the trillions of bacteria and other microbes that live in and on our bodies—to potentially protect babies born via C-section from the future onset of a variety of serious conditions. [David Holley, xconomy.com, May 10, 16]

Vortex Biosciences (Menlo Park, CA)

A scientist who helped start a biotechnology firm four years ago is set to receive an award from President Barack Obama at the White House in the coming months. While the date isn't finalized, Dino Di Carlo, co-founder/chief scientific officer of Vortex Biosciences (Menlo Park, CA; no SBIR) and a bioengineering professor at UCLA, said he was ecstatic to learn Feb. 18 he had won a Presidential Early Career Award for Scientists and Engineers -- one of 105 independent researchers nationwide to earn the honor. [Kevin Kelly, San Jose Mercury News, Mar 9, 16]

Vortex Medical (Norwell, MA)

AngioDynamics's purchase of a small [Vortex Medical (Norwell, MA; no SBIR)] will give it ownership of a product CEO Joseph DeVivo said could become “the gold standard of care” with the potential for up to $50 million in sales.... for $15 million in cash and 10 years’ worth of annual payments based on sales of Vortex’s AngioVac System. [Barbara Pinckney, The Business Review (Albany),Oct 12, 12]

Voxel

3-D Disaster (May 13) Got a great 3-D image idea? Join the mob. Just don't expect to get rich soon as the Voxel experience shows. Voxel started with the usual enthusiasm in 1988, without SBIR. Venturist Alan Wolfe soon found that a breakthrough isn't the same thing as a commercial product [Forbes, May 18]. Blame went all round. Voxel and its contractor making the prototypes got into a hassle over who was to blame for the unreliable expensive (note the cost element) prototypes. Suits, countersuits, lawyers (never cheap), quickly emptying cash drawer, no revenues, $28M of VC investment gone - all the hallmarks of a disaster. Now that the things might actually work, out of cash to buy the equipment to install in hospitals which are ready to make $60 profit per picture taken. Then the lawsuit went against Voxel and the stock plunged again (61% Monday) to a tiny $2. Meanwhile, DOD is still investing its SBIR in 3-D imagery while the companies lather on the commercial dream-soap. But since DOD is technology, not economics, driven, it will fund the best performer which may be the worst commercial prospect (even if it works). Which is OK as long DOD can fund the entire product development and production (the Cold War paradigm). If, though, YOU want to survive the development, you had better keep an open eye on your market. Or you will be Voxel-ized.

voxeljet

3-D printers can produce even junk food these days. Appropriate, as the firms making them have given investors a sharp case of indigestion. The share price of Stratasys (no SBIR) has collapsed 50% in the past 12 months, while close rival 3D Systems (no SBIR) is down more than 60% in that time. That has erased the huge gains those stocks enjoyed during a run-up in 2013. Smaller 3-D printer plays such as ExOne (no SBIR)and voxeljet (no SBIR) have charted a similar course. ExOne shares are actually 10% below their IPO price from February 2013. [Dan Gallagher, Wall Street Journal, Feb 22, 15]

Voyager Therapeutics (Cambridge, MA)

In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences (San Diego, CA; $10M SBIR) bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics (no SBIR). Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold. [Amirah Al Idrus, Fierce Biotech, Feb 3, 21]

Voyager Therapeutics (Cambridge, MA; no SBIR) up 38% [Jan 29, 19] cut a deal with Neurocrine Biosciences (San Diego, CA) to bankroll the [development] journey—and forfeit some of the financial upside for the product known as VY-AADC [for] $115 million in cash and buying $50 million worth of the company’s shares. [Ben Fidler, xconomy.com, Jan 29, 19]

Voyager Therapeutics (Cambridge, MA; no SBIR, founded 2014 with $45M VC) and Genzyme, a Sanofi company and gene therapy pioneer, announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders. .... Genzyme will make an upfront commitment of $100 million to Voyager, including $65million in cash, a $30 million equity investment in Voyager and additional in-kind contributions. Voyager is eligible to receive future potential development and sales milestone payments of up to $745 million, as well as tiered royalties on product sales. [Voyager press release, Feb 11, 15]

Voyager Therapeutics (Cambridge, MA) biotechnology company launched [Feb 12, 14] is taking aim at Parkinson’s disease and ALS with a new gene therapy that deliberately infects patients with a virus. .... plans to use a class of viruses known as adeno-associated viruses as carriers to deliver vital proteins to the brain. Intentional infection may be counterintuitive, but the viruses used in the therapy are harmless to humans, making them ideal vehicles for moving proteins through the body, without troublesome side effects. [Callum Borchers, Boston Globe, Feb 14, 14]

Voyager Therapeutics (Cambridge. MA) biotechnology launching is taking aim at Parkinson’s disease and ALS with a new gene therapy that deliberately infects patients with a virus. ... plans to use a class of viruses known as adeno-associated viruses as carriers to deliver vital proteins to the brain. Intentional infection may be counterintuitive, but the viruses used in the therapy are harmless to humans, making them ideal vehicles for moving proteins throughout the body, without troublesome side effects. ... Boston venture capital firm invested $45 million to get the company off the ground. [Callum Borchers, Boston Globe, Feb 12, 14]

Vtesse (Gaithersburg, MD)

Four years into its existence, Cydan Development, New Enterprise Associates’ orphan drug startup accelerator, has notched its first big win. Vtesse (Gaithersburg, MD; no SBIR), the first company to emerge from Cydan, has been sold in a deal valued at $200 million. Sucampo Pharmaceuticals (Rockville, MD; no SBIR) maker of a drug to treat various bowel conditions, will acquire Vtesse for $170 million in cash and 2,782,678 shares of Sucampo, which closed at $11 [Ben Fidler, xconomy.com, Apr 3, 17]

NIH touts an experimental drug for a rare metabolic disorder as one of its first big successes. But a bitter fight involving NIH, two companies, and opposing camps of researchers and parents of children with the fatal condition is marring the triumph. ... In December 2014, the center entered a cooperative research and development agreement under which Vtesse (Gaithersburg, MD; no SBIR) took over the therapy, speeding the drug into a pivotal, late-stage clinical trial in the space of 18 months. .... But Vtesse has a rival, which is starting clinical trials of its own cyclodextrin. CTD Holdings (Gainesville, FL; no SBIR) that makes cyclodextrins for a broad variety of purposes, became aware of their potential as an NPC treatment after being contacted by Chris and Hugh Hempel, the parents of twin girls with the disease. [Meredith Wadman, Science, Oct 7, 16] One positive result of SBIR is surprises for the agency on who is working on their problem outside their knowledge. Since NIH has boatloads of money, it could easily bring CTD into the game immediately.

Vtesse (Gaithersburg, MD; no SBIR) wants to commercialize a drug candidate called VTS-270, which was licensed by the National Institute of Health to treat the rare, but deadly, Niemann-Pick Type C1. Vtesse will use [$17M new] funding to develop its product and technology. The U.S., U.K. and Germany began trials on the drug last year, and Vtesse could apply for the drug's approval by 2017 if the trials are successful. [Washington Business Journal, Jul 26, 16]

After years of effort, scientists and families of young patients with the genetic condition Niemann-Pick Type C are in a position to which any rare-disease community aspires: the prospect of not one, not two, but three companies launching clinical trials to develop therapies. .... But The pool of eligible patients with a rare disease like NPC is small. Doctors say there aren’t yet reliable counts of diagnosed cases, but current estimates put the number at around 500 world-wide. The companies are Vtesse (Gaithersburg, MD; no SBIR) , CTD Holdings (Alachua, FL; no SBIR), and Orphazyme ApS (Denmark). [Amy Dockser Marcus, Wall Streeet Journal, Aug 20, 15]

Mayo Clinic, Baxter International VC arm and Velocity Pharmaceutical Development (California) are teaming up to start a biotech venture that will develop treatments for cancer and other diseases. The new business, Vitesse Biologics (South San Francisco, CA), will discover antibodies and protein therapies for the immunology, hematology and oncology markets. Mayo's role in the venture will center largely around conducting clinical trials testing Vitesse's inventions. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jun 1, 15]

Biotech accelerator Cydan Development announced $25 million in Series A funding to launch Vtesse (Gaithersburg, MD; no SBIR), which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children. ... [NIH] has transferred to Vtesse exclusive worldwide rights to cyclodextrin, delta-tocopherol and derivatives of tocopherol, all of which have been under development at NIH for the treatment of lysosomal storage diseases. ... Cydan is working to spin out additional companies with a focus on rare diseases with few viable treatments. [Kasra Kangarloo, Washington Business Journal, Jan 7, 15]

VT Silicon (Atlanta, GA)

VT Silicon (Atlanta, GA; $1.5M SBIR)raised $5.5 million in financing .... last year, raised $3.3 million in a Series A round from Menlo, to design and make prototypes of its “intelligent power amplifier” chips for the next-generation of WiMax mobile devices. [Atlanta Business Chronicle, Nov 19, 08]

vTv Therapeutics (formerly TransTech Pharma) (High Point, NC)

vTv Thera up 28% [Oct 17, 18]

vTv Thera down 10% [Oct 5, 18]

vTv Thera up 26% [Oct 5, 18]

vTv Thera down 22% [Oct 4, 18]

vTv Thera up 70% [Oct 3, 18]

vTv Therapeutics (High Point, NC; no SBIR) announced [it] has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering [most of Southeast Asia] ... will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. [company press release, May 31, 18]

Shares of vTv Therapeutics (IPO July 2015) dropped 70% after hours after the drug developer said a late-stage clinical trial of its Alzheimer's disease treatment did not meet study goals. ... The company said a Phase III study of its drug azeliragon did not significantly improve Alzheimer's Disease Assessment scores in patients given the drug compared with those patients given placebo. [Wallace Witkowski, Market Watch, Apr 10, 18]

vTv Thera down 10% [Mar 14, 18]

vTv Thera up 28% [Jan 23,18]

vTv Thera up 10% [Jan 16, 18]

Vtv Therapeutics (High Point, NC; no SBIR) announced that it has entered into a global licensing agreement [for its diabetes therapies to be developed and commercialized in China and other Pacific Rim countries] with Reneo Pharmaceuticals (San Diego, CA; no SBIR), focused on developing treatments for orphan diseases. ... grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics’ selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. [company press release, Dec 21, 17]

vTv Thera up 37% [Dec 28, 17] Barron's reports that Revlon’s Ron Perelman has been increasing his stake in vTv

vTv Therapeutics (HighPoint, NC; no SBIR) raises $10M [Triad Business Journal, Dec 20, 17] .... announced that vTv entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical (China), for rights to develop and commercialize vTv Therapeutics’ GLP-1r agonist program in China and other Pacific Rim countries. [company press release, Dec 21, 17] also announced that vTv entered into a global licensing agreement with Reneo Pharmaceuticals, a privately-held biotechnology company focused on developing treatments for orphan diseases. The agreement grants Reneo Pharmaceuticals exclusive worldwide rights to research, develop and commercialize vTv Therapeutics’ selective peroxisome proliferator-activated receptor delta (PPAR-delta) program. [company press release, Dec 20, 17]

vTv Thera up 23% [Dec 6, 17]

vTv Therapeutics (High Point, NC; no SBIR) announced that JDRF, the leading global organization funding type 1 diabetes (T1D) research, will provide funding to support a Phase 2 Proof of Concept study to explore the effect of vTv Therapeutics’ liver-selective glucokinase (GK) activator TTP399 as an oral drug for the treatment of T1D [company press release, Sep 6, 17]

vTv Thera up 11% [Aug 10, 17]

vTv Therapeutics (formerly TransTech Pharma, High Point, NC; $1.4M SBIR) received a letter from the NASDAQ Stock Market LLC saying that the stock could be delisted because the market value of listed securities has been below $50 million for 30 consecutive business days. [Katie Arcieri, Triad Business Journal, Jul 6, 17]

vTv Therapeutics down 13% [Oct 28, 16]

vTv Thera up 11% [Apr 14, 16]

vTv Thera up 12% [Feb 19, 16]

vTv Thera down 11% [Aug 21, 15]

vTv Thera up 12% [Aug 18, 15]

vTv Thera up 12% [Aug 17, 15]

vTv Thera down 20% [Jul 30,15] after IPO

vTv Therapeutics (formerly TransTech Pharma, High Point, NC; $1.5M SBIR) which is developing treatments for Alzheimer's disease and type 2 diabetes, has launched an approximately $125 million[IPO] ...has begun enrolling its first patients in what it's calling STEADFAST — Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy. [Mark Sutter,Triad Business Journal, Jul 24, 15]

A promising drug targeting Alzheimer's disease and developed by [vTv Therapeutics, formerly TransTech Pharma (High Point, NC; $1.8M SBIR)] is heading into a final phase of clinical trials. The move into Phase 3 testing of azeliragon comes nearly two years after the successful completion of Phase 2 trials during which the drug showed results in slowing cognitive decline among patients with mild or moderate Alzheimer's disease. [Owen Covington, Triad Business Journal, May 20, 15]

VUV Analytics (Lakeway, TX)

VUV Analytics (Lakeway, TX; no SBIR, founded 2009) completed a $5.8 million Series A round of financing. ... to launch a laboratory-scale molecular spectroscopy instruments business .... In August 2012, the company received a grant from the Texas Emerging Technology Fund. The company has received $250,000 of a committed amount of up to $1 million for the commercialization of a laboratory-scale Circular Dichroism instrument that investigates biologically important molecules. [Christopher Calnan, Austin Business Journal, May 19, 14]

Vuzix (Rochester, NY)

Vuzix (Rochester, NY; $250K SBIR) up 32% [Nov 1, 21] a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to report that Newsweek has included Vuzix in their 2021 list for Most Loved Workplaces, which ranks the top 100 companies as part of a collaboration with the Best Practice Institute (BPI) [company press release, Oct 28, 21]

Vuzix up 21% [Mar 11, 21]

Vuzix down 14% [Mar 8, 21]

Vuzix down 23% [Mar 4, 21]

Vuzix up 25% [Mar 1, 21] announced that the Company's M400 and M4000 Smart Glasses now support Microsoft Teams. [company press release, Mar 1, 21]

Vuzix up 27% [Feb 12, 21]

Vuzix up 20% [Jan 25, 21]

Vuzix up 21% [Jan 20, 21]

Vuzix up 19% [Dec 22, 20]

Vuzix (Rochester, NY; $250K SBIR) up 25% [Dec 18, 20] announced that Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, has successfully deployed an AR smart glasses-based remote training program globally utilizing Vuzix M400 Smart Glasses to support their fleet of more than 6,000 active temperature-controlled containers which are being used today to ship COVID-19 vaccines, as well as other pharmaceuticals in need of a temperature-controlled environment. [company press release, Dec 17, 20]

Vuzix up 18% [Sep 3, 20] announce that the Company has signed an agreement with a new major international defense contractor to build a customized waveguide solution. [company press release, Sep 3, 20] also announce that Pixee Medical, a France-based medical company, in collaboration with Dr. Villeminot and his team from Clinique St Odile in Haguenau (France), have successfully validated a new milestone by using Knee+, the first total knee replacement AR navigation system, solely guided by the Vuzix M400 AR Smart Glasses. [company press release, Sep 2, 20] also announced the Company is developing next generation product line of smart glasses powered by micro-LED technology that are expected to become available in 2021. [company press release, Sep 1, 20]

Vuzix up 19% [Jun 20, 19]

Vuzix up 23% [Jun 11, 19]

Vusix up 15% [Mar 4, 19]

Vuzix up 10% [Sep 20, 18]

Vuzix up 10% [Aug 9, 18]

Vuzix up 10% [May 15, 18]

Vuzix up 10% [Apr 17, 18]

Vuzix up 18% [Apr 10, 18]

Vuzix down 14% [Mar 21, 18]

Vuzix down 10% [Jan 25,18]

Vuzix up 10% [Jan 22,18]

While most of the tech world dismissed the “smartglasses” concept when Google put Glass to bed back in 2015, Vuzix continued toiling away on the form factor it has been working on since long before Google ever took an interest. The result, at long last: A pair of smartglasses you may actually want to wear. .... The Blade use Vuzix’s proprietary waveguide technology to superimpose bright, crystal-clear images directly in your line of sight. ... Vuzix owns the patents for the killer display that makes these glasses stand out, and wouldn’t rule out licensing it to other companies. [Nick Mokey, yahoo.com, Jan 10, 18]

Vuzix up 12% [Jan 8, 18]

Vuzix up 19%[Jan 5, 18]

Vuzix (Henrietta, NY; one SBIR) signed a $5 million deal with Toshiba Information Equipment Co. Ltd. to supply the company with smart glasses for a new computing system. [Velvet Spicer, Rochester Business Journal, Dec 7, 17] The update details the conclusion of the development agreement mentioned above and outlines a fresh agreement, a supply agreement, that's now in place with Toshiba. The supply agreement will see Vuzix sell the smart glasses technology that was developed under the terms of the development agreement to Toshiba and the product will be co-branded as a Toshiba product, powered by Vuzix. Toshiba expects to sell the product on a global basis ... Toshiba has committed to purchasing a minimum of $5 million worth of the co-branded smart glasses devices from Vuzix. [George Ronan, GuruFocus, Dec 7, 17]

Vuzix up 10% [Nov 16, 17]

Vuzix up 15% [Nov 9, 17]

Vuzix up 12% [Aug 11, 17]

companies worldwide, like John Deere, DHL, WS Kunststoff-Service, and Lee Company, have turned to the AR experts at Vuzix and their smart glasses to optimize a multitude of processes, including vision picking, communication, assembly line output, and employee training. ... the M300 is essentially a fully-integrated, high-end Android-based tablet compacted into a pair of glasses. [Accesswire, Aug 1, 17]

Vuzix signed an agreement with Tokyo-based Toshiba Client Solutions Co. Ltd., a subsidiary of Toshiba Corp., to build a pair of smart glasses. ... The firms have begun a development program with milestone payments totaling over $1 million, officials said. [Kerry Feltner, Rochester Business Journal, Feb 24, 17]

Vuzix up 16% [Feb 24,17]

Vuzix announced an update on its M300 Smart Glasses rollout to Enterprise clients and certain aspects of its general business. The M300 is now certified to ship into Europe, the USA, Canada, Australia [company press release, Feb 13, 17]

Vuzix entered into agreements to sell $14.5M of its common stock, officials announced. [Rochester Business Journal, Dec 1, 16]

Vuzix said in a filing that Intel has stopped development of Internet-connected headsets with the firm, officials said. [Rochester Business Journal, Nov 17, 16]

Vuzix down 18% [Nov 17, 16]

Vuzix up 12% [Nov 11, 16]

Vuzix down 11% [Nov 4, 16]

Vuzix up 11% [Jul 25, 16]

Vuzix up 11% [Jul 22, 16]

Vuzix up 10% [Jul 15, 16]

Vuzix up 11% [Jul 13, 16]

Vuzix up 11% [Jun 29, 16]

Vuzix up 14% [Jun 13, 16]

Vuzix down 13% [Jan 11, 16]

Vuzix up 13% [Jan 6, 16]

Vuzix down 22% [Jan 5, 16]

Vuzix down 11% [Dec 31, 15]

Vuzix up 18% [Dec 30, 15]

Vuzix (Rochester, NY; one SBIR) is moving into an approximately 30,000-square-foot facility with a stronger cash flow and better share prices despite higher operating expenses and some challenges in the marketplace for smartglasses, a wearable computer that adds information to what the user sees. ... expecting 2016 to be a turning point for augmented and virtual reality smartglasses, an industry expected to grow annually by approximately 75% through 2020, according to ABI Research. ... it ended the quarter with about $16 million cash and cash equivalent, compared to nearly $85,000 at the end of 2014. Sales in its third quarter were up about 30%. Its M100 Smart Glasses sell for $999. A related software development kit lists for $199. [Todd Clausen, Rochester Democrat and Chronicle, Nov 30, 15]

Vuzix up 10% [Nov 17, 15]

Vusix down 10% [Sep 29,15]

Vuzix (Rochester, NY; one SBIR) up 13% [Jun 19, 15]

Vuzix (Rochester, NY; one SBIR) up 18% [Apr 10,15]

Vuzix (Rochester, NY (with a variety of former names, founded 1997, at least one SBIR and some government R&D contracts) said that Intel invested $24.8 million in the company to speed up the launch of Internet-connected eyewear. Intel bought preferred stock that is convertible into common shares equivalent to 30 percent of Vuzix ... A month ago, Italy's Luxottica said it was joining forces with the US chipmaker to develop glasses that combine its top fashion brands with technology that could allow wearers to access information about their health or location. [Reuters, Jan 2, 15]

Vuzix (Rochester, NY; one SBIR 2010) maker of video eyewear products ..... raised $8 million through its offering of common stock and warrants to replenish its bottom line and pay off debt .... preparing to produce its M100 smart glasses, and its waveguide-based augmented reality monocular for the industrial space [Thomas Adams, Rochester Business Journal, Aug 13, 13]

Vuzix (Rochester, NY; one SBIR) [stock] trading was halted after the company priced a public offering of 3.5 million shares of common stock at $2 a share. [was trading at $4.45 on Toronto exchange] ... plans to use the proceeds to commercialize its M100 Smart Glasses and VFX720 video head phone products, its waveguide technologies, officials said. [Thomas Adams, Rochester Business Journal, Jul 31]

Vyriad (Rochester, MN)

Vyriad (Rochester, MN; $4.2M SBIR) announced it raised $29.5 million in Series B funding. [company press release, May 17, 2022]

Mayo Clinic spin-off Vyriad (Rochester, MN; no SBIR), maker of genetically-engineered viruses designed to destroy cancer tumors, is raising $9 million to hire and house up to 30 new employees. [Twin Cities Business2, founded 2016] formed by the merger of Omnis Pharma (Rochester, MN; no SBIR, founded 2012) and Magnis Therapeutics (Rochester, MN; no SBIR) [company press release, Mar 2016]

Vyriad (Rochester, MN; no SBIR, began in 2012 as Omnis Pharma), a clinical-stage biotech company developing powerful Oncolytic virus therapies, utilizing engineered viruses designed to selectively and rapidly destroy cancer. We have exclusively licensed the powerful Vesicular Stomatitis Virus (VSV) and measles Virus (MV) Oncolytic platforms.[company website, Apr 17, 17] ... One of the earliest adapters of Mayo Clinic’s push to encourage local entrepreneurship among its bio-researchers is preparing to leave the nest of Mayo’s business incubator for a much larger lab/manufacturing space elsewhere in Rochester. .. last merged with another Rochester start-up, Magnis Therapeutics, to form Vyriad [Don Jacobson, Twin Cities Business, Apr 12, 17]

Vyrx Pharmaceuticals (Greenwood Village, CO)

Vyrx Pharmaceuticals (Greenwood Village, CO; no SBIR) seeks to raise $28.5 million with an initial public stock offering designed to fund development of its premature-ejaculation drug called Zertane. .... is a wholly-owned subsidiary of Ampio Pharmaceuticals (NYSE MKT: AMPE), which itself raised $63 million in a March stock offering. Ampio’s primary drug is a treatment for osteoarthritis of the knee. [Greg Avery, Denver Business Journal, Apr 17, 14]

VytronUS (Sunnyvale, CA)

Medical device startup VytronUS (Sunnyvale, CA; no SBIR, founded 2006) developing novel technologies for the treatment of cardiac arrhythmias, announced that it has secured $49 million in Series C equity financing. .... developing a next-generation integrated imaging and ablation platform for cardiac electrophysiologists. Harnessing the capability of ultrasound energy, the VytronUS system creates a high resolution image of the interior of the heart for procedure planning and allows the physician to simply draw a desired treatment pattern on the image at the workstation. [company press release, Jul 29, 16] secured $31.6 million in an oversubscribed Series B financing in 2014 [company press release, Oct 29, 14]

WaferGen Biosystems (Fremont, CA)

WaferGen (Fremont, CA; no SBIR) has raised $13.7 million of a $15 million equity financing round, according to an SEC filing. .... primary product is the SmartChip Real-Time PCR System -- a genetic analysis platform for profiling and validating molecular biomarkers, an important step in drug discovery. [Vincent Lara-Cinisomo, Web contributor, Silicon Valley Business Journal, Sep 11, 13]

WaferGen Biosystems (Fremont, CA; no SBIR) closed a $7.2 million registered direct offering that includes $1 million from the company's chairman ... developer of genomic analysis systems, said it will use the funds to expand manufacturing, marketing, and sales of the SmartChip Real-Time PCR System. [San Francisco Business Times, Jul 8, 10] it raised about $6.2 million in Sept 09

WaferGen Biosystems (Fremont, CA; no SBIR) raised about $6.2 million in a series of private placements over the summer. [San Francisco Business Times, Sep 10, 09]

Wakonda Technologies (Fairport, NY)

solar-power startups in particular have seen a three-year surge, from a low of no venture investment in the third quarter of 2005 to a high of more than half a billion dollars in the second quarter of this year. CaliSolar (Sunnyvale, CA; no SBIR) $13M; Wakonda Technologies (Fairport, NY; $200K SBIR) $9M; Prism Solar Technologies (Lake Katrine, NY; no SBIR) $9M. [lDean Takahashi, MIT Tech Review, S/O 08]

Another thin-film photovoltaic technology developer has joined the ranks of the New England solar community. With $9.5 million in its first round of funding, Wakonda Technologies (Fairport, NY; $200K SBIR) will set up shop in Medford, after being founded in New York earlier this year. ...According to company statements, Wakonda’s process can increase efficiency of solar cells by up to 30%. [Mass High Tech, Jul 16]

Walden Biosciences (Cambridge, MA)

Walden Biosciences (Cambridge, MA; no SBIR), a biotechnology company focused on transforming the treatment of kidney disease, announced its launch with a $51 million Series A financing [to] develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. [company press release, Oct 6, 20]

Walden Biosciences (Cambridge, MA; no SBIR), focused on transforming the treatment of kidney disease, announced its launch with a $51 million Series A financing [to] develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. [company press release, Oct 6, 20]

Walker Magnetics Group (Worcester, MA)

Alliance Holdings has bought Walker Magnetics Group (Worcester, MA; one SBIR in 1986) for an undisclosed sum.
Alliance is an employee-owned private-equity firm based in Abington, Pa. Walker makes magnetic products for various applications. [Peter Key, Philadelphia Business Journal, May 9, 13]

Waste2Watergy (Corvallis, OR)

Waste2Watergy (Corvallis;OR; SBIR) startup formed at Oregon State University, has secured a $225,000 [NSF SBIR] to advance technology that cleans organics from brewery wastewater while producing electricity. ... previously received $150,000 from Oregon BEST [Wendy Culverwell, Portland Business Journal, Feb 26, 15]

Waveband (Torrance, CA)

Air Force (USAF) selected Sierra Nevada (Sparks, NV; $1M SBIR, founded 1963, 2500 employees) and its partner Embraer (Brazil) Defense and Security for its Light Air Support (LAS) program. ... deemed the A-29 Super Tucano aircraft, and the overall solution offered by SNC, to be the superior choice for this critical mission. The initial $427.5 million delivery order is to supply the USAF with 20 A-29 Super Tucano aircraft. ... for. light air support, reconnaissance and training capabilities to the Afghanistan military. As such, it is a vital element of the United States’ Afghan withdrawal strategy .. work will be in Jacksonville, FL [company press release Feb 27, 13] over the years it has gathered up companies: Space Dev (Poway, CA; $5M SBIR) ;MicroSat Systems (Littleton, CA; $11M SBIR) ; Straight Flight (Denver, CO; no SBIR) ; Waveband (Torrance, CA; $17M SBIR); Aviation Resources Delaware (no SBIR); Inter-4 (San Francisco, CA; no SBIR); Turtle Mountain Communications (no SBIR) ; Plano Microwave (Plano, TX; no SBIR) ; Spectral Systems (Beavercreek, OH; no SBIR) ;Advanced Countermeasure Systems (Sacramento, CA; no SBIR)

Wave Computing (Campbell, CA)

Deep learning demands new chips. The Semiconductor Industry Association and its research affiliate have enlisted 22 tech companies to launch a broad study of technologies that might bring computing advances. Alternatives range from stacking circuitry in space-saving layers to making chips from biological materials such as proteins. Development is particularly intense in deep learning --- training systems by exposing them to immense quantities of data rather than programming them with explicit instructions. ... IBM is targeting deep learning with TrueNorth, a chip unveiled in 2014 and composed of one million structures patterned after the brain’s neurons. Mr. Modha said it has shown startling acceleration of deep-learning applications and is on track to create a “business at scale” by 2019. Venture capitalists have taken notice. ... Cerebras Systems,(Los Altos, CA; no SBIR,25 employees) plans to design processors targeting deep learning, found it surprisingly easy to raise venture-capital funds, said founder Andrew Feldman. ... Other startups designing chips for deep learning include KnuEdge (San Diego, CA; no SBIR), Graphcore Ltd (UK), Cornami (Santa Clara, CA; no SBIR) and Wave Computing (Campbell, CA; no SBIR). [Don Clark, Wall Street Journal, Jan 11, 17] Why no SBIR? Such companies are reaching too far too fast needing too much capital for federal mission agencies to keep up with plodding SBIR.

Waveguide (Cambridge,MA)

Waveguide (Cambridge, MA; no SBIR) focused on health diagnostics securing $27 million in equity financing. ... focused on commercializing a handheld diagnostic device that uses imaging software similar to MRIs, according to Healthios Xchange. Called nuclear magnetic resonance spectrometer, the technology would be used to diagnose tuberculosis and ovarian cancers. [Jessica Bartlett, Boston Business Journal, Jun 17, 15]

WaveRx (Waltham,MA)

medical device company WaveRx (Waltham, MA; no SBIR) has raised $500,000 in a second round of funding, according to federal documents. WaveRx is working on technology to treat disorders of the nail and skin and said in the filing that it would use the funds for working capital. ... Founded in 2004 as ID Wave Systems, No information is available about the company’s technology on its website. [Mass High Tech, Apr 8, 10]

Weinberg Medical Physics (Bethesda, MD))

The Maryland Technology Development Corp. (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000. • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990 • Weinberg Medical Physics LLC (Bethesda, MD: $4M SBIR) received $60,000 [Baltimore Business Journal, Jul 19, 13]

WellStat Therapeutics (Gaithersburg, MD)

biotech WellStat Therapeutics (Gaithersburg, MD; no SBIR) received [FDA] approval for Vistogard, an emergency treatment for an overdose of certain chemotherapy drugs, it was announced. ... the second FDA approval the company has received for one of its drugs this fall. ... WellStat received a highly valuable priority review voucher, part of an FDA incentive program designed to encourage drug development for rare pediatric diseases. WellStat immediately sold its voucher to AstraZeneca, parent company of MedImmune, as part of a deal made back in September 2014. [Tina Reed, Washington Business Journal, Dec 14, 15]

Werewolf Therapeutics (Cambridge, MA)

Werewolf Therapeutics (Cambridge, MA; no SBIR) announced the completion of its $56 million Series A financing. The company is developing novel immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body's immune response to cancer. [company press release, Nov 21, 19]

Whole Biome (San Francisco, CA)

Mayo Clinic is adding to a growing list of collaborations with cutting-edge startups focused on understanding what the teeming microorganisms essential to digestion can tell us about a broad range of health issues..... announced it established a formal collaboration with Evelo Biosciences (Cambridge, MA; no SBIR), a new firm established last year after a $35 million investment ... Mayo’s other microbiome collaborators include: Seres Therapeutics (Cambridge, MA; no SBIR) focused on using micro-organisms as therapeutic agents for disease in clinical trials. Enterome (France) focuses on discovery and validation of gut microbiome-based diagnostics to predict responses to nutritional interventions in overweight and obese patients. Second Genome (San Francisco, CA; no SBIR) collaborate in areas such as irritable bowel disease; obesity/metabolic disease; and surgery in obese patients with and without type 2 diabetes. Whole Biome (San Francisco, CA; no SBIR) collaborating to decrease rates of preterm birth and labor, the leading cause of infant mortality in the United States, through microbiome-based diagnostics and therapies. [Don Jacobson, Twin Cities Business, Aug 31, 16]

Whole Trees (Stoddard,WI)

Eight start-up companies have been certified as qualified new business ventures by the Wisconsin Economic Development Corp., the agency said. With the certification, the companies' financial backers will be eligible for a 25% tax credit on the amount they invest in the company. The start-ups include: InControl Medical LLC (Milwaukee, WI; no SBIR) has developed an FDA-cleared device designed to treat female urinary incontinence; NitricGen (Middleton, WI; no SBIR) has developed a medical device that uses plasma technology to electronically generate gaseous nitric oxide from the air and helps speed the healing process for individuals with chronic diabetic foot ulcers; SpeechTails (Elm Grove, WI; no SBIR) has an online speech therapy and learning system; Whole Trees (Stoddard, WI; no SBIR) has a technology for digitally engineering timber to make affordable commercial construction materials that can be substitutes for concrete, steel or milled lumber. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 1, 12]

WiBotic (Seattle, WA)

WiBotic (Seattle, WA; no SBIR), a University of Washington startup, a leader in wireless power and battery intelligence solutions for the robotics industry, announced it has raised $2.5 million in a seed round [company press release, Apr 26, 17]

Wicab (Middleton, WI)

Wicab (Middleton, WI; $2.3M SBIR), whose “BrainPort” device allows blind people to, in a way, “see” the world around them by substituting touch for sight, has raised $975,000 in equity financing, according to a regulatory filing. Using a small camera fastened to sunglasses, the device converts video signals to electronic impulses that are felt on the user’s tongue. In June, the FDA gave Wicab the green light to start selling the BrainPort in the U.S. [Jeff Buchanan, xconomy.com, Feb 5, 16]

Wickr

Wildcat Discovery

Semprius (Durham, NC; $500K SBIR) startup that claims to have developed the world’s most efficient solar panel made a prestigious roster of the most important emerging technologies in the world.- the annual list compiled by [MIT] Technology Review, [on] criterion for emerging technologies: their potential to change the world .... has raised $44 million from venture capitalists and Siemens [John Murawski, Raleigh News & Observer, May 2, 12] The other nine technologies are: egg stem cells by OvaScience (Boston, MA; no SBIR) ; A camera that lets images be adjusted after the shot by Lytro (Mountain View, CA; no SBIR); solar powered micro-grids by Mera Gao Power (Reusa, India); 3-D transistors by Intel; a faster Fourier transform by MIT; nanopore DNA sequencing by Oxford Nanopore
(Oxford, England); crowd-funding by Kickstarter (New York City); high speed materials discovery by Wildcat Discovery Technologies (San Diego, CA; no SBIR); and Timeline interface by Facebook.

Fifty Nifty Techno-Innovators as judged by Technology Review magazine [Apr 12]. In the company of investment magnets like Facebook and Google are a few companies and ideas that would be fit for a realistic SBIR program intent on seeding technically uncertain innovation with a future if it can be shown to work.
Alta Devices (no SBIR) high-efficiency gallium arsenide–based solar cells provide a way to lower the cost of solar power. Can economically produce robust cells that use only small amounts of the expensive semiconductor.
Integrated Diagnostics (Baltimore, MD; $1M SBIR) By reducing the cost of diagnostic tests, it has allowed the monitoring of more disease markers. Its synthetic antibodies replace more expensive antibodies widely used in diagnostics.
Suntech (no SBIR) Has developed a low-cost way of making better silicon solar cells. Its new panels are more efficient because they reflect less light and use thinner electrodes that block less light.
Sakti3 (no SBIR) Its high-energy batteries, which will first appear in consumer devices, could make electric cars cheaper and improve their range. Making batteries without the flammable liquid found in conventional electric-car batteries means they can store more energy.
LanzaTech (no SBIR) Makes fuel and chemicals from the carbon monoxide produced by processes such as steelmaking. Genetically engineered organisms turn the gas into ethanol and other useful chemicals.
First Solar (Toledo, OH; $750K SBIR) It is reducing the cost of utility-scale photovoltaic installations. constrains costs with vertical integration of everything from plant construction to the manufacture of high-efficiency cadmium telluride cells.
Wildcat Discovery (no SBIR) Has used high-speed methods to find materials that improve the performance of batteries. Identified a pair of materials that could increase energy density by 25 percent in batteries for cars and portable electronics.
Siluria (no SBIR) Its catalytic process is able to convert cheap and abundant natural gas into ethylene, a commodity chemical used to make plastic. Developed a family of catalysts that selectively cause methane to react to form ethylene.
Organovo (San Diego, CA; $260K SBIR) Its three-dimensional artificial tissue structures can be used for drug testing and are likely to find therapeutic applications. A printing process methodically deposits layers of cells and gel material to build up new tissues.    Cellular Dynamics International (Madison, WI; $500K SBIR) Using human iPS cells in drug screening could accelerate the development of new therapies. Its new product derived from iPS cells is meant for use in vascular targeted drug discovery, tissue regeneration, and life science research.
Foundation Medicine (no SBIR) Its new diagnostics exploit a growing understanding of the molecular basis of cancer.   It has developed a comprehensive cancer diagnostic test and is partnering with pharmaceutical companies to use the test in drug development.

Wilder Systems (Austin, TX)

Wilder Systems (Austin, TX; one SBIR) won a $564,000 NIST] grant earlier this summer to develop the robotic system [to] do quick Covid-19 tests. [Mike Cronin, Austin Business Journal, Aug 5, 2020]

Wiliot (San Diego, CA)

The start-up Wiliot (San Diego, CA; no SBIR, founded 2017) recently backed by Qualcomm Ventures is developing battery free Bluetooth beacons that aim to push wider adoption of the micro-location technology in everything from retail to product packaging., said earlier this month that it raised $5 million from Qualcomm Ventures and M Ventures, the venture capital arm of conglomerate Merck KGaA. ... on top of a $14 million funding round that the company launched when it opened. [Mike Freeman, San Diego Union Tribune, Nov 20, 17]

Willow Garage (Menlo Park, CA

PR2 can fold laundry and fetch drinks .... Leila Takayama has had an especially big influence on the design of an advanced robot from Willow Garage (Menlo Park, CA; no SBIR) an early prototype of a new generation of robots that promise to be indispensable to the elderly, people with physical challenges, or anyone who simply needs a little help around the home or office.[Jessica Leber, Technology Review, S/O12]

Wilocity (Sunnyvale, CA)

Qualcomm said it has purchased startup Wilocity (Sunnyvale, CA; no SBIR), a bet that a high-speed wireless technology called WiGig will become a standard feature on smartphones and other products. Financial terms weren't disclosed. [Don Clark, Wall Street Journal, Jul 3, 14] Wilocity says it is delivering the world's first multi-gigabit wireless chipsets based on the new WiGig 60GHz and IEEE802.11ad standards for super high-speed downloads, docking, networking, and high definition video at over 10x today's typical Wi-Fi transmission rates. [company website]

Wilson Greatbatch

Wilson Greatbatch (AKA Greatbatch) which moved its corporate headquarters to Texas in 2012 – will be called Integer and will be traded on the New York Stock Exchange as ITGR. [Dan Miner, Buffalo Business First, May 31, 16]

Greatbatch down 15% [Mar 1,16]

Greatbatch’s latest effort to defend its patented medical device technology has been successful. Following a two-week trial earlier this month, Greatbatch’s claim of infringement by AVX (founded 1922 as Radiola) was upheld and it was awarded $37.5 million [Michael Petro, Buffalo Law Journal Buffalo Business First, Jan 28, 16] Radiola became Aerovox in 1924, AVX in 1973, grown by acquisition since. [company website]

Greatbatch down 11% [Oct 6,15]

Greatbatch up 14% [Aug 27, 15] said it would acquire Lake Region Medical (Chaska, MN; no SBIR) [got its start in the Twin Cities making Medtronic’s pacemaker leads in the 1960s] in a cash-and-stock deal that will create a combined medical-device components manufacturer with 9,000 employees and sales on three continents. [Neal St. Anthony, Minneapolis Star Tribune, Aug 27, 15]

Greatbatch (Frisco, TX; no SBIR) is eliminating about 175 jobs from its medical device manufacturing operation in Plymouth [MN] and moving the work to Mexico. ... Greatbatch was founded in 1970 by late inventor Wilson Greatbatch, who licensed the first implantable pacemaker to Medtronic in 1961. [Jim Hammerand, Minneapolis / St. Paul Business Journal, Jan 6, 15]

[Wilson] Greatbatch announced plans to cut 170 jobs at its Electrochem Solutions portable medical manufacturing facility in Beaverton )OR). The jobs will transfer to a “new state of the art facility in Tijuana, Mexico by the end of 2015,” according to a news release from Greatbatch .... A division of Greatbatch acquired Beaverton battery pack manufacturer Micro Power Electronics (no SBIR) in 2011. The name was later changed to Electrochem. [Elizabeth Hayes, Portland Business Journal, May 28, 14]

Wilson Greatbatch [92], whose invention of the implantable cardiac pacemaker has kept millions of hearts beating in rhythm, died ...received more than 150 national and international patents, including one for the pacemaker, which was first implanted in humans in 1960. Today, hundreds of thousands of people worldwide receive them every year. [AP, Sep 27]

Greatbatch up 15% [Mar 4, 09]

Greatbatch up 15% [Nov 5, 08]

Greatbatch announced plans to idle three of its facilities outside its Western New York base. [Business First of Buffalo, Nov 1, 08] No mention of outsourcing abroad. The company employs about 2,445 workers.

Greatbatch down 11% [Oct 15, 08]

GreatBatch down 11% [Oct 9, 08]

Electrochem, a subsidiary of Greatbatch, said it will relocate 230 employees this week from Canton to a much larger "green" facility in Raynham (above). [Boston Globe, Aug 14, 08]

Greatbatch down 14% [May 7, 08]

Greatbatch down 16% after lowering its 2007 earnings and revenue guidance by about 12%. [Sep 26, 07]

Greatbatch made a slower pace to a mere $3M profit on $60M revenue and its stock price slipped to only 50 times earnings. [Oct 05]

Customer Takes Heart. Even the battery supplier Wilson Greatbatch rose 10% when customer Guidant found that its new defibrillator works much better than even hoped for and could end the clinical trials and set off towards production and a doubling of sales. [facts from Christopher O'Connor, smartmoney.com, Nov 21] Note that GB makes money and sells at 1 PE of 41 with an expected profit growth rate of 20% (says the Yahoo consensus). .

In 1956, a University of Buffalo electrical engineer named Wilson Greatbatch was using some early silicon transistors to build a circuit to help the nearby Chronic Disease Research Institute record fast heart sounds. He accidentally installed the wrong resistor into the circuit, and it started to pulse in a recognizable "lub-dub" rhythm. Greatbatch was already aware of a problem called "heart block," in which the organ's natural electrical impulses don't travel properly through the tissue; he quickly realized that this circuit was exactly what was needed to steady these sick hearts. At the time, clunky external cardiac pacemakers existed, but they plugged into wall outlets and had external electrodes that burned the skin. Greatbatch's circuit formed the basis for a painless, implantable device. But he found little enthusiasm for his invention until April 1958, when he met William Chardack, chief of surgery at the Buffalo VA Hospital, who immediately saw the pacemaker's potential. Three weeks later, on May 7, Chardack and Greatbatch successfully implanted their first model in a dog. However, bodily fluids seeped past the electrical tape used to seal the gadget, shorting it out after only four hours. Greatbatch recast the pacemakers in epoxy blocks, and within a year prototypes lasted four months. The team began looking for its first human patient but Greatbatch's employer, Taber Instrument, did not want to take on the potential legal liability of the unproven device. So armed with $2,000, he set out on his own. He hand made 50 pacemakers in a barn workshop, and in April 1960, Chardack implanted the first of 10, seen above, into patients. That year, Minneapolis-based medical electronics firm Medtronic licensed Greatbatch's invention; it remains the top manufacturer of cardiac pacemakers. Greatbatch continued to improve his creation's design and soon developed a corrosion-free lithium battery, helping extend the life of pacemakers from two years to 10. Today, Wilson Greatbatch Technologies of Clarence, NY, is the world's largest manufacturer of implantable lithium batteries. [Technology Review, Sep 01]

Profit in the Heart(Jul 24)Wilson Greatbatch reported record sales and earnings for the quarter, sales up 41$ and profits up and a profit of $2.6M against a loss in last year's quarter. WB makes batteries for pacemakers and such, GB also palns a secondary issue of 6M shares this week to raise $50M for the company and $150M for exiting shareholders. It is also big enough now to be in the Russell 3000 index.

Wilson Greatbatch has nearly doubled in a month to 400+ times earnings. GB makes power for pacemakers and other implantable devices that keep people ticking. Whether you believe GB is making money depends on how you read the variuous extraordinary items that are an accountant's job security.

Wilson Greatbatch Technologies (Clarence, NY) rose a third from its IPO price after the first week of trading. It raised $80M and now has a market cap of $400M.

Greatbatch Makes the Pace Of the 23 IPOs this week in an again hot IPO market, one, Wilson Greatbatch , a battery company had $1M of SBIR in 1990 and now has 750 employees and revenues of $75M. It will trade on the NYSE. It claims that Over 90% of the pacemakers and implantable cardioverter defibrillators, or ICDs, manufactured worldwide in 1999 used power sources either manufactured by us or produced by third parties under agreements with us to use our patented technology. At its IPO price of $16, it will start with a $290M market cap. The company dates to 1970 when Mr Wilson Greatbatch incorporated it to develop his 1958 invention - the implanatable pacemaker.

Wilson Tool International (White Bear Lake, MN)

Wilson Tool International (White Bear Lake, MN; no SBIR) [with $150 million in revenue] is seeking investment targets after assembling a $40 million fund to buy up new manufacturing technology. .... will look first at companies in precision manufacturing, ideally in Minnesota and Wisconsin [Mark Reilly, Minneapolis / St. Paul Business Journal, Mar 3, 14]

Wilson Wolf Manufacturing (New Brighton, MN)

Wilson Wolf Manufacturing (New Brighton, MN; $3.5M SBIR) got a $3.76 M SBIR from NIH. ... will work in collaboration with the Diabetes Institute for Immunology and Transplantation (DIIT) at the University of Minnesota. DIIT is researching the transplanting of insulin-secreting cells, or islets, for potential treatment of Type 1 diabetes. [Minneapolis Star Tribune, Apr 15, 08]

WiMax.com (Texa)

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes. Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund..... Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital. [Lori Hawkins, Austin American Statesman, Jan 26, 12] Graduates: Agile Planet, Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar, Savara Pharmaceuticals, Spredfast, Terapio ($500K SBIR), Unwired Nation, WiMax.com.

Windlift (Madison, WI)

Three Madison technology companies have been qualified to receive investor tax credits under the state's angel investor and venture fund tax credit programs. The companies are: Windlift LLC, which is developing a wind-powered pump that has a patent pending; Centrose LLC, which is trying to use sugar chemistry to make a variety of existing and failed drugs less toxic and more effective; and Symbiont Web Inc., which is developing software to create a relationship between network, Web and mobile space to promote faster data flows and more stable Internet connections. The tax credit program provides a dollar-for-dollar reduction for state income taxes owed to investors in qualified companies. [Milwaukee Journal-Sentinel, Nov 3, 07] No SBIR for the firms.

Windtree Therapeutics (Warrington, PA)

Windtree Therapeutics (Warrington, PA; $6M SBIR as Discovery Laboratories, founded 1992) focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced it closed a $2.6 million private placement [company press release, Apr 4, 18]

WinSanTor (San Diego, CA )

UC San Diego and Canadian scientists said they have discovered a potential way to prevent and reverse peripheral neuropathy — a painful and disabling condition affecting 40 million Americans and hundreds of millions worldwide. A Phase 1 clinical trial of a drug based on this finding — designed to assess safety — is scheduled to be launched in April by start-up, WinSanTor (San Diego, CA; no SBIR, founded 2011) . A Phase 2 trial to test proof of concept is expected to begin by the end of this year. The drug, pirenzepine, is already approved in other countries for treating stomach ulcers. [Bradley Fikes, San Diego Union Tribune, Jan 17, 17] transformative discoveries originally developed and patented at the University of Manitoba, the University of California at San Diego, and University of Toronto [company website]

Wintegra (Austin, TX)

Wintegra (Austin, TX; no SBIR) hopes to raise $115 million in an IPO. ... a 10-year-old company with operations in Austin and Israel. It designs network processors that allow faster transmission on cellular networks. ... founded by a group of former Motorola Semiconductor employees. Wintegra has about two dozen employees in Austin, who work on software development, sales and marketing. [Austin American-Statesman, May 8, 10]

WISErg (Redmond, WA)

WISErg (Redmond, WA; no SBIR) that takes food scraps from grocery stores and restaurants and converts them to fertilizer, has raised $5 million in a Series B funding round. ... will use the funding to enter California later this year. The company, founded in 2010 by former Microsoft employees Larry LeSueur and Jose Lugo, has raised $7.75 million to date [Benjamin Romano,xconomy.com, Jun 27]

Wizbe Innovations (Manchester,ME)

Maine Technology Institute today announced four new Development Awards — conditional loans — totaling $761,348 for four Maine technology companies. The awards by MTI, a publicly financed non-profit, were matched with combined contributions over $890,047 by the recipients: Wizbe Innovations (Manchester, ME) $64,000 to develop parachute fabric for the U.S. Army with controllable and adjustable permeability. Wizbe initially began their work with a U.S. Army SBIR to develop a prototype fabric. ... Pika Energy (Gorham, ME; no SBIR) $274,291 to develop a wind turbine system that offers lower upfront costs to make it easier and less expensive for families and businesses to produce clean renewable electricity. Early stage development was supported with an MTI Seed Grant. ... Cerealus Holdings(Waterville, ME; no SBIR) $261,849 to commercialize their Cerecarb, which is designed to enable paper mills to reduce costs by substituting ash filler for expensive pulp fiber. ... RainStorm (Orono, ME; no SBIR) $161,208 to expand access to affordable education opportunities nationally by providing local adult education programs with a simple, affordable course catalog and online registration website. [Mass High Tech, Jun 27, 11]

WMR Biomedical (Watertown, MA)

Arsenal Medical (Watertown, MA, formerly WMR Biomedical; no SBIR)., a developer of targeted therapies for patients with chronic conditions, has raised $2.05 million in debt financing from nine investors, [Mass High Tech, Jan 21, 10]

Wolfspeed ---- see Cree

Wolf Technical Services (Indianapolis, IN)

Wolf Technical Services (Indianapolis, IN; $1M SBIR), inventor of a high-tech mobile seatbelt for aircraft, has been chosen to design and develop a restraint system for the military.... a U.S. Navy contract valued at $12 million. [Tom Spalding, Indianapolis Star, Sep 22, 09]

WoundZoom (Longmont,CO)

WoundZoom (Longmont, CO; no SBIR) whose first product is a digital, hand-held device to measure the size of wounds, will move to Stevens Point [WI] after securing private, state and local funding. ..... an undisclosed amount of funding from the Pavelski family, which owns Heartland Farms, a Stevens Point-area potato grower ... three full-time employees, but told the city it expects to create at least 40 jobs [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 2, 13]

Woven Orthopedic Technologies

Woven Orthopedic Technologies (no SBIR) startup company is aiming to be part of a bioscience cluster developing in the state ... Anthony, John and Marc Viscogliosi have put together the money to commercialize the inventions of doctors again and again over the past 15 years. The most recent sale of one of the companies they launched was for $375 million, in 2014, according to a trade publication. ... The idea this time — a plastic woven tube that would sit between a screw and the hole in a bone — is designed to improve outcomes of surgeries that use screws. ... is developing the invention of Dr. Alex Jones of Denver, has three patents and 16 patents pending for the design of the braided polymer sleeves. Starting in early 2014, the company set a goal of raising $6.5 million in its first round of funding. It has raised almost $5 million. The money came partly from the Viscogliosi Brothers ... received a $100,000 grant and a $300,000 loan through the State's Small Business Express program. [Mara Lee, Hartford Courant, Mar 7, 15]

Wright Materials Research (Beavercreek, OH)

the Official Ribbon Cutting Ceremony of Wright Materials Research Company (Beavercreek, OH; $8M SBIR)’s New Scale-Up/Production Building on May 12th with Congressman Hobson and other public officials and dignitaries joining this grand celebration. [Dayton Daily News, May 9, 08] It helps to live near the flagpole.

Wright Therapy Products (Oakdale, PA)

Wright Therapy Products (Oakdale, PA; no SBIR, founded 1983) closed on $4.1 million from investors, according to [SEC] filing ... develops compression therapy devices that treat conditions where blood pools in a patient's leg, causing valve damage, immobility and other medical conditions [Patty Tascarella, Pittsburgh Business Times, Nov 10, 14]

W Solar Group (Chatsworth, CA)

W Solar Group (Chatsworth, CA; no SBIR) that plans to make solar panels will open a plant in Wisconsin and move its corporate headquarters and research and development facilities to Dane County [Madison area], ultimately creating about 620 jobs, Gov. Jim Doyle said Thursday. ... and begin manufacturing in 2012, ... The state helped attract the company to Wisconsin with $28 million in enterprise zone tax credits. The project represents a capital investment here of more than $300 million, Doyle's office said. ... about 20 employees and to this point has been focused on R&D [Paul Gores, Milwaukee Journal Sentinel, Dec 30, 10]

X4 Pharmaceuticals (Cambridge, MA)

X4 Pharma (Cambridge, MA; no SBIR) down 17% [Apr 12, 19] priced its public offering to raise $85M [company press release, Apr 12, 19]

X4 Pharmaceuticals (Cambridge, MA; no SBIR), a clinical-stage biopharmaceutical focused on the development of novel therapeutics for the treatment of rare diseases, announced the completion of its merger and the reverse stock split with Arsanis (Waltham, MA; no SBIR) . [X4 press release, Mar 13, 19]

Arsanis (Waltham, MA; no SBIR) announced its entrance into a definitive merger agreement with X4 Pharmaceuticals (Cambridge, MA; no SBIR). X4 Pharmaceuticals will merge with a subsidiary of Arsanis. X4 will focus on the development and commercialization of X4's lead product candidate, X4P-001, and the advancement of X4's pipeline of treatments for rare diseases of the immune system and rare cancers." [Hannah Genig, Benzinga, Nov 28, 18]

X4 Pharmaceuticals (Cambridge, MA; no SBIR) has developed drugs that it says can help restore these [low immune cell] counts to normal, and the company now has $27 million to test them in key clinical trials. ... has two lead candidates, one an immuno-oncology drug for solid tumors, and a second for WHIM syndrome, a rare immunodeficiency disorder. [Frank Vinluan, xconomy.com, Nov 16, 17]

drug developer, Amylyx Pharmaceuticals (Cambridge, MA; no SBIR) received a $5 million Series A financing to take its nerve cell-targeting treatment, AMX0035, into a Phase 2 trial for ALS patients. The treatment is a combination of sodium phenylbutyrate, a drug commonly used to remove ammonia from the body, and tauroursodeoxycholic acid, a derivative of stomach bile acid. ... funding was ]partly] provided by former Genzyme CEO Henri Termeer. Since selling Genzyme to Sanofi for $20 billion in 2011, Termeer has been an active investor and advisor to startup biotechs, including Moderna Therapeutics, Lysosomal Therapeutics (Cambridge, MA; no SBIR), Aura Biosciences (Cambridge, MA; no SBIR) , and X4 Pharmaceuticals (Cambridge, MA; no SBIR). [David Holley, xconomy.com, Aug 22, 16]

Xanofi (Raleigh, NC)

Xanofi (Raleigh, NC; no SBIR) has pulled in $150K SBIR, N.C. State University spinoff is prepping to launch its first product, a 3D cell culture dubbed “XanoMatrix.” ... build a working prototype for spraying tiny fibers in product manufacturing lines. The endgame is to build a nanofiber spraying system so that nanofibers can be applied more widely in the nonwovens manufacturing sector. [Lauren Ohnesorge, Triangle Business Journal, Jul 12, 13]

Xanthus Pharmaceuticals

Xanthus Pharmaceuticals (Cambridge MA; $2.5M SBIR) won orphan drug approval by the European Commission for its acute myeloid leukemia treatment [Mass High Tech, Oct 26]

Xanthus Pharmaceuticals $25 M in an equity financing. Xanthus Life Sciences (same address) had one $2.4M Phase 2 SBIR.

XBiotech USA (Austin, TX)

XBiotech down 24% [Feb 13, 20]

XBiotech (Austin, TX; no SBIR) up 75% [Dec 9, 19] announced today that it has entered into a definitive agreement with Janssen Biotech,[Johnson & Johnson sub], to sell XBiotech's novel antibody (bermekimab) that neutralizes interleukin-1 alpha (IL-1 ). IL-1 promotes disease-causing inflammation in a wide range of medical conditions. Janssen will acquire all rights to bermekimab, and XBiotech will be free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1 to treat non-dermatological diseases. XBiotech plans to re-enter clinical development expeditiously with a next generation anti-IL-1 therapeutic. ... Janssen will make a cash payment of $750 million [and] XBiotech may receive up to $600 million in potential milestone payments. [company press release, Dec 7, 19]

XBiotech up 15% [Nov 14, 19]

XBioTek down 21% [May 31, 19]

XBIOTECH up 18% [Mar 1, 19] announced breakthrough results from its Phase 2 clinical trial of its antibody therapy, bermekimab [company press release, Mar 1, 19]

XBiotech up 17% [Feb 6, 19]

XBiotech up 16% [Feb 5, 19]

XBiotech up 10% [Aug 21, 18]

Xbiotech up 10% [Jun 26, 18]

XBiotech up 20% [Jun 22,17]

XBIOTECH up 31% [Jun 12,17]

XBIOTECH down 66% [Jun 9,17] announced today that an Independent Data Monitoring Committee (IDMC) ... recommended the early termination of the study since the findings were not sufficient to meet efficacy or the threshold forcontinuation, which involved a prospectively defined acceptance boundary for the interim analysis [company press release, Jun 9, 17]

XBiotech down 10% [Jun 5,17]

XBIOTECH up 27% [Jun 1,17] Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer ... Data Show Reduced Disease Progression and Improved Survival for Patients Achieving Primary Endpoint [company press release, Jun 1, 17]

XBIOTECH down 10% [May 11,17]

XBiotech down 40% [Apr 21, 17] announced that the European Medicines Agency (EMA) rendered a negative "trend" vote ... related to the Company's marketing authorization application (MAA) for its candidate antibody for the treatment of colorectal cancer. [company press release, Apr 20, 17]

Xbiotech (Austin, TX; no SBIR) released new clinical trial results that have been called into question by one long-time critic, who specifically focused on a combined, dose-escalation Phase 1 and Phase 2 trial in Staphylococcus aureus bloodstream infections last week. Four patients died during the study, and Xbiotech said the drug was not responsible for three of those deaths, according to a panel of “experts certified in blinded reviews.” [Angela Shah, xconomy.com, Apr 13, 17]

XBIOTECH up 12% [Mar 22, 17]

XBiotech up 15% [Dec 27, 16]

XBiotech down 22% [Dec 16, 16]

XBiotech down 11% [Nov 18, 16]

XBiotech up 10% [Aug 5, 16]

Earlier this month, Xbiotech (Austin, TX) announced phase 3 study results that it called a “breakthrough.” Unfortunately, investors, peers, and the medical society whose conference was the backdrop to the announcement disagree with that conclusion. Xbiotech makes a monoclonal antibody to treat colorectal cancer but critics said the company’s results aren’t reliable and that the data were not reported correctly. [Angela Shah, xconomy.com, Jul 25, 16]

XBiotech down 13% [Jul 25, 16]

XBiotech down 15% [Jul 14, 16]

Xbiotech up 23% [Jul 11, 16]

after [Xbiotech] released Phase 3 trial results for its colon cancer drug over the long weekend. The Street’s Adam Feuerstein dissected the company’s claims, calling them “absurd.” [Alex Lash, xconomy.com, Jul 8, 16]

Xbiotech down 14% [Jul 6, 16]

Xbiotech down 33% [Jul 5, 16]

Xbiotech up 19% [Jul 1, 16]

XBIOTECH down 13% [Jun 9, 16]

XBiotech down 10% [May 19, 16]

XBiotech down 10% [Apr 19, 16]

XBiotech up 14% [Apr 15, 16]

XBiotech up 11% [Mar 24,16]

XBiotech up 12% [Dec 22, 15]

Xbiotech up 51% [Dec 7, 15] Announces Positive Results in European Phase III Study for Its Breakthrough Therapy for Colorectal Cancer [Wall Street Journal, Dec 7, 15]

X Biotech down 34% [Nov 24, 15]

XBiotech down 10% [Oct 19,15]

XBiotech up 11%[Oct 15,15]

XBiotech down 10% [Aug 4,15]

XBiotech up 12% [Jul 17,15]

XBiotech up 10% [Jul 16,15]

XBiotech down 10% [Jul 8, 15]

XBiotech down 13% [Apr 27,15]

XBiotech down 16% [Apr 24,15]

Xbiotech (Austin, TX; no SBIR, 55 employees) shares closed up 22% [from their IPO] in their initial day of trading. .... raised about $80M ... founded in the mid-2000s with a $50 million initial investment [Chad Swiatecki, Austin Business Journal, Apr 15, 15]

XBiotech USA (Austin, TX; no SBIR) pharmaceutical company [filed for IPO] ... help fund the development of Xilonix [currently in Phase III trials], the company's colorectal cancer-fighting therapy that is its leading drug candidate, and to move ahead with the construction of a planned $200 million campus on 48 acres in southeast Austin ... founded in the mid-2000s with a $50 million initial investment. It currently has 55 employees. Company President and CEO John Simard has said he expects the workforce to eventually grow to about 2,000 workers. [Chad Swiatecki, Austin Business Journal, Feb 24, 15]

XBiotech USA (Austin, TX; no SBIR), an emerging drug developer, will break ground on the first manufacturing and research facility at its 48-acre siteoff Riverside Drive in Southeast Austin that is expected to eventually house a $200 million campus of buildings. .... and start manufacturing and shipping the company’s colorectal cancer-fighting drug Xilonix by early 2016. That drug is currently going through Phase 3 trials in the U.S. and Europe. .... was started in the mid-2000s and has raised more than $50 million. Simard said the company is constantly raising capital to fund development and clinical trials, with a new drug intended to fight MRSA-resistant staph infection expected to start clinical trials late this year or in early 2015. [Chad Swiatecki, Austin Business Journal, Sep 25, 14]

XBiotech USA (Austin, TX; no SBIR) life science company, has acquired the patent estate from Strox Biopharmaceuticals (no SBIR) that relate to antibody therapies for methicillin resistant staph infections, or MRSA. .... [Xbiotech's]True Human antibody therapy for staph infections is derived from an antibody cloned from a natural immune response in humans. [Chad Swiatecki, Austin Business Journal, Apr 3, 14]

XBiotech USA (Austin, TX; no SBIR). has started pre-clinical development of a new True Human drug therapy for methicillin resistant staphylococcus aureus (MRSA). The company believes the treatment could cause a major transformation in the treatment of drug-resistant staph infection by counteracting the bacteria’s evasion strategies, allowing its clearance by a patient’s immune system. .... founded in 2007 and employs about 100 people [Chad Swiatecki, Austin Business Journal, Sep 6, 13]

X-Body Biosciences (Waltham, MA)

X-Body (Waltham, MA; no SBIR) has boosted its November fundraising tranche to $4.14 million .... focused on technology to discover and develop human antibodies to treat certain types of cancer and other diseases. [Rodney Brown, Mass High Tech, Jan 24, 12]

X-Body (Biosciences) (Waltham, MA; no SBIR) boosted a funding round started in 2009 from $1 million to $3.5 million, according to federal documents. ... on the heels of a deal announced last month in which X-Body partnered with Tanabe Research Laboratories (TRL) U.S.A. Inc., a San Diego subsidiary of Mitsubishi Tanabe Pharma Corp., to identify human antibody treatments for autoimmune diseases.... founded in 2008, is focused on technology to discover and develop human antibodies to treat certain types of cancer and other diseases [Rodney Brown, Mass High Tech, Nov 8, 11]

Xcede Technologies (Rochester, MN)

After raising more than $5 million in debt financing since its inception three years ago, Mayo Clinic-backed start-up Xcede Technologies (Rochester, MN; a joint venture between Mayo and Dynasil Corporation) says it has now secured a financial path for bringing its touted blood-loss patch into human clinical trials. ... SEC documents filed in late December revealed the joint venture reached a financial milestone in the fourth quarter – all of the debt was converted to 5.4 million shares of preferred stock. [Don Jacobson, Twin Cities Business, Jan 4, 17]

Med-tech firm Xcede Technologies (sub of Dynasil (Watertown, MA), Rochester, MN; no SBIR) closed on nearly $3 million for development of a patch that stops bleeding and seals tissue. [Minneapolis/ St Paul Business Journal, Dec 1, 15] Mayo Clinic has a financial interest in the technology .... Revenue Mayo receives is used to support the clinic's not-for-profit mission in clinical practice, education and research. [Dynasil press release, 2013]

XCELL BIOLOGIX (Kennesaw, GA)

XCELL BIOLOGIX™ (Kennesaw, GA; no SBIR, founded 2015) focused on commercializing innovative regenerative medicine technologies, announced that it has entered into an exclusive worldwide license agreement with the Wake Forest Institute for Regenerative Medicine (WFIRM), part of Wake Forest School of Medicine, for development and commercialization of its novel amnion derived product candidates that accelerate wound closure and re-epithelialization for the protection, healing and repair of chronic wounds and severe burns. [company press release, Dec 11, 17]

X-Biotix Therapeutics (Waltham, MA)

X-Biotix Therapeutics (Waltham, MA; no SBIR) focused on the discovery and development of small molecule antibiotic compounds targeting multidrug-resistant (MDR) Gram-negative pathogens, announced today pipeline and corporate progress updates. The company has successfully closed an [$4M] extension to its Series A financing [company press release, Nov 13, 19]

Xcell Biosciences (San Francisco, CA)

Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them. ... provides genomics-focused startups with capital, lab space at Illumina Accelerator’s offices in San Francisco, access to Illumina’s sequencing equipment and expertise, and advice on developing a business from legal experts, recruiting professionals, and Illumina executives and scientists, says Amanda Cashin, co-founder and head of the accelerator. ..... takes an 8 percent equity stake .. Checkerspot: designing advanced physical materials that can be used in industrial applications; Chimera Bioengineering: aims to improve the efficacy and reduce the side effects of engineered cell therapies for oncology; Encompass Bioscience: wants to integrate genetic information into the healthcare system; Mantra Bio: studies exosomes, small lipid vesicles that are excreted from cells and deliver information, aiming to discover new drug targets and therapies; Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources .... Of the previous 13 startups that have completed the program since 2014, a few have already made some funding splashes. Xcell Biosciences (San Francisco, CA; no SBIR) develops a type of cell culture that can be used in certain types of cell propagation and gene editing, raised a $12 million Series A round of funding in February. EpiBiome (South San Francisco, Ca) raised a $6 million seed Series A round of funding for its process of engineering microbiomes that might be used against drug-resistant bacteria in early 2016. Trace Genomics (New York) raised a $4 million seed round in mid-2016 for its work sequencing and analyzing the genomes of soil. [David Holley, xconomy.com, Jul 26, 17]

Illumina revealed the first three companies admitted to its six-month accelerator program in San Francisco for genomics-related startups. The three companies—Encoded Genomics (San Francisco, CA; no SBIR), Xcell Biosciences (San Francisco, CA; no SBIR), and EpiBiome (Union City, CA; no SBIR) —get full access to Illumina’s next-generation gene sequencing systems. [Alex Lash, xconomy.com, Oct 17, 14]

Xcellerex (Marlborough, MA)

Xcellerex (Marlborough, MA; no SBIR) a provider of manufacturing systems for biotherapeutics and vaccines, has begun a Phase 1 clinical trial of its yellow fever vaccine, XRX-001. ... In 2007, Xcellerex pulled in $20 million in a second round of financing .. Series C round of financing came later in 2007 with an investment of $31 million. [Mass High Tech, Jan 13, 10]

XChanger Companies (Annapolis, MD)

X-COR Therapeutics (Allston, MA)

X-COR Therapeutics (Allston, MA; no SBIR) developer of a novel extracorporeal carbon dioxide removal device, closed a $2.6M seed round [Rowan Walrath, BostInno, Nov 13, 20]

Xencor (Monrovia, CA)

Xencor (Monrovia, CA; $800K SBIR) and CytomX (Santa Barbara, CA; $500K SBIR) have taken a scalpel to their pipelines, stopping work on an ex-AbbVie ADC and pulling back from a Genentech co-development deal.

Xencor (Monrovia, CA; $1M SBIR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, announced it has entered into a technology license agreement with Vir Biotechnology (San Francisco, CA; no SBIR) in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. [Xencor press release, Mar 25, 20]

Exagen (Vista, CA, formerly in Albuquerue, NM; one SBIR) up 64% [Mar 17, 20] an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it has entered into a strategic partnership with Sonora Quest, the nation's largest integrated laboratory system. [company press release, Mar 17, 20]

Xencor up 38% [Mar 17, 20]

Xencor (Monrovia, CA; $900K SBIR, founded 1997) biopharma firm reached a licensing deal with pharma giant Gilead Sciences to develop and commercialize a group of Xencor’s antibody drugs to treat HIV. In exchange for licensing the drugs to Gilead, Xencor will receive an unspecified upfront payment and royalties from future commercialization of the drugs. (Howard Fine, LA Business Journal, Jan 8, 20] total funding $108M [crunchbase.com]

Xencor down 20% [Aug 7, 19]

Xencor (Monrovia, CA; $900K SBIR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306. XmAb24306 is an IL-15/IL-15Rα cytokine complex engineered with Xencor's bispecific Fc domain and Xtend™ Fc technology and is Xencor's most advanced preclinical cytokine program. ... Genentech will pay Xencor $120 million upfront, and Xencor will be eligible to receive up to $160 million in development milestones for the XmAb24306 program and up to $180 million in development milestones for each new IL-15 drug candidate.[Xencor press release, Feb 5, 19]

Xencor (Monrovia, CA, $900K SBIR, founded 1997), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today announced it will regain rights to develop and commercialize XmAb13676, a CD20 x CD3 bispecific antibody, from Novartis effective June 20, 2019, due to strategic pipeline reprioritization by Novartis. [company press release, Jan 14, 19] total funding $108M [crunchbase.com]

Xencor down 11% [Jan 17, 17]

Xencor (Monrovia, CA; $800K SBIR) up 13% [Nov 14, 16]

Xencor up 10% [Aug 3, 16]

Xencor up 12% [Jun 29, 16]

Xencor up 32% [Jun 28, 16]

Novartis (Swiss) has received rights with Xencor (Monrovia, CA; $800K SBIR) to develop bispecific antibodies for treating cancer. ... "Xencor is receiving a $150 million upfront payment from Novartis and the two companies will equally share the cost to jointly develop two Xencor antibodies targeting the CD3 domain," Novartis said. Novartis would additionally receive rights to develop and commercialize four further bispecific antibodies and to use Xencor's antibody technology in up to 10 additional molecules, the companies said. While Xencor would retain full commercial rights in the United States, Novartis would receive commercial rights outside the United States. [Brenna Hughes Neghaiwi, Reuters, Jun 28, 16]

Xencor (Monrovia, CA; $800K SBIR) down 17% [Sep 28,15]

Xencor (Monrovia CA; $800K SBIR) up 15% [Sep 16, 15]

Xencor (Monrovia, CA; $800K SBIR) up 30% [Dec 17, 14]

Xencor (Monrovia, CA; $800K SBIR) up 11% [Mar 31, 14]

Xencor (Monrovia, CA; $800K SBIR) up 10% [Dec 10, 13]

Last week, Celladon (San Diego, CA; no SBIR) , Xencor (Monrovia, CA, $800K SBIR) and Palo Alto’s CardioDx (Palo Alto, CA; no SBIR) all postponed their IPOs. [Bruce Bigelow, xconomy.com, Nov 22, 13]

X-energy (Greenbelt, MD)

the Department of Energy is providing $80 million in funding to two advanced reactor programs. At $40 million each in matching funds over the next five years, the grants will go to X-energy (Greenbelt, MD; no SBIR, founded in 2009 by Kam Ghaffarian, who previously founded Stinger Ghaffarian Technologies (no SBIR), a major contractor for NASA.), a little-known startup that is developing a new version of a pebble-bed reactor, and to Southern Company, the giant Atlanta-based utility that is working with TerraPower on molten-salt reactors. [Richard Martin, technologyreview.com, Jan 21, 16]

Xenetic Biosciencs (Lexington, MA)

Xenetic Biosciences down 31% [Jul 22,19] announced it closed its previously announced $15.0 million underwritten public offering [company press release, Jul 22, 19]

Xenetic Biosciences down 49% [Jul 17, 19] announced the pricing of an underwritten public offering [to raise] approximately $15 million. [company press release, Jul 17, 19]

Xenetic Biosciences down 16% [Jul 15, 19]

Xenetic Biosciences down 17% [Jul 8, 19]

Xenetic Biosciences up 39% [Jul 5, 19]

Xenetic Bio down 17% [Jul 2, 19]

Xenetic Biosciences up 35% [Jun 28, 19]

Xenetic Biosciences (one SBIR, founded 2015) down 13% [Oct 23, 18]

Xenetic Biosciences up 28% [Oct 22, 18]

Xenetic Bio down 21% [Sep 24, 18]

Xenetic Biosciences up 35% [Sep 21, 18]

Xenetic Bio down 10% [Aug 15, 18]

Xenetic Bio down 15% [Aug 14, 18]

Xenetic Bio up 28% [Aug 13, 18]

Xenetic Biosci down 13% [Jul 27, 18]

Xenetic BioSci up 10% [Jul 19, 18]

Xenetic BioSci down 10% [Jul 18, 18]

Xenetic Biosciences down 12% [Jul 6, 18]

Xenetic Bio up 22% [Jul 6, 18]

Xenetic Bio up 15% [Jul 5, 18]

Xenetec Biosciences down 12% [Jun 29, 18]

Xenetic Biosciences down 19% [Jun 27, 18]

Xenetic Biosciences (Lexington, MA; no SBIR, founded 2011, market cap $24M) up 103% [Jun 25, 18] total funding $10M [crunchbase.com]

Xenetic Biosciences down 11% [Apr 4, 17]

Xenetic Biosciences down 59% [Apr 3, 17]

Xenetic Biosciences down 16% [Mar 31, 17]

Xenetic Biosciencs (Lexington, MA; no SBIR) up 44% [Mar 30, 17] focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics ... Shire plc is a significant stockholder of the Company, having invested $10 million in the Company during 2014. [company press release, Mar 29, 17]

Xenex Disinfection Services (San Antonio, TX)

A County district judge has granted Xenex Disinfection Services (San Antonio, TX; no SBIR) request for a temporary restraining order against a competing biotech company from Tennessee, Tru-D SmartUVC (no SBIR), Xenex officials said. ... Xenex is seeking a permanent injunction that would prevent Tru-D from claiming that its device is six times more effective than the Alamo City company's germ-zapping robots. [W. Scott Bailey, San Antonio Business Journal, Oct 5, 15] Beware any ads that claim n times better, because the base is usually some slippery definition. There's also the fact that most ad readers don't know the difference between "n times better than x" and "n times as good as x."

Xenex Disinfection Services (San Antonio, TX; no SBIR) developer of robotic devices used to disinfect hospital facilities and eradicate often deadly health care infections, is expanding its product reach internationally. Xenex has struck a deal with Serenus Biotherapeutics, which is introducing the local biotech company’s pulsed xenon, ultraviolet room disinfection system to a number of African nations, including Botswana, Namibia and South Africa. ... already in use in more than 300 health care facilities across the U.S., Canada and Europe. [W. Scott Bailey, San Antonio Business Journal, Sep 18, 15]

Xenex Disinfection Services (San Antonio, TX; no SBIR) secured $25 million in new funding from multiple investors. ... has seen increased interest among health care facilities for its robotic germ-zapping device, will use the new capital to fund product development, international expansion and a larger sales force. ... Xenex officials said decreased reimbursements and increased scrutiny for hospitals dealing with health care-associated infections have driven up demand for the company's patented pulsed xenon device, which eliminates deadly microorganisms that can cause serious hospital-acquired infections [W. Scott Bailey, San Antonio Business Journal, Jan 27, 15]

Xenex Disinfection Services (San Antonio, TX; no SBIR), the world leader in UV room disinfection systems for healthcare facilities, today announced it has secured $11.3 million in funding. .... will be used for product development, international expansion, and increasing the company’s U.S. sales force. [company press release, Nov 11, 13] Xenex’s patented pulse xenon UV disinfection systems are utilized for the advanced cleaning of the patient environment in healthcare facilities. Only Xenex uses pulsed xenon and contains no mercury. [company press release, May 10, 13]

Xenex Healthcare Services (Austin, TX)

Officials with Xenex Healthcare Services (Austin, TX; no SBIR) say the company is growing after its disinfection machine has drawn raves for fighting hospital-acquired illnesses. Xenex, which was started in 2009, produces a machine that uses bursts of ultraviolet light to kill organisms and so-called superbugs, such as MRSA, which sicken hospital patients. [Brian Gaar, Austin American Statesman, Jun 26, 11]

XenoGen Biosystems (Madison, WI)

Eight Wisconsin biotech companies have been selected as winners of the BioForward 2013 Emerging Company Showcase: ABL Technologies LLC (Greenfield, WI; no SBIR); Co-D Therapeutics (Madison, WI; no SBIR); Imbed Biosciences (Madison, WI; no SBIR) medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants [company website]; Insert MRI (no SBIR) developing a platform technology for encapsulating workflow 'apps' to interactively guide magnetic resonance (MR) image-guided surgical procedures [company website]; Microscopy Innovations (Marshfield, WI; no SBIR) New Capsule-based System for preparing Microscopy Specimens [company website]; Regenerative Medical Solutions (Chicago/Madison; no SBIR) develop a protocol to grow healthy and resilient pancreatic stem cells [company website]; Stealth Therapeutics (Madison, WI; no SBIR) less invasive medical devices [company website]; and XenoGen Biosystems ( Madison, WI; no SBIR) Mathematical Modeling and Computing for the Life Sciences [company website]. ... represent "a cross section of emerging companies in our industry sector that we feel are going to make an impact down the road," said Bryan Renk, BioForward's executive director. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 13]

Xenomics (NY, NY)

Xenomics (NY, NY; no SBIR) accused Sequenom of deliberately doctoring test data on what was considered a promising Down syndrome test. Small firm Xenomics, which has a pending lawsuit against Sequenom, says it gave the company an exclusive license on urine-testing technology for fetal testing based on the promise of the Down syndrome test. Now it wants out of the agreement and is also seeking up to $300 million in damages. [Thomas Kupper, San Diego Union Tribune, Dec 18, 09]

Xenoport

XenoPort up 56% [May 23, 16] Arbor Pharmaceuticals, LLC (Arbor) and XenoPort, announced that they have signed a definitive agreement under which Arbor will acquire XenoPort for a total equity value of approximately $467 million. The purchase price per share represents a 60 percent premium [joint companies press release, May 23, 16] Some XenoPort shareholders crying foul about price.

Xenoport down 11% [Nov 16, 15]

XenoPort up 11% [Oct 16,15]

XenoPort down 12% [Oct 6,15]

XenoPort up 24% [Oct 2,15] a broader restructuring will eliminate about 25 jobs as the biopharmaceutical company focuses on its treatment for restless leg syndrome, the company said [Dow Jones Newswire]

XenoPort down 28% [Sep 15, 15]

Xenoport down 13% [Aug 6, 15]

Xenoport up 11% [Mar 16, 15]

Xenoport down 10% [Feb 3, 15]

Xenoport down 10% [Apr 23, 14]

Xenoport up 13% [Apr 22, 14]

XenoPort up 12% [Jul 11, 13]

XenoPort down 15% [May 20, 13] said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo. [Reuters, May 20, 13]

XenoPort down 10% [Mar 12, 13]

Xenoport up 10% [Jan 3, 13]

Xenoport raised $20 million selling equity and securities to one investor. [Lisa Ward, Silicon Valley / San Jose Business Journal, Nov 20, 12]

XenoPort down 11% [Oct 25, 12]

XenoPort down 11% [Oct 12, 12]

XenoPortup 15% [Oct 5, 12]

Xenoport up 24% [Jul 26, 12]

XenoPort up 12% [Jun 14, 12]

Xenoport down 10% [Jun 7, 12]

XenoPort up 12% [Jun 4, 12]

Xenoport up 14% [May 14, 12]

Xenoport up 10% [May 11, 12]

Xenoport up 10% [Jan 11, 12]

XenoPort up 56% [Apr 7, 11] after U.S. regulators approved its first product following more than a year of delays. [Bloomberg, Apr 7]

Xenoport up 22% [Sep 13, 10] said it plans to advance its drug candidate arbaclofen placarbil, also known as XP19986, into Phase III testing. [Market Watch, Sep 13]

XenoPort down 27% [Jul 7, 10] after the biopharmaceutical developer and U.K. health-care giant GlaxoSmithKline reported that their migraine drug failed a mid-stage trial. ... said its treatment gabapentin enacarbil "did not demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches" during a Phase IIb study. [MarketWatch, Jul 7]

XenoPort up 11% [Mar 15, 10]

XenoPort said it plans to cut its work force by about half and focus its resources on advancement of later-stage drug candidates. [Silicon Valley/ San Jose Business Journal, Mar 5, 10]

Xenoport down 10% [Feb 23, 10]

Xenoport up 26% [Feb 19, 10]

XenoPort up 10% [Nov 6, 09]

XenoPort down 13% [Oct 28, 09]

XenoPort up 26% [Sep 17, 09] after GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study. [AP,Sep 17]

Xenoport down 10% [Jul 8, 09]

XenoPort said it will sell 2.5 million shares of its common stock, increasing the number of outstanding shares by more than 9 percent. ... The proceeds will go to fund research and development of its drug candidates, possible sales and marketing activities and for general corporate purposes, the company said in a regulatory filing. [AP, Jul 7, 09]

XenoPort up 12% [Jun 2, 09]

Xenoport down 16% [Apr 27, 09] the company and large-cap GlaxoSmithKline said their drug Solzira failed to meet the goals of a Phase 2 study to treat loss of feeling in the extremities of diabetics. [Wall Street Journal, Apr 28, 09]

XenoPort up 11% [Mar 23, 09]

Xenoport down 11% [Mar 5, 09]

XenoPort down 35% [Dec 2, 08] as results from a midstage trial comparing the tablet XP19986 with a placebo for the treatment of a reflux disease did not reach statistical significance. [AP,Dec 2]

Xenoport up 14% [Nov 13, 08]

XenoPort down 13% [Nov 10, 08] and large-cap GlaxoSmithKline said their new drug application for Solzira, a treatment for moderate-to-severe primary restless legs syndrome, has been withdrawn. [Wall Street Journal, Nov 11]

Xenoport up 13% [Oct 16, 08]

Xenoport up 16% [Oct 13, 08]

Xenoport down 11% [Oct 9, 08]

Xenoport down 10% [Sep 17, 08]

Xenoport up 11% on news of a drug deal with Glaxo. [Feb 8, 07]

Xerion Advanced Battery (Westminster, CO)

Also Army Futures Command awards Xerion Advanced Battery (Westminster, CO; $15M SBIR) to develop innovative power solutions for the service. [breakingdefense.com, Jan 30, 22]

Xeris Pharmaceuticals (Austin, TX)

Xeris Pharmaceuticals (Chicago, IL; no SBIR) up 28% [May 22, 20], a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery. [company press release, May 22, 20]

Xeris Pharma down 13% [Feb 14, 19]

Xeris Pharma (Chicago, IL; $8.7M SBIR, founded 2005) down 21% [Feb 12, 19] announced that it filed a registration [for] a proposed public offering of 5M shares of its common stock [company press release, Feb 11, 19] prior funding $148M [crunchbase.com]

Xeris Pharma up 18% [Aug 14, 18]

Idera Pharma up 15% [Aug 14, 18]

Xeris Pharmaceuticals (Chicago, IL, no SBIR, founded 2005) filed a prospectus for a $75M IPO. The specialty pharmaceutical firm develops ready-to-use injectable and infusible drug products, including Glucagon Rescue Pen, a room temperature-stable liquid formulation that does not require any preparation or reconstitution, for the treatment of severe low blood sugar (hypoglycemia) in diabetics. [seekingalpha.com, May 25,18] total funding $202M [crunchbase.com]

Xeris Pharmaceuticals (Austin, TX; one SBIR) biotech raised $41 million in a Series C funding ... is developing what it calls the XeriSol platform for injectable drug formulations. Its leading product is a stable, soluble, and ready-to-inject glucagon for diabetics. [Angela Shah, xconomy.com, Jan 10, 17]

Xeris Pharmaceuticals (Austin, TX; $800K SBIR), a biopharmaceutical developer of injectable drugs, has completed a $41 million Series C round of funding.... will invest the capital in its flagship product, a glucagon injection for people experiencing low blood sugar [Christopher Calnan, Austin Business Journal, Jan 7, 16]

Xeris Pharmaceuticals (Austin, TX; $150K SBIR) completed a $17.9 million capital raise (a Series B preferred stock offering) to advance its injectable drug formulations that treat diabetes [Greg Barr, Austin Business Journal, Jan 8, 15]

Xeris Pharmaceuticals (Austin, TX; $800K SBIR) raised $7.2 million to fund development of its various technologies to treat diabetes. [Chad Swiatecki, Austin Business Journal, Oct 8, 14]

The Austin Technology Incubator is graduating 25 new companies. Two had SBIR: Xeris Pharma ($2.8M) and Yan Engines (Ohio, one Ph I). [siliconhillsnews.com, Jan 29, 14]

Xeris Pharmaceuticals (Austin, TX; one SBIR) received [$678,696 in the first phase of the fast-track] NIH SBIR grant to speed up development of its glucagon mini-dose pen used by individuals with diabetes to treat hypoglycemia. ..... Xeris said it had raised $2.3 million from investors. Back in February, the company received $1.9 million through the Texas Emerging Technology Fund for commercialization of its lead product, the Glucagon Rescue Pen. [Greg Barr, Austin Business Journal, Sep 26, 13]

Xeris Pharmaceuticals (San Rafael, CA; one SBIR) has updated a previously reported $1.7 million financing to $2.3 million. .... founded in 2005, develops injectable drugs to treat endocrine and metabolic diseases. The company employed five workers in 2011 [Christopher Calnan, Austin Business Journal, Jul 11, 13]

Xeris Pharmaceuticals (Austin, TX (San Rafael, CA); $500K SBIR) received $1.7 million of planned $3 million financing. and a $1.9 million grant from the Texas Emerging Technology Fund for the commercialization of its lead product, the Glucagon Rescue Pen and a follow-on product. .... founded in 2005, develops injectable drugs to treat endocrine and metabolic diseases. ... employed five workers in 2011. [Christopher Calnan, Austin Business Journal, Feb 19, 13]

Xeris Pharmaceuticals (Austin, TX; one SBIR in California) has been awarded [$337K NIH SBIR] for a formulation of a hormone called glucagon that helps regulate blood sugar. .... to further the development of Xeris' glucagon rescue pen, which could help diabetic patients avoid a severe form of hypoglycemia that can be life-threatening. [Austin American Statesman, Aug 6, 12]

Xeris Pharmaceuticals (Larkspur, CA; one SBIR), which is developing injectable products to treat endocrine and metabolic diseases, announced that it would move its headquarters to Austin ... drawn to Austin's entrepreneurial culture and its resources in the life sciences and biotech fields. "And from a business perspective, (Texas) is the business-friendliest state in the country," he said. The company was admitted into the Austin Technology Incubator and is working on commercializing its first product, which treats low blood sugar in diabetics. ...has three employees [Brian Gaar, Austin American Statesman, May 9, 11]

Xetrios Therapeutics (San Diego, CA)

Xetrios Therapeutics (San Diego, CA; no SBIR) was purchased by Kolltan Pharmaceuticals (New Haven, CT; no SBIR) [Xetrios] owns intellectual property from [founder Greg] Lemke’s research into the Axl and Mer receptors, along with another receptor called Tyro3. On Sep 12 Kolltan filed for a potential [IPO]. ... Lemke found that two cellular receptors or switches, once believed to work in similar ways, actually play different roles. Knowing which receptor does what is essential for treating disorders caused when one or the other malfunctions, Lemke said. [Bradley Fikes, utsandiego. com, Sep 15, 14]

XF Technologies (Albuquerque, NM)

XF Technologies (formerly Incitor, Albuquerque, NM; no SBIR) raised another $1.5 million to continue to develop its biofuels ... makes a fuel additive from biomass that has some unique properties, said company president Len Rand. ... raising more than $5 million last year and building a new plant ...it’s biomass chemicals are turning out to be good replacements for both chlorinated solvents as well as plasticizers, which are chemicals in plastics that are banned in many countries. ... Since 2012 XF has raised more than $8.3 million [Dan Mayfield, Albuquerque Business First, Jun 24, 15] using a novel catalytic process [company website]

During the first quarter of 2014, four venture capital deals with a combined value of $4.8 million closed in New Mexico, according to the new MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association: XF Technologies (Albuquerque, NM; no SBIR) $2 million, formerly known as Incitor, working to develop a new type of biofuel; Masterson Industries (Albuquerque, NM; no SBIR) $1.5 million, developing new specialty materials; Trilumina (Albuquerque, NM; no SBIR), $250,000, developing and manufacturing high-speed lasers.

xG Technology (Sarasota,FL)

xG Technology (Sarasota, FL; no SBIR) down 90% [Aug 14, 15] developer of patented wireless communications and spectrum sharing technologies, announced [IPO] pricing to raise $5M [company press release]

Xidex (Austin,TX)

Xidex (Austin, TX; $3M SBIR) won a $750,000 DOE contract to develop tiny [nanotechnology] devices to improve the resolution of powerful high-tech microscopes. [Austin American-Statesman, Dec 10]

Xilio Therapeutics (formerly Akrevia Thera)

Boston startups ended the first quarter of 2020 with a bang. The disruption caused by COVID-19, the respiratory disease caused by the novel coronavirus, notwithstanding, 60 Beantown startups raised over $1.5B. Chief among those were monster rounds raised by biotech companies: Cambridge-based Sarepta Therapeutics raised $400M; Xilio Therapeutics, formerly known as Akrevia Therapeutics, raised $100.5M in a Series B round; and Cambridge biotech Kymera Therapeutics raised $102M.

span style="font-weight=:bold;">Xilio Therapeutics (formerly Akrevia Thera), developing potent, tumor-selective immuno-oncology (IO) therapies for patients with cancer, announced the closing of a $100.5 million Series B financing. [to] progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional tumor-selective cytokine programs using Xilio’s proprietary technology. [company press release, Mar 2, 20]

Xitronix (Austin, TX)

Xitronix (Austin, TX; no SBIR) received $200,000 of a planned $500,000 round of funding.... developing technology to test silicon wafers, received the financing from four investors, according to[SEC] filing ... founded in 2006, develops technology designed to enable chipmakers to identify problems early in the manufacturing process. In 2008, it received a $500,000 grant from the Texas Emerging Technology Fund. Before that, Xitronix raised another $500,000 from private investors. [Austin Business Journal, Jun 2, 10]

From the Texas Emerging Technology Fund, Image Trends (Austin, TX; no SBIR) which develops image correction and enhancement products for commercial and amateur photographers will receive $1 million, and RFMicron (Austin, TX; no SBIR) $250,000 to speed development of its microchip technology [Lori Hawkins, Austin American-Statesman, Jul 14, 08] Og ten central TX companies fed from the fund, only one has failed so far: Nanocoolers (no SBIR) Tried to create a thermoelectric cooling system that would help cool semiconductors. Closed in 2007. The others: Molecular Imprints Inc. Nanotechnology company that makes advanced equipment used in producing computer chips, disk drives and other products. Monebo Technologies (no SBIR) Heart monitoring device called CardioBelt that enables users to obtain their own electrocardiogram while at home. Quantum Logic Devices ($1+M SBIR, moved from NC) Developing a system that uses single-electron devices to analyze DNA, protein and other molecular interactions. Receptor Logic Ltd. (no SBIR) Developing antibodies to improve understanding of the immune system and lead to better drugs and vaccines. Xitronix (no SBIR) Developing advanced semiconductor testing technology. XTreme Power (no SBIR) Developing electrical storage systems that are used to cut energy bills for commercial and industrial plants.

Xitronix (Austin, TX; no SBIR) won a $500,000 grant from the Texas Emerging Technology Fund to develop an advanced semiconductor testing technology. The year-and-a-half-old Austin startup uses a technology called photo-reflectance to quickly identify whether wafers being processed inside a chip factory are defective. The company says its technology can save chip manufacturers time and money by finding and fixing process problems more rapidly. ... partnering with the Austin Technology Incubator, the Nanomaterials Application Center at Texas State University and the Sematech research consortium in its technology and business development. .. already has received $500,000 from private investors, and will use the state grant to accelerate commercialization of its system for chip factories that process 12-inch silicon wafers. [Austin American-Statesman, Apr 4, 08]

XL Hybrids (Somerville, MA)

XL Hybrids (Boston, MA; no SBIR) provider of a low-cost hybrid electric powertrain designed for commercial fleet vehicles, said that it has raised $4 million in a series B investment round. ... brings the total amount of funding for XL Hybrids to about $8 million. [Boston Globe, Mar 13, 13]

Clean energy startup XL Hybrids (Somerville, MA; no SBIR) has raised $4.4 million of a planned $6.4 million new round of funding, according to federal documents. .... developing a proprietary technology that will allow for the conversion of gas-powered or diesel-powered vehicles to become hybrids, specifically focusing on converting larger fleet vehicle like limousines. [spun out of MIT] The company was founded in 2008 as Entergem Ventures [Rodney Brown, Mass High Tech, Jan 14, 11]

XL Hybrids (Somerville, MA; no SBIR; first founded as Entergem Ventures) has secured $300,000 in new investments, just a month after reporting capping a recent funding round at $1.5 million, according to a regulatory filing. ... has said little about what it’s working on, but its website does state that XL Hybrids has a proprietary technology that will allow for the conversion of gas-powered or diesel-powered vehicles to become hybrids. [Kyle Alspach, Mass High Tech, Aug 16, 10]

Stealthy clean energy startup XL Hybrids (Somerville, MA; no SBIR, founded 2008) has bumped up its initial funding round from $850,000 it reported in February to $1.58 million, according to federal documents [Rodney Brown, Mass High Tech, Jul 14, 10]

XL Scientific (Albuquerque,NM)

XL Scientific, LLC dba Verus Research (ALBUQUERQUE, NM; $14M SBIR) announces the award by the Naval Surface Warfare Center (NSWC) Crane Division in Indiana of a $52M, 56-month effort to establish a radiation combined environments test capability. Contracted under the “Cornerstone” Other Transaction Authority (OTA), the program will design, develop, integrate, test, and deliver a combined environment test capability comprised of neutrons and gamma radiation energy. [company press release, Feb 3, 2023]

Xlumena (Mountain View, CA)

In its third round of venture funding, medical device company Xlumena (Mountain View, CA; no SBIR) raised $25 million. .... lead product, a stent device to improve drainage between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst, has been approved by European regulators, but is not yet cleared for use in the United States. [Stephen EF Brown, San Francisco Business Times, Dec 3, 13]

Xoc Pharmaceuticals (Los Gatos, CA)

Xoc Pharmaceuticals (Los Gatos, CA; no SBIR) is developing a pill meant to prevent migraines that could offer a cheaper option than a new, emerging class of injectable medicines, [CEO] Borland says. .... Borland already has experience in migraine drug development [as]a senior neurology executive at MAP Pharmaceuticals, a Bay Area startup that had partnered with, and was then acquired by Allergan in a $1 billion deal for an inhalable form of dihydroergotamine, an old, generic drug for treating migraines. ... now has $30M Series A. [Frank Vinluan, xconomy.com, Feb 7, 18]

Xollai (St. Paul, MN)

ReconRobotics (Edina, MN; no SBIR) said it has acquired Xollai, (St. Paul, MN; no SBIR) that develops systems to help military drones land. ReconRobotics makes throwable microrobots for the military, ... a spokesman for ReconRobotics, said Xollai's St. Paul office will remain open and all nine of its employees will stay with the company. ReconRobotics now has 54 employees, Klobucar said. [Ed Stych, Minneapolis / St Paul Business Journal, Apr 4, 12]

Xolve (formerly Graphene Solutions) (Platteville, WI)

Xolve (formerly Graphene Solutions, Middleton, WI; no SBIR) nanotechnology firm, has raised $1.8 million of a proposed $2.8 million funding round, according to [SEC] filing ... , is looking to deploy a nanomaterials process developed at the University of Wisconsin-Platteville for a variety of applications. The company grew out of work by James Hamilton, a professor at UW-Platteville, and the late Philip Streich. They discovered a means to dissolve graphene and make single-particle carbon nanotubes that don't clump together in bundles. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 27, 15]

[Wisconsin]EDC certified four other companies to receive the tax credits They were: MPSP LLC, Milwaukee; HuTerra LLC, De Pere; and HealthMyne Inc., Madison. Pegasus Sustainability Solutions Inc., Fitchburg, was approved to receive the certification and a $125,000 loan. WEDC also said Tuesday that it has approved low-interest loans for two other emerging companies. Xolve Inc., Middleton, will receive a $330,000 loan; and Shamrock Energy Corp., Neenah, will get a $150,000 loan.[Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 2, 13] None had SBIR.

venture capital funding by state officials. Xolve (Middleton, WI; no SBIR) a nanotechnology company, received $2 million the result of WHEDA's participation in the State Small Business Credit Initiative, which was created as part of the federal Small Business Jobs Act of 2010 to make capital more accessible to entrepreneurs and small businesses. Wisconsin received $22.4 million for small-business lending programs to help create private sector jobs. WHEDA is administering the program funds. Xolve and Hopster are the state's first recipients.[Paul Gores, Milwaukee Journal Sentinel, Oct 12, 12]

Xolve (Platteville, WI, no SBIR) first known as Graphene Solutions, a young nanotechnology company that grew out of research at the University of Wisconsin-Platteville, said it has raised $2 million. ... grew out of the discovery of a new principle in materials science by UW-Platteville professor James Hamilton and then-student Philip Streich. Their discovery addresses a key technical problem - how to make nanomaterials dissolve in industrial solvents - that has held back their adoption in practical applications. ... funders included DSM, a global Dutch materials and chemicals company [Kathleen Gallagher, Milwaukee Journal Sentinel, Dec 23, 10]

XOMA (Berkeley,CA)

XOMA (Santa Monica, CA; $500K SBIR) up 20% [Jan 5, 2023] New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy [company press release, January 4, 2023]

XOMA up 20% [Mar 26, 21]

XOMA up 14% [Oct 23, 20]

XOMA up 14% [Feb 13, 19]

Johnson & Johnson reached a deal to buy medical technology firm Auris Health for about $3.4 billion in cash. J&J said that Auris’s technology will help it develop a digital solution addressing different parts of patients’ lung-cancer treatment. If certain milestones are reached, Auris could also receive as much as $2.35 billion more in the deal. .... [Co-founder] Dr. Frederic Moll is also a co-founder of Intuitive Surgical that makes the da Vinci robotic-assisted surgery system as well as the Ion endoluminal system, designed for lung biopsies. [Allison Prang and Peter Loftus, Wall Street Journal, Feb 13, 19]

XOMA down 14% [Oct 18, 18]

XOMA up 14% [Sep 26, 18]

XOMA up 15% [Aug 14, 18]

XOMA down 12% [Aug 13, 18]

XOMA down 21% [Aug 8, 18] reported earnings

XOMA up 11%[Feb 27, 18]

XOMA up 13% [Dec 7, 17]

XOMA up 11% [Nov 30, 17]

XOMA up 11% [Nov 20, 17]

XOMA down 13%[Nov 17, 17]

XOMA down 11% [Nov 14, 17]

XOMA up 18% [Nov 7, 17] We made significant progress on multiple fronts executing our new business strategy, and in doing so we completely transformed the Company. [CEO Neal, company press release, Nov 6, 17]

XOMA up 44% [Sep 5, 17]

XOMA (Berkeley, CA; $500K SBIR in 1980s), a pioneer in the discovery and development of therapeutic antibodies, today announced it has licensed the global commercial rights to gevokizumab, a novel anti-IL-1 beta allosteric monoclonal antibody, to Novartis. In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease. [XOMA press release, Aug. 25, 2017]

XOMA up 24% [Aug 25, 17]

XOMA up 12% [Aug 24, 17]

XOMA up 14%[Apr 18, 17]

XOMA up 13%[Mar22, 17]

XOMA up 21% [Feb 14,17]

XOMA up 20% [Feb 13, 17]in a registered direct offering.XOMA anticipates its aggregate gross proceeds from the offering will be approximately $25.0 million.[company press release, Feb 13, 17]

XOMA up 10% [Feb 1, 17]

XOMA up 18% [Jan 3, 17]

XOMA up 16% [Nov 11, 16]

XOMA down 15% [Oct 19, 16]

XOMA down 11% [Oct 18, 16]

Xoma over 30 years has lost more than $1 billion, tried out drugs in hepatitis, diabetes, hypertension, cancer, rheumatoid arthritis and acne, and has yet to bring a drug to market. And now the company, as part of a cost-cutting initiative that included shedding half its workforce, has killed its one-time savior program, the experimental drug gevokizumab. ... The company now says it is focused on endocrine drugs — a broad category that includes metabolism, sexual function, sleep and more [Ron Leuty, San Francisco Business Times, March 10, 16]

Down-but-not-out biotech Xoma ($500K SBIR in the 1980s) will sell its Berkeley antibodies manufacturing plant to Agenus (Lexington, MA; no SBIR) in a $6 million cash and stock offer, unload its biodefense program and trim its workforce by more than half. ... Xoma six years ago employed 350 people but that had fallen to 180 this year, in part because it sold its large-scale manufacturing facility in Berkeley three years ago to CMC Biologics (no SBIR). Now it will have less than 100 employees. .... Also, Xoma said it will divest its biodefense program to Nanotherapeutics (Alachua, FL; $2.7M SBIR) .... The company has an accumulated deficit of nearly $1.2 billion and its one-time savior-to-be antibody, gevokizumab, failed in a clinical trial for the eye disease Behcet's uveitis. [Ron Leuty, San Francisco Business Times, Nov 5, 15]

Novartis (Swiss giant) said it broadened its immuno-oncology pipeline with the acquisition of Admune Therapeutics (Danvers, MA; no SBIR) and licensing agreements with Xoma and Palobiofarma (Spanish) [Reuters, Oct 21, 15]

XOMA ($500K SBIR) down 77% [Jul 22,15] after the company said its eye drug failed in a late-stage study. [Lisa Beilfuss, Dow Jones Wire, Jul 22]

XOMA up 21% [Jul 9, 15]

XOMA up 12% [May 8, 15]

XOMA down 10% [Dec 23, 14]

XOMA up 15% [Nov 24, 14]

XOMA up 10% [Nov 20, 14]

XOMA down 19% [May 8, 14]

XOMA up 20% [Apr 29, 14]

XOMA down 14% [Mar 24, 14]

XOMA down 28% [Mar 5, 14]

XOMA up 12% [Feb 21, 14]

XOMA down 10% [Jan 24, 14]

XOMA up 14% [Jan 9, 14]

XOMA up 22% [Dec 2, 13]

XOMA up 15% [Oct 1, 13]

XOMA up 11% [Aug 28, 13]

XOMA up 12% [Aug 22, 13]

XOMA up 12% [Aug 20, 13]

Xoma down 21% [Aug 8, 13] after the biotechnology company said its second-quarter loss widened in a performance that fell short of Wall Street expectations. [AP]

Xoma, which 18 months ago bought the U.S. rights to the hypertension treatment Aceon and related experimental drugs, dealt the programs to a startup created by former Xoma executives. ... transferred the perindopril franchise to Symplmed Phaarmaceuticals LLC (no SBIR)and took an equity position in the new company.[Ron Leuty, San Francisco Business Times, Jul 3, 13]

Xoma up 15% [Jul 12, 13]

XOMA up 22% [May 9, 13] after the company reported top-line Phase II data for its Behcet's Uveitis treatment, Gevokizumab, that the firm views as positive. [Yahoo Finance, May 9]

Xoma. filed a shelf offering that would let it sell $100 million worth of common stock, preferred stock, debt securities and warrants ... and Xoma Corp. lead drug, gevokizumab, was granted orphan drug status for an inflammatory eye disease, the company said [San Francisco Business Times, Aug 22, 12]

Xoma down 11% [Aug 1, 12] has burned through a lot of shareholder cash over 30 years in business—$916 million at last count. Now that the venerable Berkeley, CA-based biotech has come under pressure to shed employees and assets, it’s created new opportunity for a contract manufacturer to swoop in. CMC Biologics, the contract biotech drugmaker in Copenhagen, Denmark and Bothell, WA, is announcing today it has acquired Xoma’s large-scale biotech drug manufacturing operations in Berkeley. [Luke Timmerman, xconomy.com, Jul 31, 12]

Xoma up 11% [Jul 6, 12]

Xoma up 15% [Jul 3, 12]

Xoma announced it is cutting its workforce by about a third to focus primarily on developing its lead drug candidate, an anti-inflammatory agent it hopes will prove useful for treating various health problems. [San Jose Mercury News, Jan 6, 12]

Xoma up 11% [Apr 7, 11]

Xoma down 30% [Mar 23, 11]

XOMA down 14% [Jan 7, 11] company announced mixed results from an on-going study of a potential anti-inflammatory treatment for type 2 diabetes patients [AP, Jan 7]

XOMA up 38% [Jan 4, 11] after it signed a development and licensing deal with Les Laboratoires Servier potentially worth more than $500 million for an anti-inflammatory drug candidate. [AP, Jan 4]

XOMA down 23% [Dec 28, 10]

XOMA up 59% [Dec 23, 10]

XOMA up 11% [Dec 22, 10]

Drug development company Xoma plans to raise about $21 million by selling stock and warrants. [San Francisco Business Times, Feb 2, 10]

Xoma will receive $6 million from Arana Therapeutics Ltd. for the use of the company’s research and development technologies, including a new antibody library that could make it easier for Arana to find rare and unique antibodies. [San Francisco Business Times, Sep 9, 09]

Xoma (Berkeley, CA; $500K SBIR) won a $65 million, six-year contract from the National Institute of Allergy and Infectious Diseases to study a treatment for botulism poisoning. ... the third contract, totaling $100 million, awarded to -based Xoma from the unit of the National Institutes of Health. [East Bay Business Times, Sep 9, 08]

XRpro Sciences (Cambridge, MA)(Also Viejo, CA)

Icagen (formerly XRpro Sciences, Cambridge, MA; $700K SBIR) ion channel drug discovery firm , is moving its headquarters to Durham [NC], where it will consolidate with the company’s existing R&D site. In July, XRpro bought Icagen from Pfizer [Frank Vinluan, xconomy.com, Oct 6, 15]

X-Ray Optical (East Greenbush, NY)(Aliso Viejo, CA)

X-Ray Optical (East Greenbush, NY; $18+M SBIR, founded in 1990, about 100 employees), which makes devices that measure sulfur content in petroleum, expanded its international focus about four years ago when it opened a subsidiary in China. ... was acquired by Danaher in March 2012, for an undisclosed price [The Business Review (Albany), Sep 13, 13]

X-Spine (Miamisburg, OH)

X-Spine Systems (Miamisburg, OH; no SBIR, founded 2003), a division of Xtant Medical will close its facility completely early next year, laying off 54 employees [company presss release, Oct 30, 17]

Xtant Medical Holdings (Belgrade, MT; no SBIR) a leader in the development of regenerative medicine products and medical devices, announced the closure of its Dayton, Ohio facility [55 employees] and the transitioning of its fixation operations to the Company’s headquarters in Belgrade, Montana. ... "In an effort to maximize the benefit of the 2015 merger with X-Spine (Miamisburg, OH; no SBIR), and optimize synergies including efficiencies and cost savings, we made the difficult decision of transitioning operations to Montana and closing the Dayton facility," said Carl O’Connell, CEO [company press release, Oct 6, 17]

XSunX(Aliso Viejo, CA)

Most solar panels are bulky, pricey, and difficult to install. But imagine if you could turn windows -- or entire skyscrapers -- into solar power generators. That’s the goal of XsunX, http://www.xsunx.com/ a startup in Aliso Viejo, Calif., that has invented a way to stick semitransparent solar cells on plastic film, which manufacturers can use to transform ordinary windows into PowerGlass. “It’s like a power-plant skin on a building,” says XsunX CEO Tom Djokovich. Why no SBIRs yet reported? Perhaps because the founder/CEO has a long business track record that would satisfy investors seeking innovative enterprises with good (think markets and profits) management.

Xtalic (Marlborough, MA)

Xtalic (Marlborough, MA; one SBIR, founded 2005) plans to debut a new metal alloy toward the end of this year that aims to serve as a lower-cost replacement for gold in electronics, including mobile devices, CEO Tom Clay said in an interview. .... The material, named Luna, will be made from a new metal alloy (which isn't being disclosed right now). [Boston Business Journal, Feb 27, 14]

Nanotechnology coatings company Xtalic (Marlborough, MA; one SBIR) has landed $8 million in its latest round of financing. ... has now raised at least $23.7 million since it was founded in 2005, according to company officials. [Rodney Brown, Mass High Tech, Jan 24, 11]

Nanotech firm Xtalic (Marlborough, MA; no SBIR) raised $10M in a second round. [Mass High Tech, Nov 3, 08]

Xtent

Stent-maker Xtent (no SBIR) was the fifth company to go public this week. [Jan 07]

Xtant Medical Holdings (Belgrade, MT)

Xtreme Power(Kyle, TX)

Younicos AG, the German company that last year bought the assets of Xtreme Power (Austin, TX; no SBIR, founded 2004) and recently moved to a new space in Southeast Austin, reports commitments for $50 million in growth capital. The energy storage systems company plans to use the capital to expand the deployment of its energy storage solutions. Investors include First Solar [Christopher Calnan, Austin Business Journal, Dec 11, 15]

Younicos AG (German) that acquired the assets of Xtreme Power (Kyle, TX; no SBIR) earlier this year paid $14 million ... in addition to assuming Xtreme Power’s $580,000 mortgage after it filed for Chapter 11 bankruptcy protection in January [Christopher Calnan, Austin Business Journal, Jun 19, 14]

energy storage company Xtreme Power (Kyle, TX; no SBIR) has filed for bankruptcy and officials say that layoffs will occur as the company seeks a new owner. ... makes energy storage and power management systems for utilities, wind farms and manufacturing companies, had plans to build large battery banks next to solar and wind farms across the world. Two years ago, it employed 285 people .... received a $2 million grant from the Texas Emerging Technology Fund in 2007. [Brian Gaar, Austin American Statesman, Jan 27, 14]

Energy storage and system developer Xtreme Power (Kyle, TX; no SBIR) reported receiving $1 million of a planned $3.5 million financing. .... founded in 2004, develops batteries, electronics and control systems comprising hardware and software. It employs about 100 workers. [Christopher Calnan, Austin Business Journal, Nov 25, 13]

Energy storage and system developer Xtreme Power (Kyle, TX; no SBIR) is about one-third of the way toward a $10 million financing goal. .... has collected $3.2 million the capital from six investors .... founded in 2004, develops batteries, electronics and control systems comprising hardware and software. .. employs about 100 workers. [Christopher Calnan, Austin Business Journal, Sep 25, 13]

Xtreme Power (Kyle, TX, no SBIR) which makes energy storage and power management systems for utilities, wind farms and manufacturing companies — has just raised $29.5 million in venture capital.... for technology development, the expansion of production of existing products and as working capital for large-scale power management projects ... received a $2 million grant from the Texas Emerging Technology Fund in 2007 [Barry Harrell, Austin American Statesman, Jul 27, 10]

Xtreme Power (Kyle, TX; no SBIR) won a $2M grant from the Texas Emerging Technology Fund to speed the commercialization of its electrical storage systems that are used to cut energy bills for commercial and industrial plants. [Austin Statesman-American, Mar 21]

XTuit Pharmaceuticals (Cambridge,MA)

Robert Langer, the MIT chemist and engineer whose inventions have already helped found at least 26 companies in recent decades, can add one more to the list: XTuit Pharmaceuticals (Cambridge, MA; no SBIR) biotech that’s revealing itself for the first time. ... has a $22 million Series A investment to develop drugs to treat cancer and fibrotic diseases. Its particular aim is what it calls the body’s “disease-promoting microenvironment,” and it is developing drugs designed to block certain biological mechanisms that cause cancers and fibrotic inflammatory conditions. [Don Seiffert, Boston Business Journal, Jun 11, 15]

Xunlight (Toledo, OH)

startup Xunlight (Toledo, OH; no SBIR) has developed a way to make large, flexible solar panels. It has developed a roll-to-roll manufacturing technique that forms thin-film amorphous silicon solar cells on thin sheets of stainless steel. Each solar module is about one meter wide and five and a half meters long. [Prachi Patel, MIT Tech Review, Jun 4, 09]

XyloCor Therapeutics (Malvern, PA)

XyloCor Therapeutics (Malvern, PA; no SBIR, founded 2013) focused on the development of gene therapy for unmet needs in cardiovascular disease, announced the close of a $17 million Series A financing [to] advance the development of lead product candidate XC001, a cardiovascular angiogenic gene therapy, and expand the company’s business and operational structure. [company press release, Dec 6, 18]

Xynomic Pharma

U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials. The company hasn’t revealed the amount of the series B financing but says it will be enough to start trials of abexinostat—originally developed by Pharmacyclics (Sunnyvale, CA; one SBIR) - in blood cancers and solid tumors over the next 12 months. It will also fund initial clinical testing of XP-102, a pan-RAF inhibitor licensed from Boehringer Ingelheim in a $502 million deal last November, in colorectal cancer and melanoma. [Phil Taylor, Fierce Biotech, Jun 1, 18]

Y-Carbon (King of Prussia, PA)

As a graduate student in materials science at Drexel University, Ranjan Dash used a novel chemical recipe to engineer nanoscopic pores into the carbon materials used in ultracapacitors. The tiny pores, whose size can be tuned with subnanometer precision, provide more surface area for charged particles to stick to, doubling the amount of energy the ultracapacitors can hold. Dash cofounded Y-Carbon (King of Prussia, PA; no SBIR) to commercialize the technique, and he now serves as its chief technology officer. He says that his company has already developed a prototype ultracapacitor. [Neil Savage, MIT Tech Review, Sep/Oct09]

Yan Engines(ohio)

Yan Engines (Austin, TX; one SBIR in Ohio, founded 2006), announced it has raised $700,000 to launch a subsidiary in the United Kingdom. The latest fundraise makes a total of $5 million for the startup. [Angela Shah, xconomy.com, Aug 28, 15]

Yan Engines (Austin, TX and Dublin, OH; one SBIR, moved to Austin in 2006) startup out of the Austin Technology Incubator (ATI) developing engine fuel economy technology, has raised new capital, bringing its total funding to $4M, according to the ATI. [Texas Tech Pulse, May 28, 14]

The Austin Technology Incubator is graduating 25 new companies. Two had SBIR: Xeris Pharma ($2.8M) and Yan Engines (Ohio, one Ph I). [siliconhillsnews.com, Jan 29, 14]

Yardney Technical Products (Stonington, CT)

Subsidies promise no loyalty. Rhode Island is welcoming a Connecticut-based high-tech battery maker Yardney Technical Products (Stonington, CT; $20M SBIR) ... Gov. Lincoln Chafee will join executives in East Greenwich to mark the company's relocation. ... brings 165 jobs to Rhode Island. The Rhode Island Economic Development Corp. offered Yardney more than $500,000 in tax exemptions and guaranteed $5 million in bonds. ... manufactures batteries for the military and the aerospace industry and developed the batteries in the Mars rovers. [AP, Apr 18, 11] Two years ago Yardney was negotiating for millions in additional financial assistance from the state. [Eric Gershon, Hartford Courant, Jul 3, 09]

Yield 10 (Woburn, MA)

Yield 10 Bioscience (Woburn, MA; no SBIR) up 77% [Jan 15, 21]

Y-mAbs Therapeutics (New York, NY)

Y-mAbs Therapeutics (New York, NY; no SBIR, founded 2014), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced its $96 million IPO [company press release, Sep 21, 18] total funding $96M [crunchbase.com]

AE Industrial Partners, a private equity firm focused on the aerospace and government markets, has wrapped up its acquisition of a majority stake in small satellite builder York Space Systems (Denver, CO; one SBIR) [Naomi Cooper, govconwire.com, November 15, 2022]

Yulex (Phoenix, AZ)

biotech Kultevat (St Louis, MO; no SBIR, founded 2010) has entered a research and development agreement with Japan-based Sumitomo Rubber Industries to expedite the development of an alternative source of natural rubber from Russian dandelions. ... because the dandelions can be grown in many more regions around the world, including North America ... Kultevat is the brainchild of [CEO Dan] Swiger, who in 1995 founded Yulex (Phoenix, AZ; no SBIR), a company that makes rubber latex from guayule plant extracts. ... Kultevat was recruited to St. Louis in 2013 by Roger Beachy, founding president of the Donald Danforth Plant Science Center. [Ryan Collins, St. Louis Business Journal, Aug 11, 15]

SGB Biofuels (San Diego, CA; no SBIR, founded 2007) is teaming up with Yulex (Phoenix, AZ; no SBIR, founded 2000) to more quickly develop guayule rubber [plant that] can replace traditional tropical or petroleum-based rubber .. collaborating to establish a genomics and molecular breeding platform focused on accelerating the crop improvement of guayule. .... In January, Yulex forged a partnership with Milan, Italy-based Versalis to launch an industrial production complex in Southern Europe to make guayule-based biorubber materials. It also has been working with the University of Arizona, and recently gave a $3 million grant to the Tucson university to apply classical breeding along with modern tools for improving the guayule crops. .... In 2012, Yulex received a $6.9 million USDA-DoE grant [Angela Gonzales, Phoenix Business Journal, Nov 12, 13]

Yumanity Therapeutics (Cambridge, MA)

Yumanity Therapeutics (no SBIR) and Proteostasis Therapeutics (no SBIR) entered into a definitive merger agreement. In conjunction with the merger, Proteostasis reduced its workforce by 79%. [Rowan Walrath, BostInno, Aug 24, 20]

A year after making its public debut and announcing plans to seek out a big financing round, Yumanity Therapeutics (Cambridge, MA; no SBIR) resurfaced with a $45 million Series A round [Ben Fidler, xconomy.com, Feb 11, 16]

Yumanity Therapeutics (Cambridge, MA; no SBIR, founded 2014) focused on transforming drug discovery for diseases caused by protein misfolding, announced a $45 million Series A financing from leading life sciences investors.... proprietary platforms aimed at identifying novel therapies to treat neurodegenerative diseases caused by protein misfolding including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. The accumulation of misfolded proteins is believed to play a central role in the initiation and progression of virtually all neurodegenerative diseases. [company press release, Feb 10, 16]

Yurie (Landover, MD)

[Jeong] Kim left Allied Signal and created Yurie (Landover, MD) in 1992 as an 8(a) company. A company spokesman said Yurie has never sought or received any government contracts through the programs because Kim "does not believe in" such government help. [Washington Post, Apr 28] Yurie makes video transmission equipment principally for government, employs 240 people, and Kim just sold it for $1B to Lucent. No SBIR. Yep, those small companies sure need SBIR to get into government procurement. Kim keeps $500M of the proceeds.

Z

Z Corp. plucked a futuristic technology from the labs of MIT - a printer that can produce three-dimensional objects, in color - and built it into a $60 million-a-year business. Companies like Reebok, Raytheon, and Avid Technology use the printers to create prototypes of new products, quickly and inexpensively. ...."3-D printing should migrate anywhere people are using 3-D data," Kawola says, envisioning the new venture as something that could generate "$20 million, $30 million, $50 million in revenue" for the company.... founded in 1994 to commercialize a technology developed at MIT, which uses standard ink-jet printer heads - the kind you'd find in any home printer - to spray a glue or binder and colored pigment over a thin layer of a powdery substance. ... In 2005, acquired by Contex Scanning Technology, a Danish company, ... In turn, Contex was sold to a private equity firm in Sweden last year, for about $240 million. [Scott Kirsner, Boston Globe, Sep 7]

Zacharon Pharmaceuticals (San Diego, CA)

BioMarin (Novato, CA: $300K SBIR) bought Zacharon Pharmaceuticals (San Diego, CA; $2.7M SBIR) for $10 million. [Stephen EF Brown, San Francisco Business Times, Jan 7, 13]

Zacharon Pharmaceuticals (San Diego, CA; $1.9M SBIR) startup that got $3.5 million in venture capital and a $2.2 million research grant in 2008, has raised another $500,000 ... developing small molecule drugs to block the production of complex carbohydrates known as glycans, which can alter the function of proteins [Bruce Bigelow, signonsandiego, Jul 8, 10]

Zacharon Pharmaceuticals, (San Diego, CA; $2M SBIR) that got $3.5 million in venture capital and a $2.2 million research grant in 2008, has raised another $500,000 in additional funding that includes debt, securities, and warrants or rights, according to a [SEC filing]. ... intends to raise $1.9 million. ... developing small molecule drugs to block the production of complex carbohydrates known as glycans, which can alter the function of proteins. [Bruce Bigelow, signonsandiego.com, Jul 2, 10]

ZafGen (Cambridge, MA)

Troubled Massachusetts drugmaker Zafgen plans to lay off 48% of its employees after another setback with its diabetes drug. [Srividya Kalyanaraman, BostonInno, Sep, 23, 19]

Zafgen (Boston, MA; no SBIR) suspended plans to begin human testing of its experimental drug ZGN-1258 due to worrisome safety signs in preclinical tests. The disclosure marks another setback for Zafgen, which scrapped one drug due to safety problems and saw the FDA temporarily halt testing of another. [Frank Vinluan, xconomy.com, Mar 15, 19]

Zafgen (Cambridge, MA; no SBIR) and its fat-burning drug prospect beloranib got a good reception from Wall Street ... incubated by Atlas Venture almost 10 years ago, ... raised $96 million [IPO] ... ended its first trading day up about 23% [Ben Fidler, xconomy.com, Jun 20, 14]

Zafgen, (Cambridge, MA; no SBIR) pharmaceutical company, announced the closing today of a $33 million Series C financing.... focused on obesity therapeutics that target imbalances in fat metabolism. [Chris Reidy, Boston Globe, Jul 7, 11]

ZafGen (Cambridge, MA; no SBIR) secured $14 million in a second round of funding, according to published reports. ... develops obesity-related treatment [Mass High Tech, Nov 18, 08]

Zalgen Labs (Germantown, MD)

Zalgen Labs (Germantown, MD; $2.8M SBIR) has inked a contract with the Coalition for Epidemic Preparedness Innovations, a foundation that invests in vaccine development for emerging infectious diseases including Covid-19, to run a clinical trial in West Africa. There, it will study Lassa fever. ... CEPI plans to buy more than $750K of diagnostics from Zalgen “in the short term,” to get the trial going, [Sara Gilgore, DCInno, Sep 23, 21]

Zavante Therapeutics (San Diego, CA)

Nabriva Therapeutics (Ireland) announced that it has acquired Zavante Therapeutics (San Diego CA; no SBIR, founded 2015), developing novel therapies to improve the outcomes of hospitalized patients, for upfront consideration of approximately 8.2 million shares of Nabriva. In addition, Zavante Therapeutics’ to receive up to $97.5 million upon the achievement of specified regulatory and commercial milestones. [joint Navibra press release, Jul 24, 18] Zavante total fundung $65M [crunchbase.com]

Zavante Therapeutics (San Diego, CA; no SBIR, founded 2015) antibiotic developer, has raised $45 million from VCs for clinical testing of its product to combat serious infections, including those caused bacterial "superbugs." The drug is an injectable form of fosfomycin, intended to be used against a broad spectrum of multi-drug resistant bacteria. .... "We had the management team and the experience to do [a key development step], so we acquired the company and kept the name," Schroeder said. [Bradley Fikes, San Diego Union Tribune, Apr 13, 16]

ZBB Energy (Menomonee Falls, WI)

EnSync Energy Systems (Menomonee Falls, WI), formerly ZBB Energy, now has a four-year supply agreement with Solar Power, a Chinese solar project developer, that's expected to yield sales of $80 million to $120 million. [Thomas Content, Milwaukee Journal Sentinel, Apr 6, 16]

ZBB Energy (Menomonee Falls, WI; no SBIR) announced it is changing its name to EnSync [Milwaukee Journal Sentinel, Aug 17, 15]

A Chinese venture capital firm plans to invest $3.2 million in a Chinese joint venture that will expand the market reach of energy storage systems designed by ZBB Energy (Menomonee Falls, WI; no SBIR). The announcement came as ZBB filed plans with securities regulators for a public stock offering .... If the venture investment is approved by the Chinese government, ZBB's joint venture company, Anhui Meineng Store Energy System Co. Ltd., will receive the investment to help Meineng fund its operations and growth. .... Meineng, which opened for business more than two years ago, is positioning itself to provide energy storage and power electronics systems for the microgrid and renewable energy markets in China. [Thomas Content, Milwaukee Journal Sentinel, Aug 18, 14]

ZBB Energy plans a reverse stock split later this month to boost the trading price of its stock, after it received a deficiency letter from the New York Stock Exchange saying it fell out of compliance with standards for being listed [Milwaukee Journal Sentinel, Oct 18, 13]

ZBB Energy (Menomonee Falls, WI; no SBIR) that develops energy storage systems, said Aspire Capital Fund LLC has committed to investing $10 million in the company over the next two years. [Guy Boulton, Milwaukee Journal Sentinel, Mar 15, 13]

ZBB Energy said it has won a contract from Eaton to provide an energy storage system for use in a military micro-grid application aimed at testing off-grid energy storage. The 500-kilowatt hour energy system will be a demonstration project in Fort Sill, Okla., and will be used to develop standards for a U.S. Army’s “energy surety micro-grid program,” ZBB said. [Milwaukee Journal Sentinel, Apr 5, 11]

ZBB Energy (Menomonee Falls, WI; no SBIR) said its ZESS 500 energy storage product has been deemed a fully operational and validated success at a project in Australia. The ZESS 500 is installed at CSIRO's Energy Centre in Newcastle, Australia, as part of the Advanced Electricity Storage Technologies program. [Milwaukee Journal Sentinel, Dec 28, 10]

ZBB Energy said it has delivered four ZESS 50 batteries and a power and energy control center system to Powertech Labs as part of its Bella Coola Hydrogen Assisted Renewable Power project in Bella Coola, British Columbia. [Milwaukee Journal Sentinel, Aug 2, 10]

ZBB Energy (Menomonee Falls, WI; no SBIR) that builds high-efficiency fuel cells, will provide the energy storage system for what could be a high-profile exhibit at this summer's Olympic Games in Beijing, the firm said ... raised about $20M in a public stock offering last June [Rick Romell, Milwaukee Journal-Sentinel, Apr 3, 08]

ZBB Energy (Menomonee Falls, WI; no SBIR) went public for $20M. ZBB says its zinc-bromine batteries store and discharge electricity more efficiently than traditional lead-acid batteries and can be combined easily in modules to meet various power requirements. The 9-year-old company has done only limited manufacturing. It lost $2.9 million in fiscal 2006 and expects to continue losing money through mid-2008, according to its prospectus. [Milwaukee Journal Sentinel, Jun 19]

ZBB Energy (Menomonee Falls, WI) seeks $15M public stock offering. A 35-employee basically Australian small company holds a proprietary position on zinc-bromine batteries. [Rick Romell, Milwaukee Journal-Sentinel, Jan 4]

ZeaChem (Golden, CO)

ZeaChem ( Lakewood, CO; one SBIR) which is developing sustainable fuels and chemicals, said it raised $19 million... research and development lab is in Menlo Park [CA].... said it has a demonstration biorefinery where it will produce sustainable fuels and chemicals in Boardman,OR., starting this year. [Lindsey Rindell, San Francisco Business Times, Oct 25, 11]

ZeaChem (Golden, CO; one SBIR) has won a $25 million federal grant to build an advanced biofuel plant in Boardman [OR] that converts poplar trees to motor vehicle fuel. ... one of 19 nationwide to receive $564 million in grants from federal economic stimulus money [Scott Learn, The Oregonian, Dec 4, 09]

ZeaKal (San Diego, CA)

Plant science company ZeaKal (San Diego, CA; no SBIR, founded 2010) said it closed a $15 million Series C financing round to advance its PhotoSeed technology, which increases crop yield by increasing a plant’s capacity for photosynthesis. [Sarah de Crescenzo, xconomy.com, Sep 10, 19]

San Diego-based investment firm Kapyon Ventures has raised $5.8 million for two of its agricultural biotechnology companies. The companies are developing microbial and plant technologies under the lean "virtual biotech" model that has become popular in the industry. Algenetix (no SBIR) , a company that's developing biofuels and other products from microbes, has raised $2 million. Investors include Two Oceans, a Sydney, Australia-based investment firm. ZeaKal (no SBIR) a developer of technologies to increase yields from soybeans and rice, has raised $3.8 million [Bradley Fikes, utsandiego.com, Apr 29, 13]

Zebra Imaging (Austin, TX)

Zebra Imaging (Austin, TX; $800K SBIR) has raised $2 million of a planned $3.5 million financing. ..... founded in 1996, develops technology producing 3-D images that can be seen without special glasses. The company employed 55 workers in 2009. [Christopher Calnan, Austin Business Journal, May 13, 13]

Zebra Medical Vision (Israel)

Zebra Medical Vision (Israel, founded 2014) raised $12 million in a funding round led by Utah-based healthcare provider Intermountain Healthcare ... Zebra Medical seeks to teach computers to automatically read and diagnose medical imaging data. Its analytics engine helps physicians and healthcare providers analyze millions of imaging records. [Yahoo finance, May 24, 16]

Ze-gen

Clean energy company Ze-gen Inc., which makes gasification technology to convert municipal waste streams into synthesis gas, says that it has closed on $2.5M in venture debt[Mass High Tech, Jan 10]

ZenBio (Research Triangle Park, NC)

ZenBio (Research Triangle Park, NC; founded in 1995; at least $1.4M SBIR) received a $1.88 million Phase II SBIR grant from the National Institutes of Health to develop a unique tool for cancer, obesity and diabetes research. [Raleigh News & Observer, Jan 28, 09]

Sleep tracking device maker Zeo (Newton, MA; no SBIR) raised $2 million in a debt round of funding, according to an amendment filed with the SEC. ... recently secured a partnership with training, physical therapy and nutrition company Athletes’ Performance to provide wannabe-pro football players with its sleep tracking technology, Sleep Manager Bedside and the mobile version of the technology to track and measure their sleep. [Patricia Resende, Mass High Tech, May 3, 12]

Zenomics (Durham,NC)

Zenomics (Durham, NC; no SBIR) startup co-founded by Zhen Gu, PhD, a scientist in the UNC-NC State Joint Biomedical Engineering Program, raised $5.8 million in investment ... from MicroPort Scientific (China), a biomedical device company that promotes the translation of Gu’s patented smart insulin technology. [news.unchealthcare.org, Jun 30, 17]

Zentalis (San Diego, CA)

Zentalis (San Diego, CA; no SBIR) a clinical-stage biopharmaceutical focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the completion of an $85 million Series C financing. The Company has raised a total of $147 million in gross proceeds from private financings since its founding in December 2014. [company press release, Dec 9, 19]

Zentalis Pharma (New York, NY)

The global economic crash means the window for initial public stock offerings is all but closed but that didn’t stop Zentalis Phamaceuticals from pushing through. The clinical-stage drug developer priced its IPO late Thursday, raising $165.2 million in its stock market debut. [Frank Vinluan, xconomy.com, Apr 3, 20]

after nabbing a series C as part of its coming out of stealth in December, quiet biotech Zentalis Pharma (New York, NY; no SBIR) is turning up the volume with a $100 million IPO attempt. [Ben Adams, Fierce Biotech, Mar 9, 20]

Zenverge (Santa Clara, CA)

Freescale bought Zenverge (Santa Clara, CA; no SBIR, founded 2006, 55 employees) the developer of high-definition content processing integrated circuits. Financial terms of the deal were not disclosed. ... Its technology is designed to enable the conversion of one media stream into multiple streams, each formatted for the specific Internet connected device or platform where it will be displayed, according to a Freescale announcement. ... Freescale, which was spun out of Motorola in 2006, develops embedded processors. It employs about 19,000 workers, including 5,000 in Austin. [Christopher Calnan, Austin Business Journal, Dec 3, 14[

Zeo

Sleeping. Founded in 2003 by three Brown University students, sleep-tracking startup Zeo (no SBIR) .... raised more than $30 million from Johnson & Johnson Development Corp., Best Buy Capital, iRobot co-founder Colin Angle and a handful of venture capital firms, then quietly shut down some time in late 2012 or early 2013. [Boston Globe, Oct 31, 13] One of thirteen Boston area firms to close in 2013, a list heavy on eateries.

Zephyr Technology (Annapolis,MD)

3M subsidiary 3M New Ventures said it has invested in Zephyr Technology (Annapolis, MD; no SBIR), a developer of real-time devices that monitor human performance through smart-fabric sensor technology. The amount was not released. [Ed Stych, Minneapolis / St Paul Business Journal, Apr 16, 12] founded 2003 In addition to the US, Zephyr™ has distributors and representatives in key markets such as the UK, Germany and Singapore. [company website]

ZeptoMetrix (Buffalo, NY)

ZeptoMetrix (Buffalo, NY; $600K SBIR, founded 1999, 60 employees) is looking at [expansion] options as it continues to grow. [Tracey Drury, Buffalo Business First, Aug 1, 16] reliable and trusted products and services for Infectious Disease Diagnostic Development and quality control. ... Known to have one of the world’s largest commercial archives of clinical specimens [company website]

ZeptoMetrix (Buffalo, NY; $600K SBIR) will expand into the Innovation Center Annex (where the state-sponsored advanced manufacturing center is also being built). The company expects to create 10 new jobs and invest $575,000. ... admitted to the Start-Up NY tax breaks program through the University at Buffalo, according to an announcement from state Gov [Dan Miner, Buffalo Business First, Oct 21, 14]

ZeroFOX (Baltimore, MD)

ZeroFOX (Baltimore, MD; no SBIR) has raised $10.7 million in a Series A funding round to grow all aspects of the company. .... focuses on providing businesses and the government with ways to prevent cyber attacks that come through social media networks. [Ryan McDonald, Baltimore Business Journal, Apr 30, 14]

Zero Locus (Milwaukee, WI)

Zero Locus (Milwaukee, WI; no SBIR, founded 2013) run by two MIT-trained engineers ... is using little-known mathematical techniques to create software that will evaluate hundreds, even thousands of variables and calculate probabilities to help companies digest their data and make better business decisions. The company has raised an undisclosed amount of funding .... Data analytics, the area Zero Locus operates in, has the potential to add $155 billion to $325 billion to the U.S. economy by 2020, according to a July report by McKinsey Global Institute [Kathleen Gallagher, Milwaukee Journal Sentinel, Dec 4, 13] Unlike most software ideas that are only business risks and thus unsuitable for subsidy, this sounds like it has a tech risk with a giant payoff if it works. We do need efficient ways to handle the piles of data we are accumulating with our tireless information machine. But whether a start-up can do it better than a large entity remains to be seen, and for all we know such a project could be well along already in the back rooms of Google or Oracle or IBM.

Zero Mass Water (Scottsdale, AZ)

Bill Gates's Breakthrough Energy Ventures (BEV) aims to invest $1 billion into radical energy startups capable of drastically cutting global emissions. The investees: QuantumScape (San Jose, CA; no SBIR, founded 2010, total funding $100M) building an all-solid-state battery; Commonwealth Fusion Systems (Cambridge, MA; no SBIR, founded 2017, total funding $65M) nuclear-fusion reactor that uses high-temperature superconductors and aims to be the first fusion system to produce net-positive energy ; Pivot Bio (Emeryville, CA; one SBIR, founded 2010, total funding $17M) microbial solution that can replace nitrogen fertilizers; CarbonCure (Canada, founded 2007, total funding $9M) trapping carbon dioxide in concrete blocks, while endowing them with greater strength than conventional concrete; Fervo Energy (San Francisco, CA; no SBIR) rethinking geothermal power with the help of modern computational models and horizontal-drilling; DMC Biotechnologies (Boulder, CO; $900K SBIR, founded 2017, total funding $2M) tailoring microbes to produce high-value chemicals, including biofuels; Zero Mass Water (Scottsdale, AZ; founded 2014, no SBIR) specialized panels that use solar power and batteries to pull water from the air. [Akshat Rathi, Quartz, Sep 26, 18]

ZetaRx Biosciences (Seattle, WA)

ZetaRx Biosciences (Seattle, WA; no SBIR) got $2M venture roundfor undiscliosed biotechnology.[xconomy.com,Dec 13, 12] In contrast, SBIR's public money demands disclosure of your purpose for the money.

Zeteo Tech (Sykesville, MD)

Zeteo Tech (Sykesville, MD; $1.4M SBIR) that has developed a revolutionary new class of fieldable biological mass spectrometers, announced a contract of up to $6.5 million (including options) from the U.S. Department of Homeland Security to develop and test a new sensor technology that enables real-time detection of aerosolized biological threat agents including bacteria, viruses, and toxins [company press release, Apr 14, 19]

Zeus (Orangeburg, SC)

NASA has a nice piece by Mike DiCicco of Goddard Space Flight Center on commercialization from four NASA SBIR/STTR awardees. Read the stories.. Companies: Serionix (Champaign, IL), Cambrian Innovation (Watertown, MA), Electric Power Systems (Lombard, IL), Zeus (Orangeburg, SC)

Zikani Therapeutics (Watertown,MA)

Zikani Therapeutics (Watertown,MA; no SBIR) which is developing novel Ribosome Modulating Agents (RMAs as therapeutics for patients with limited treatment options, raised $7.5M in equity, according to an SEC filing. [Rowan Walrath, BostInno, Apr 16, 20]

Zilker Labs (Austin, TX)

Zilker Labs (Austin TX; no SBIR) a five-year-old chip company, raised $10M in its fourth venture investment round. Zilker says its chips give engineers an easy-to-use method of controlling the delivery of precise amounts of electrical power inside the circuit boards that control complex systems such as servers, storage systems, communications equipment and industrial control equipment. The company says it is working on design projects with its 50 or so active customers. [Austin American-Statesman, Oct 3]Zilker raises $8M. Semiconductor startup Zilker Labs http://www.zilkerlabs.com/ has raised $8 million in its third round of venture capital investment funding to pay for high-volume production of its first chip and development of new products. ... Zilker develops chips that precisely manage electrical power within advanced communications equipment, servers and other electronics products. The company says its products will simplify and speed the design of complex circuit boards. [Austin Statesman-American, May 11]

Zinc Matrix Power (Camarillo, CA)

Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

An alternative to lithium-ion batteries--silver-zinc batteries--could add several hours to the time that laptops can run between charges, while at the same time avoiding the safety issues that have resulted in the recent massive recalls of laptop batteries, says Zinc Matrix Power (Camarillo, CA). .. has now demonstrated the silver-zinc in a laptop ... plans to begin distributing test batteries to manufacturers early next year, focusing on laptops and cell phones. [Kevin Bullis, MIT Tech Review, Oct 11] ZMP got some of its capital from the Army trial VC program run by On Point.

Zinc Matrix Power, which makes a silver-zinc battery that lasts twice as long as lithium-ion batteries of the same size, closed $7 M in VC funding, suggesting there could soon be more portable power options for notebook computers and other devices. ... to establish and staff a pilot production facility in Camarillo, California. .. currently testing its batteries with the U.S. Army and will release batteries to be tested on notebook computers later this year. [Red Herring, Apr 14]

Zintera (San Diego, CA)

A high-tech mix of five [more] start-up and relocated companies will locate in University at Buffalo [NY] facilities: Cytocybernetics (Buffalo, NY; no SBIR), a new company pledged to create four new jobs, invest $41,000 and has developed a device that aims to help improve drug safety screening for the pharmaceutical industry; Greenwich Geriatrics (Buffalo, NY; no SBIR) , a new company which pledged to create 20 new jobs, invest $355,000 ... company’s decision-support software aims to help caregivers and health professionals make recommendations for individuals with complex medical problems; Geocove (Orlando, FL; no SBIR), expanding to Buffalo, pledged to create five new jobs, invest $60,000 builds custom GIS tools to a multitude of industries, and will partner with UB’s geography department and GIS program.; Zintera (San Diego, CA; no SBIR) expanding in Buffalo, pledged to create five new jobs, invest $91,000 ... company’s platform uses an approximation of the biological human mind to pursue solutions in healthcare, genomics and life sciences applications; Natural Energy Systems, (Canadian), pledged to create five new jobs and invest $50,000. .. converts sustainable organic waste to clean-burning renewable fuel using a process patented by the company’s founder. [Dan Miner, Buffalo Business First, Apr 27, 15]

Ziopharm Oncology (NY, NY)

Ziopharm Oncology (Boston, MA; no SBIR) developing immuno-oncology gene and cell therapies, raised $19.5M in equity, according to an SEC filing. [Rowan Walrath, BostonInno, Sep 17, 19]

Ziopharm Oncology (NY, NY; no SBIR) is offering about 15.5 million common shares and warrants to buy 7.7 million shares in a public offering. ... to net about $45M ... for clinical development of its product candidates and other corporate purposes. [AP, Dec 4, 09]

Ziptronix (Raleigh,NC)

in buying Raleigh-based RTI International (non-profit) spinoff Ziptronix (Raleigh, NC; no SBIR) for $39 million in August, Silicon Valley-based Tessera Technologies scored an innovation that’s already received solid interest from Sony, but it also inherited a lawsuit. .... Specifically, Tessera inherited pending litigation filed by Ziptronix in 2010 against Taiwan Semiconductor Manufacturing and Omnivision Technologies, alleging that the companies infringed on certain Ziptronix patents. [Lauren K. Ohnesorge Triangle Business Journal, Nov 10, 15]

Ziptronix (Raleigh, NC; no SBIR), a small semiconductor technology company that spun out of RTI International in 2000 has been acquired for $39 million in cash by Tessera Technologies (San Jose, CA; $250K SBIR) which like Ziptronix focuses on licensing its technology to others [David Ranii, Raleigh News & Observer, Aug 28, 15]

Ziptronix (Raleigh, NC; no SBIR) electronics firm has netted a deal that could put its technology in future Sony devices – everything from smartphones to tablets. ... has licensed similar technology to defense contractor Raytheon and has had a smaller deal with Sony in 2011. ... founded in 2000 as a venture-backed spinoff of RTI International and has been issued 45 U.S. patents and 42 international patents. The firm sold its Morrisville development lab in 2013 and moved its remaining six employees ... While the technological development happened in the Triangle, the actual product manufacturing moves overseas with Sony. [Lauren K. Ohnesorge, Triangle Business Journal, Mar 24, 15]

Ziptronix (Raleigh, NC; no SBIR) announced it has sold its development lab to Tezzaron Semiconductor (Napierville, IL; $2.5M SBIR) Corp. for an undisclosed sum. The lab will be operated by Novati Technologies, a subsidiary of Tezzaron. ... to use the facility to further develop its own memory chips [David Bracken, Raleigh News & Observer, Dec 9, 13]

Zogenix (San Diego, CA)

Zogenix (Emeryville CA; no SBIR) down 39% [Feb 7, 20] reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA(R) (ZX008, fenfluramine oral solution) in Lennox-Gastaut Syndrome (LGS), a severe and treatment-resistant childhood-onset epilepsy. [company press release, Feb 6, 20]

Nine months after Zogenix (Emeryville, CA; no SBIR) got a stock rally going by touting late-stage data for a new drug to prevent seizures due to Dravet syndrome, the FDA handed back their marketing application with a failing grade on inadequate and incomplete work. Officially, that’s called a refuse-to-file notice, [John Carroll, Endpoints News, Apr 11, 19

Zogenix (Emeryville, CA; no SBIR, market cap $1.6B) up 21% [Jul 12, 18] reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. [company press release, Jul 12, 18]

Zogenix down 19% [Nov 8, 17]

Zogenix up 11% [Oct 2, 17]

Zogenix (Emeryville, CA; no SBIR, market cap $320M)up 172% [Sep 29, 17] reported positive top-line results from its first Phase 3 trial (Study 1) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. The trial met its primary objective of demonstrating that ZX008, at a dose of 0.8 mg/kg/day, is superior to placebo as adjunctive therapy in the treatment of Dravet syndrome in children and young adults. [company press release, Sep 28, 17]

Zogenix up 18% [Mar 14,16]

Zogenix(San Diego, CA; no SBIR) cratered nearly 40 percent in after-hours trading Friday, after a Food and Drug Administration advisory panel voted against recommending approval of its painkiller Zohydro. [Anna Edney, utsandiego.com, Dec 7, 12]

Shares of Zogenix (San Diego, CA; no SBIR) were down slightly in late trading Tuesday, a day after the maker of a needleless migraine headache treatment injector raised $53.4 million in an [IPO]. The 14 million shares sold in the IPO were priced at $4 each, far below the $12 to $14 range the company originally had planned. [Keith Darce, signonsandiego.com, Nov 23, 10]

Zogenix (San Diego, CA; no SBIR) which has developed a needle-free injector and drug for quick treating of migraines, has amended its IPO filing, saying it intends to raise about $78 million in its initial offering on Nasdaq. [Bruce Bigelow, signonsandiego.com, Nov 4, 10]

Zogenix (San Diego, CA; no SBIR) which markets a needle-free injector for treating migraines, intends to raise $90 million [IPO] ... The biotech startup has also been developing compounds for treating pain and central nervous system disorders, and plans to pair each new drug with its proprietary “DosePro” injector as a drug-and-device combination in seeking FDA approval. Zogenix CEO Roger Hawley told me the company has raised nearly $200 million ($164 million in venture funding and $35 million in debt financing) since it was founded in 2006. ... company also identifies extensive competition among large, well-capitalized companies offering treatments for migraines which, like Zogenix’s injection, are in the so-called triptan class. Zogenix says it expects its losses and negative cash flows to continue at least for several more years. [Bruce Bigelow, signonsandiego.com, Sep 23, 10]

Zogenix (San Diego, CA; no SBIR, formed in 2006) maker of a needleless migraine headache treatment injector, said it will try to raise as much as $90 million from investors in an initial public stock offering. [Keith Darce, signonsandiego,com, Sep 9, 10]

Zosano Pharma (Fremont, CA)

Zosano Pharma down 27% [Apr 9, 19] announced the pricing of an underwritten [$17M] public offering of its common stock [company press release, Aug 9, 19]

Zosano Pharma down 24% [Feb 22, 19]

Zosano Pharma (Fremont, CA; no SBIR, founded 2006, IPO 2015) up 171% [Feb 21, 19], a clinical-stage biopharmaceutical company, announced the completion of the second and final goal of the long-term safety study for [proprietary] Qtrypta, in which patients treated migraine attacks over a one year period. The long-term data generated in this trial reinforced the well-tolerated safety profile and strong efficacy results previously reported in the six-month dosing portion of this safety study and in the randomized Phase 2/3 ZOTRIP pivotal study. [company press release, Feb 20, 19] total funding $166M [crunchbase.com]

Zosano Pharma up 13% [Jul 17, 18]

Zosano Thera down 10% [Jun 18, 18]

Zosano Pharma up 11% [May 14, 18]

Zosano Pharma down 45% [Mar 29, 18] announced the pricing of an underwritten [$50M] public offering of common stock at $5.00 per share [to] complete the long-term safety study of its lead product candidate, M207. [company press release, Mar 29, 18]

Zosano Pharma down 24% [Mar 28, 18]

Zosano Pharma down 11% [Mar 12, 18]

Zosano Pharma up 27% [Mar 8, 18]

Zosano Pharma up 57% [Mar 7,18]

Zosano Pharma (Fremont, CA; no SBIR, founded 2006) up 25% [Mar 6, 18] announced Notice of Allowance of our patent application titled "Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines" has resulted in the issuance of a U.S. patent [company press release, Mar 2, 18] total funding $144M [crunchbase.com]

After feedback from Japanese regulatory authorities that would have required additional clinical trials to support its marketing application there (and delayed commercialization for one year), Zosano Pharma (Fremont, CA; no SBIR) decides to terminate its development of once-daily ZP-PTH for severe osteoporosis. After discussing the situation with collaboration partner Eli Lilly, the companies agreed to end their partnership. .; shares plummet 37% after hours [http://seekingalpha.com, Sep 28, 15]

medical patch maker Zosano Pharma (Fremont, CA; no SBIR) IPO raised $50 million

A trio of Bay Area life sciences companies — Tobira Therapeutics (South San Francisco, CA; no SBIR, founded 2006, backed by Danish drug developer Novo A/S ), Zosano Pharma (formerly Macroflux, Fremont, CA; no SBIR, founded 2006) and IntersectENT (Menlo Park, CA; no SBIR) — will seek more than $200 million in upcoming IPOs. [Ron Leuty, San Francisco Business Times, Jun 24, 14]

Zosano Pharma (Fremont, CA; no SBIR), which focuses on products based on its transdermal delivery technology, said Tuesday it closed a $30 million round of funding. ... support the ongoing scale-up for Phase 3 clinical development and manufacturing readiness for Zosano’s lead program, a rapid delivery patch for the treatment of osteoporosis. [Silicon Valley/San Jose Business Journal, Jul 7, 09]

ZPower (Camarillo, CA)

ZPower (Camarillo, CA; no SBIR) , included in the list of GoingGreen 100 Top Private Companies, has recently announced that the company is releasing the hotly anticipated silver-zinc batteries in 2009. .... ZPower claims that silver-zinc batteries have 40-percent longer lifespan than other current batteries in the market. Silver-zinc is also reportedly more chemically stable than lithium-ion. [Mariella Moon, GoodCleanTech, Aug 22]

ZS Genetics

North Shore InnoVentures, a technology incubator based in Beverly [MA], said that six startup companies in the clean technology and life sciences sectors have joined its program over the last few months. .... Lariat Biosciences (no SBIR), is developing a non-invasive diagnostic to detect early signs of cancer based on circulating free DNA within the bloodstream. ... Other startups recently joined include Akita Innovations, RAN Biotechnologies, Quad Technologies, and ZS Genetics, none has SBIR. .... A total of 21 companies are now in [residence]. [Chris Reidy, Boston Globe, Jun 5]

zSpace (Sunnyvale, CA)

Two Silicon Valley companies have developed a 3-D virtual reality kit that lets medical students and doctors practice surgeries and organ dissections without the messiness of working on real cadavers. Three-dimensional holographic imaging display maker zSpace (Sunnyvale, CA; no SBIR) provides the hardware, including stereoscopic VR displays and transparent glasses. EchoPixel (Mountain View, CA; no SBIR) which makes medical imaging technology, provides the software. ... They plan to submit a proposal next week to [FDA] that, if approved, would allow them to start selling the kits for $75,000 — for use in clinical settings with real patient data. [Jose Fermoso, Silicon Valley Business Journal, Dec 9, 14]

ZS Pharma (Coppell, TX and Menlo Park, CA)

ZS Pharma up 41% [Nov 6, 15]

Anglo-Swedish drug firm AstraZeneca has acquired biopharmaceutical company ZS Pharma (Coppell, TX and Menlo Park, CA; no SBIR, founded 2008, IPO 2014) in a deal worth $2.7 billion. [AP, Nov 6, 15]

After generating approximately $112 million in net profit, ZS Pharma (Coppell, TX and Menlo Park, CA; no SBIR, founded 2008) closed its [IPO] ... is developing ZS-9, a drug used to treat hyperkalemia, a kidney condition that produces high levels of potassium in sufferers. [Korri Kezar, Dallas Business Journal, Jun 24, 14]

ZSX Medical (King of Prussia,PA

An experimental technology being developed by medical-device company ZSX Medical (King of Prussia, PA; no SBIR) to improve laparoscopic surgeries is heading into the clinic for testing on humans. ... recently raised $1.4 million in a private stock sale... for clinical studies of the Zip-Stitch device, a surgical-closure device, under development initially for women undergoing laparoscopic hysterectomies, that uses biomaterials to repair damage. [John George, Philadelphia Business Journal, Jun 7, 13]

Zumobi

Zenzui, which was spun out of Microsoft, has been renamed Zumobi. The Seattle-based startup said the name better represents the business it's in -- mobile. On Dec. 14, it plans to launch a beta version of its mobile-phone software. ... launched in March after spinning off from Microsoft and raising $12M [Seattle Times, Nov 17]

Zunum Aero(Kirkland, WA)

Boeing plans to buy Aurora Flight Sciences (Manassas, VA; $24M SBIR), a leader in drone technology. Boeing executives say Aurora would bring it a cutting-edge research-and-development shop that it could apply to to both defense and commercial projects. The companies already work together on a hydrogen-powered drone called Phantom Eye (Aurora builds the wing and did engine development). Aurora also helped develop Boeing's new 777X jetliner. ... When [Greg Hyslop, Boeing's chief technology officer and senior vice president of Boeing Engineering, Test & Technology] was asked what the deal to buy Aurora might say about other types of technology might Boeing be looking to acquire? His response: "We're always looking at a lot of different things to acquire. He mentioned investment by the firm's VC arm HorizonX in Zunum Aero (hybrid electric aircraft, Kirkland, WA; no SBIR), SparkCognition (artificial intelligence, Austin, TX; no SBIR), Upskill (augmented reality for manufacturing), and C360 (360° video and augmented/virtual reality, Marietta, GA; no SBIR). [Marcus Weisgerber, Defense One, Oct 4, 17]

Zurex Pharma (Madison, WI)

Zurex Pharma (Middleton, WI; no SBIR, founded 2010) developing antimicrobial products for preventing infections acquired in hospitals, clinics, and home care settings, says it has raised $9 million in new funding... to support the development of its lead product candidate, a pre-surgical skin preparation called ZurexPrep. .... has raised a total of more than $27 million [Jeff Buchanan, xconomy.com, Jun 12, 18]

Zurex Pharma (Middleton, WI; no SBIR), which is developing antimicrobial products for healthcare-associated infections, has raised more than $6.2 million in equity funding, ... said the money is an “initial close of a Series C financing,” and will be used in part to support a late-stage clinical trial of its lead product candidate, ZuraPrep, a pre-surgical skin preparation. .... has raised more than $16 million since 2012 [Jeff Buchanan, xconomy.com, Aug 11, 16]

Zurex Pharma (Middleton, WI; no SBIR) developing products to help prevent infections in health care settings, has raised $5.1 million of equity funding, according to [SEC] filing. ... raised $6.2 million in 2012 ... moved to Wisconsin from Indiana in 2010 after being spun out of Ash Access Technology (Lafayette, IN; $2.8M SBIR) [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 2, 14]

Zurex BioPharma (Madison, WI; no SBIR) said it has secured an additional $1 million in debt financing.... used as working capital to build inventory and support commercial operations.The company also said it launched a hygiene technology product, the ECAlogix System, at the 2012 World Ag Expo in Tulare, Calif. "The additional working capital will help Zurex PharmAgra effectively launch new technologies and accelerate our growth in 2012," said CEO Carmine Durham. [Milwaukee Journal Sentinel, Mar 2, 12]
Other [Wisconsin] companies the MoneyTree report showed raising venture funding in the second quarter were: Aquarius Technologies (Port Washington, WI; no SBIR) developer of wastewater treatment technologies, $4 million; NeuWave Medical (Madison, WI; no SBIR) medical device company, $2.63 million; ProCertus BioPharm (Madison, WI; $1.6M SBIR) drug developer, $1.7 million; and Zurex Pharma (Madison, WI; no SBIR) drug developer, $1 million. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 19, 11]

Zurex PharmAgra LLC (Madison, WI; no SBIR) has been certified as a qualified new business venture by the state Department of Commerce, a move that makes its investors eligible for tax credits. With the state certification, financial backers will be eligible for a 25% tax credit on the amount they invest in the company.Zurex will initially focus its infection-fighting technology on preventing dairy mastitis, a persistent inflammatory reaction cows have to infection in their udder tissue, Carmine Durham, the company's president and chief executive, said in a statement Wednesday. The company has said its technology has potential to prevent infections humans acquire in health care settings as well. Zurex is developing products that use a non-iodine based substance that works against microorganisms. The majority of surgical scrubs and antimicrobial animal health products use iodine. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 13, 11]

Zurex Pharma (Madison, WI; no SBIR) with a unique infection-fighting technology has raised $1 million in venture capital. ... developing products that use a non-iodine based substance that works against microorganisms. The majority of surgical scrubs and antimicrobial animal health products use iodine, Smith said. ... expected to benefit from the huge disruption in the iodine supply that has resulted from Japan's problems, and concerns about some of the tainted iodine-based solutions that have been coming out of China .... company is a subsidiary of Ash Access Technology Inc., a Lafayette, Ind., company that sells dialysis products and was founded by Stephen Ash, a kidney doctor. [Kathleen Gallagher, Milwaukee Journal Sentinel, May 2, 11]

Lured by state incentives, a small medical technology firm spun off from an Indiana company said Monday it will locate in Madison, WI. Zurex Pharma is developing products to help patients avoid infections from catheters and in surgical sites, said [CEO] Carmine J. Durham. Durham will run the company from offices in University Research Park, with help from four other investor-owners. All of them were involved with Zurex's parent company, Ash Access Technology (Lafayette, IN; $2.7M SBIR) .... Stephen Ash, a kidney doctor with Clarian Arnett Health in Lafayette, Ind., and a founder of Ash Access Technology."To get (these products) to market takes the kind of experience and enthusiasm that Carmine has," said Ash, who has invented more than 50 medical devices. ... Zurex is applying for Wisconsin's investor tax credits and for other incentives, such as low-interest loans the state Commerce Department offers for young technology companies, [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 9, 10]

Zwitter Technology (Seattle, WA)

Three companies in Washington will receive Proof of Concept grants to accelerate maturation of promising health-related technologies from ideas into commercial products, the Life Sciences Discovery Fund (LSDF) announced: Zwitter Technology (Seattle, WA; no SBIR), $250,000 to conduct preclinical testing of a new leukemia treatment anticipated to have greater efficacy than current drugs; M3 Biotechnology (Seattle WA; no SBIR), $250,000 to validate the effectiveness and safety of a novel treatment for Parkinson’s disease in preparation for clinical testing; LumiThera (Poulsbo, WA; no SBIR), $250,000 to build and test a device that may delay progression of the dry form of age-related macular degeneration. [press release, Life Sciences Discovery Fund, Apr 21, 14]

Zyga Technology (Minnetonka, MN)

Medical-device maker Zyga Technology (Minnetonka, MN; no SBIR) closed on $10 million in financing ... to ramp up U.S. sales of its system for treating patients who experience chronic pain due to sacroiliac joint dysfunction, a condition caused by excessive movement in the joints that connect hips to the spine. .... raised$25 million in venture capital in 2012. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Sep 25, 14]

Zygo

Zygo (Middlefield, CT ; one SBIR) up 32% [Apr 11, 14] said it agreed to be purchased by AMETEK Inc. in a cash deal worth $364 million. .... it would mark the end of independence for a Connecticut homegrown technology stalwart that was founded in 1970 and showed growth but was rarely a home run for investors. [Dan Haar, Hartford Courant, Apr 11, 14]

Zygo has landed $6 million in metrology systems orders from two Chinese optical research and manufacturing organizations. [Mass High Tech, Sep 1, 11]

Zygo (one Phase 1 SBIR) is among the more successful Connecticut-bred tech firms, with 375 local employees and a solid market niche. Its merger [with Electro Scientific (no SBIR)] — which is being contested in court by a shareholder group — would leave Zygo under the control of another company. But that is the best plan for nurturing the business, Zygo officials said. ... The deal is typical of a market where tech companies are searching for growth and capital, said Matthew Nemerson, president and CEO of the Connecticut Technology Council. [Kenneth St Onge, Hartford Courant, Dec 19, 08]

Zymergen (Emeryville, CA)

Zymergen (Emeryville, CA; no SBIR, about 200 employees), said it had raised $130 million in its latest round, led by the Japanese telecommunications giant SoftBank. ... has used robotics and machine learning to better manipulate microbes used in processes like industrial fermentation, making customers’ operations more efficient. [MICHAEL J. de la MERCED, New York Times, Oct 11, 16]

Biotech startup Zymergen (Emeryville, CA; no SBIR, founded 2013) raised $44 million in Series A funding to use biology to engineer the materials of the future. ... to become a leader in what is being called the “new bioeconomy,” where companies uses microbes to manufacture high-value chemicals and new materials. Zymergen counts several Fortune 100 companies among its customers. [Gina Hall, Silicon Valley Business Journal, Jun 16, 15]

Zymeworks (Canada)

Zymeworks (Canada) announced the closing of its[IPO] for a total of U.S.$58,5M in aggregate gross proceeds. [company press release, May 3, 17]

ZymoGenetics

ZymoGenetics ($900K SBIR in 1980s, founded 1981) early focus on the development of production systems for recombinant proteins led to a 1982 collaboration with Novo Nordisk A/S for the production of recombinant human insulin in yeast. In 1988, Novo Nordisk acquired ZymoGenetics as a wholly owned subsidiary. ZymoGenetics served as the primary U.S. discovery arm of Novo Nordisk for 12 years, contributing to the development of several of Novo Nordisk's current marketed products and pipeline candidates. In November 2000, ZymoGenetics was re-established as an independent biotechnology company, and in February 2002, began trading on the NASDAQ stock exchange. ZymoGenetics’ commitment to innovation has led to regulatory approval of nine recombinant protein therapies. Bristol-Myers Squibb acquired ZymoGenetics in October 2010 after entering into a strategic collaboration to co-develop PEG-Interferon lambda. ... announced Dec 13, 2016 that it will not renew its lease at the Lake Union Steam Plant site in Seattle. [Bristol-Myers website]

Bristol-Myers Squibb has laid off as many as 20 people in its clinical development/operations group at ZymoGenetics in Seattle as part of a companywide R&D restructuring [=1% R&D cut], Xconomy has learned. Bristol-Myers acquired ZymoGenetics for about $885 million in October 2010. ..... ZymoGenetics site had about 150 employees left [of the 275 at acquisition] heading into today’s cuts ... BMS says it is “discontinuing broad based discovery work in hepatitis C, diabetes and neuroscience.” The company is making those cuts so it can put more money into cancer immunotherapy and continue to focus on HIV, hepatitis B, heart failure, oncology, immunoscience, and fibrotic diseases [Luke Timmerman, xconomy.com, Nov 7, 13]

Bristol-Myers Squibb said it's completed its acquisition of Zymogenetics for $885 million. [Puget Sound Business Journal, Oct 13, 10]

ZymoGenetics said its potential melanoma treatment IL-21 showed positive results in a midstage study. ... said patients taking IL-21 for advanced melanoma had a median overall survival of 12.4 months. It said at 12 months, 53 percent of patients taking IL-21 survived.[AP, Sep 29, 10]>

Bristol-Myers Squibb agreed to acquire biotechnology company ZymoGenetics for $735 million, in a move to strengthen its pipeline of drugs for hepatitis and other diseases. [Wall Street Journal, Sep 8, 10]

ZymoGenetics up 84% [Sep 8, 10] on news of Bristol Myers acquisition.

Zymogenetics up 12% [Jun 10, 10]

A potential skin-cancer treatment from ZymoGenetics met key goals in a midstage study, the company said. The company said 23.1 percent of the skin cancer patients had an overall response and a median survival rate of 4.3 months without the disease progressing. [AP, Jun 7, 10]

ZymoGenetics up 14% [Jun 3, 10]

ZymoGenetics down 12% [May 6, 10]

ZymoGenetics said its stock offering of 14 million shares was priced at $6 per share, ... its net proceeds will be approximately $79 million [Seattle Times, Jan 9, 10]

Zymo Genetics down 10% [Jan 7, 10]

ZymoGenetics said it will sell 12 million shares of stock [for $80M] in a public offering, using the proceeds to expand sales of its sole product and to continue its R&D efforts. [Seattle Times, Jan 7, 10]

Bayer has received approval to market ZymoGenetics' only product, Recothrom, in Canada. The milestone entitles ZymoGenetics to a $3.5 million payment. [Seattle Times, Dec 16. 09]

Bayer has withdrawn its application to market the ZymoGenetics drug Recothrom in Europe [Seattle Times, Dec 14, 09]

ZymoGenetics has struck a deal with its former parent from Denmark, Novo Nordisk, that will give Novo a jumpstart on its quest to become a bigger player in autoimmune diseases. Novo said it agreed to pay $24 million in upfront cash, and milestone payments worth as much as $157.5 million over time to ZymoGenetics [Luke Timmerman, xconomy Seattle, Dec 8, 09]

Zymo Genetics up 11% [Nov 6, 09]

ZymoGenetics said rival King Pharmaceuticals has obtained a temporary restraining order barring the Seattle-based biotechnology company from making certain claims regarding how its only marketed product, Recothrom, compares to the competing drug from King. [Seattle Times, Nov 5, 09]

ZymoGenetics said that it started a midstage study on a potential hepatitis C treatment, triggering a $70 million payment from its partner, Bristol-Myers Squibb. The Seattle company is studying PEG-Interferon lambda, called IL-29, as a potential combination treatment with the hepatitis C drug ribavirin. It could receive up to $1.12 billion in the collaboration with Bristol-Myers. [Seattle Times, Oct 28, 09]

ZymoGenetics said Merck Serono has discontinued mid-stage studies of the Seattle company's drug atacicept in multiple sclerosis, after one study showed patients did worse with the treatment than without it. [Seattle Times, Sep 28, 09]

ZymoGenetics said that its drug atacicept “did not meet the pre-specified level of disease control activity” to support further testing in recent clinical trials. [Puget Sound Business Journal (Seattle), Sep 10, 09]

Zymo Genetics up 19% [Jul 20, 09] in sympathy with tripling of Human Genome Sciences's after success of their Benlysta drug in the treatment of lupus. [tickerspy.com, Jul 20]

ZymoGenetics up 12% [May 11, 09]

Four days after announcing it will lay off more than 160 employees and will discontinue some of its research efforts, ZymoGenetics said it will license eight of its “noncore assets” to Seattle Life Sciences (no SBIR). [Puget Sound Business Journal, May 4]

ZymoGenetics will slash its workforce by one third, cutting 161 jobs, as it narrows its research and development efforts, the Seattle biotechnology company said today. The company expects to save $30 million a year in operating expenses, it said in a statement. ZymoGenetics said it will continue to expand the market for its sole approved product, the blood-clotting compound Recothrom Thrombin, but will "focus all future research efforts in immunology, its core strength." [Seattle Times, Apr 29, 09]

Zymo Genetics up 12% [Mar 23, 09]

Zymo Genetics up 15% [Mar 12, 09]

Zymo Genetics up 10% [Mar 10, 09]

ZymoGenetics down 12% [Mar 5, 09]

Bristol-Myers Squibb said it will team with ZymoGenetics to develop a hepatitis C treatment, in a deal that could eventually bring ZymoGenetics more than $1 billion. [Wall Street Journal, Jan 13, 09] up 26%

ZymoGenetics up 14% [Dec 12, 08]

ZymoGenetics down 11% [Dec 1, 08] On a stock bloodbath day

Zymo Genetics down 10% [Nov 14, 08]

ZymoGenetics up 14% [Nov 13, 08]

ZymoGenetics down 15% [Nov 12, 08]

ZymoGenetics said that quarterly sales for its only commercial product increased by 27 percent but still fell short of expectations, spurring a new strategy to ramp up sales. [Angel Gonzalez, Nov 5, 08]

Zymo genetics up 17% [Nov 3, 08]

Zymo Genetics up 18% [Oct 30, 08]

ZymoGenetics shares fell 29% after a trial of its drug to treat kidney disease in lupus patients was discontinued by Merck Serono because of high risk of infection. [Seattle Times, Oct 27, 08]

Zymogenetics up 18% [Oct 16, 08]

Zymogenetics up 11% [Oct 13, 08]

Seeking to reduce the rate at which it burns cash, ZymoGenetics is handing off the development and commercialization of one of its key compounds to partner Merck Serono, the company is expected to announce today. [Angel Gonzalez, Seattle Times, Sep 3, 08]

In a move to raise cash without selling more of its battered stock, ZymoGenetics announced Monday a deal to borrow up to $100 million from investment fund Deerfield Management. [Seattle Times, Jul 1, 08]

Facing a tough stock market and Wall Street skepticism over the recent launch of its first commercial product, ZymoGenetics (Seattle, WA; $1M SBIR in the 1980s) is reining in spending by cutting 80 jobs [Angel Gonzalez, Seattle Times, Feb 14]

ZymoGenetics down 17% [Jan 18, 08]

ZymoGenetics (Seattle, WA; $800K SBIR) fell 7% as a Bank of America analyst downgraded the company ...raised concerns about the lead product, rThrombin, expected to be approved next month by the Food and Drug Administration. ... the area's largest independent biotech, also announced the start of a midstage clinical trial to test one of its cancer-fighting therapies on patients with metastatic melanoma. [Seattle Times, Dec 19, 07]

Zymogenetics up 10%. [Aug 8, 07]

ZymoGenetics up 12% [Aug 2, 07] after a Banc of America Securities analyst upgraded the stock to "Buy" on hopes the company's drug rHThrombin is near federal approval.

Zymtronix (Durham, NC)

Zymtronix (Durham, NC; $3.4M SBIR), a developer of cell-free process technologies, and Ginkgo Bioworks (Boston,MA; $3M SBIR), which is building the leading platform for cell programming and biosecurity, announced a partnership to optimize enzymes used in Zymtronix's proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals. [company press release, Feb 16, 2023]

Zynerba Pharmaceuticals (Radnor, PA)

Zynerba Pharma down 27% [Mar 16, 21]

Zynerba Pharma up 49% [Mar 15, 21]

Zynerba Pharmaceuticals down 30% [Feb 11, 21]

Zynerba Pharmaceuticals up 47% [Feb 10, 21]

Zynerba Pharma up 18% [May 22, 20]

Zynerba Pharma up 22% [May 18, 20]

Zynerba Pharma down 22% [Sep 18, 19] the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced positive top line results from the open label Phase 2 BELIEVE 1 (Open Label Study to Assess the Safety and Efficacy of Zygel(TM) (ZYN002) Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial. [company press release, Sep 18, 19]

Zynerba Pharma up 17% [Jun 11, 19]

Zynerba Pharma down 15% [Jun 2, 19]

Zynerba Pharma up 17% [Apr 22, 19]

Zynerba Pharma up 29% [Apr 2, 19]

Zynerba Pharma up 15% [Mar 19, 19]

Zynerba Pharma up 25% [Jan 29, 19]

Lyndra Therapeutics [Watertown, MA; no SBIR, founded 2015), which is moving toward making daily pills a thing of the past, today announced it has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up. [company press release, Jan 29, 19] prior funding $84M [crunchbase.com]

Zynerba Pharma up 25% [Jan 2, 19]

Zynerba Pharma up 10% [Sep 18, 18]

Zynerba Phrma up 18% [Aug 29, 18]

Zynerba Pharma up 10% [Aug 6, 18]

Zynerba Pharma down 24% [Jul 20, 18] announced the pricing of public [to raise] $32.5 million [company press release, Jul 20, 18]

Zynerba Pharma down 11% [Jun 27, 18]

Zynerba Pharma down 11% [Aug 2, 18]

Zynerba Pharma down 13% [May 8, 18]

Zynerba Pharma up 14% [Apr 3, 18]

Zynerba Pharma up 15% [Mar 12, 18]

Zynerba Pharmaceuticals (Devon, PA; no SBIR), dedicated to developing and commercializing innovative pharmaceutically- produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders, announced the results of a positive meeting held with [FDA] regarding its planned development strategy for ZYN002 in Fragile X syndrome (FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability and autism spectrum disorder. [company press release, Mar 5, 18]

Zynerba Pharma down 11% [Dec 6,17]

Zynerba Pharma up 11% [Nov 14, 17]

Zynerba Pharma up 13% [Oct 3, 17]

Zynerba Pharma up 53% [Sep 28, 17] announced positive top line results from an open label exploratory Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). ... achieving a 46% improvement (p<0.0001) in the total score of Anxiety, Depression, and Mood Scale (ADAMS) at week twelve compared to baseline. [company press release, Sep 28, 17]

Zynerba Pharma up 21% [Aug 9, 17]

Zynerba Pharma (Devon, PA; no SBIR) down 56% [Aug 7, 17] announced top-line results from its double-blind placebo controlled Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 (cannabidiol [CBD] gel) in adult epilepsy patients with focal seizures. ZYN002 did not demonstrate a statistically significant reduction of focal seizures during the treatment period compared to the baseline period for either the high or low dose cohorts compared to placebo. [company press release, Aug 7, 17]

Zynerba Pharma down 11% [Jul 31, 17]

Zynerba Pharma up 12% [Apr 10, 17]

Zynerba Pharma down 19% [Jan 19, 17]

Zynerba Pharma up 10% [Jan 10, 17]

Zynerba Pharma up 15% [Jan 3, 17]

Zynerba Pharma up 10% [Dec 6, 16]

Zynerba Pharma down 10% [Nov 22, 16]

Zynerba Thera up 11% [Sep 26, 16]

Zynerba Pharma up 16% [Sep 19, 16]

Zynerba Pharma up 12% [Sep 6,16]

Zynerba Pharma up 11% [Aug 4, 16]

Zynerba Pharma up 13% [May 31, 16]

Zynerba Pharma up 15% [Apr 5, 16]

Zynerba Pharma down 12% [Mar 23,16]

Zynerba Pharma down 25% [Mar 16,16]

Zynerba Pharma down 32% [Mar 15,16]

Zynerba Pharma up 149% [Mar 14,16] making significant progress in advancing our pipeline of first-in-class transdermal cannabinoid treatments. Most notably, the initial results of the ZYN002 cannabidiol (CBD) gel single rising dose study demonstrated excellent safety and tolerability, and provide compelling rationale for continued development," said Armando Anido, Chairman and CEO [company press release, Mar 14, 16]

Zynerba (Devon, PA; no SBIR, founded 2004) specialty pharmaceutical company working on synthetic cannabinoid therapies, is planning [IPO for $52M] ... to continue its development of experimental treatments for epilepsy, fibromyalgia, peripheral neuropathic pain and other pain-related conditions. relocated to this region last year [John George, Philadelphia Business Journal, Jul 27, 15]

Zynerba Pharmaceuticals (Radnor, PA, successor company to AllTranz (Lexington, KY; $200K SBIR, recently acquired by [an investment bank]) a specialty pharmaceutical company developing transdermal cannabinoid treatments (aka synthetic marijuana therapies), said it has raised $13 million in a private stock sale. ... to advance our two highly innovative and proprietary cannabinoid therapeutic development assets for large unmet patient populations," [John George, Philadelphia Business Journal, Oct 15, 14]

Zyomyx (Fremont, CA)

Drug maker Mylan Inc. invested about $6 million in Zyomyx (Fremont, CA; no SBIR) diagnostic company working on a point-of-care HIV test that could speed treatment of the deadly disease in Africa and other AIDS hotspots. .... The Bill and Melinda Gates Foundation, which supported Zyomyx with $6 million in milestone-driven payments from 2007 to 2009 and $10 million to push the test toward commercialization. [Ron Leuty, San Francisco Business Times, Jul 10, 13]

Zystor Therapeutics (Wauwatosa, WI)

BioMarin (Novato, CA; $300K SBIR) will buy ZyStor Therapeutics (Milwaukee, WI; no SBIR) and a possible treatment for a rare degenerative muscle disease in a deal that could be worth up to $115 million. It is the fourth major deal in less than a year for Novato [Ron Leuty, San Francisco Business Times, Aug 20, 10]

Zystor Therapeutics (Wauwatosa, WI; no SBIR) has been acquired by BioMarin Pharmaceutical (Novato, CA; $300K SBIR), a deal that could attract investors for other Midwestern companies and venture funds. ... agreed to pay $22 million initially for privately held Zystor, based in Wauwatosa. BioMarin will pay as much as $93 million more if certain development, regulatory and commercial milestones are achieved, the company said. [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 17, 10]

Zyvex Technologies (Columbus,OH)

Zyvex Technologies (Columbus, OH; no SBIR) will be able to improve existing products and introduce new ones – as varied as medical prosthetics, aerospace coatings, and hockey sticks – within the next nine months as a result of its recent acquisition by carbon nanotube maker Ocsial (Luxembourg) (of apparently Russian origin). ... forms the world’s largest nanotechnology company, engineering products at the atomic scale. ... Zyvex Technologies spun out from Zyvex Corp. in Texas and moved to Columbus in 2007. [Carrie Ghose, Columbus Business First, Jun 23, 14]